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ABSTRACT 
Ronna L. Chan 
Maternal health exposures and pregnancy outcome: Examining symptoms of nausea and 
vomiting in early pregnancy, maternal caffeine consumption, and spontaneous abortion 
utilizing regression and propensity score methodologies 
 
(Under the direction of Andrew F. Olshan, Ph.D., and David A. Savitz, Ph.D.) 
 
 
 This dissertation addressed two important issues concerning pregnant women: 
caffeine consumption and nausea and vomiting in early pregnancy (NVP). Factors 
influencing NVP have not been well established and methodological limitations in previous 
research merit closer evaluation on the caffeine consumption-spontaneous abortion (SAB) 
and NVP-SAB relationships. This study examined potential risk factors or markers for NVP, 
and the associations between NVP, caffeine exposures, and SAB using refined classifications 
of NVP and traditional and novel analytic methodologies.  
Our analyses included 2,430 newly pregnant women, who participated in a 
prospective cohort epidemiologic study from 2000 to 2004. Detailed NVP and caffeine 
consumption data and other health and pregnancy outcome information were collected 
through interviews, ultrasound assessments, and medical and vital records. Modified Poisson 
regression with robust error variance models generated risk ratios for potential risk factors to 
NVP characteristics. Discrete-time continuation ratio logistic survival models were used to 
estimate week-specific pregnancy loss associated with NVP and caffeine exposures. 
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Additionally, we introduced propensity score methods to evaluate the effects of caffeine 
exposures on SAB.  
Most maternal characteristics were not associated with having NVP, except for 
plurality. Increased risk for delayed onset was found with increasing maternal age, among 
non-Hispanic Blacks, Hispanics, or age at menarche between 12 and 13 years old. 
Additionally, older women and non-Hispanic Blacks were less likely to experience 
symptoms beyond first trimester. Absence of NVP is associated with an increased risk for 
SAB, compared to having any symptoms. Furthermore, age was found to modify the 
association between symptom severity and duration and SAB. Reduced risks for SAB was 
found across all age groups for longer duration, but the effects were much pronounced in the 
oldest age groups. There was little indication of potential harmful effects of caffeine on SAB; 
our results showed no overall meaningful differences in estimates from traditional covariate 
adjustment versus propensity score models.  
Using improved exposure assessments and analytic methodologies, we identified 
characteristics that are associated with subclasses of NVP, in addition to providing better 
understanding in NVP-SAB and caffeine-SAB relationships. Finally, our findings suggest 
that propensity score methodology is an important addition in studying pregnancy health.  
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 
1.1 Introduction 
 
Nausea and vomiting in early pregnancy (NVP) affects 50%-90% of pregnant women 
some time before 20 weeks’ completed gestation.1, 2 The exact cause for NVP is not 
known, but the biochemical changes during pregnancy may be responsible for this 
phenomenon. Several hormones may contribute to the symptoms of NVP. Most notably, 
human chorionic gonadotropin (hCG) has been proposed as the most likely contributor to 
NVP due to the rapid increase in its levels in the first trimester.3 Although some studies 
have reported that the presence of NVP is associated with decreased adverse pregnancy 
outcomes, particularly spontaneous abortion (SAB),3-8 the role of NVP has not been 
studied extensively. Earlier studies had methodological limitations which may potentially 
underestimate the association between NVP and SAB.   
Spontaneous abortions or miscarriages are pregnancies that are lost prior to 20 
completed weeks’ gestation from the first day of the last menstrual period (LMP). Studies 
of SABs are often challenging, primarily due to the difficulty in identifying women early 
in pregnancy. In most cases, recognition of pregnancy can be detected with standard 
assays for hCG prior to a missed period or via home urine pregnancy test kits by the time 
of a missed menstrual period. Nonetheless, challenges in identifying women early in their 
pregnancy persist because many women may not be aware that they were pregnant due to
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unintentional and/or unplanned pregnancies. Because most pregnancy losses are 
concentrated in the earlier weeks of gestation, early enrollment of women into the 
research study is critical in the early identification of pregnancies and the identification of 
pregnancy losses. Current knowledge on the etiology of SAB is limited but several risk 
factors have been shown to be influential. Advanced maternal age and history of previous 
SABs have shown to be the strongest predictors,9, 10 while other risk factors such as 
cigarette smoking,11 caffeine consumption,12-14 occupational chemical exposures,15 and 
drinking water disinfection by-products16 are also possible contributors. Earlier 
epidemiologic studies have repeatedly demonstrated that absence of nausea in the early 
gestation period may be indicative of a pregnancy already lost or as a predictor of an 
impending pregnancy loss. Additionally, timing of onset and duration of NVP may also 
potentially be indicators of adverse pregnancy outcomes such as SAB, though no prior 
research has examined these relationships.  
Finally, observational data are often used in reproductive and perinatal research to 
make inferences on causal effects. Because it is often unjust and unethical to randomize 
pregnant women to specific exposures, observational research is the best type of study in 
studying exposure-outcome relationships. However, the causal interpretation from 
observational data is complicated because the exposure groups may differ systematically 
with respect to relevant observed covariates, and therefore, not be directly comparable 
and these differences may lead to biased effect estimates.17-20 One notable research 
question in reproductive epidemiology that often rely on the use of observational data is 
the association between caffeine exposure in pregnancy and the risk of SAB. Results 
from earlier epidemiologic studies have generated much controversy and public health 
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interest since the 1980’s; however, conclusive evidence has not been established.21 The 
concern for the impact of caffeine consumption is caffeine’s ability to affect pregnant 
women differently than non-pregnant women. Methodological limitations in earlier 
studies, including differences in measuring and quantifying exposure and control of 
confounding, pose a challenge to the interpretation of results from previous studies.    
 
1.2 Specific Aims 
 
Symptoms of nausea and vomiting in early pregnancy (NVP) are common 
phenomenon that affects the majority of pregnancy women some time during the course 
of their pregnancy. Spontaneous abortion (SAB) is defined as pregnancy loss at less than 
20 completed weeks’ gestation and occurs in approximately 10% of all clinically-
recognized pregnancies.22 In this dissertation, I addressed the following specific aims:  
 
1.2.1 Specific aim 1 
Specific aim 1 of this study was to determine various maternal factors that 
influence symptoms of NVP. Potential risk factors or markers for the characteristics of 
NVP symptoms involving severity, time of onset, and duration were examined in specific 
aim 1. Factors that were examined include sociodemographic variables, maternal health 
behaviors, and women’s reproductive and medical histories. We hypothesized that 
women are more likely to experience NVP if they were younger, African-American, non-
smokers, non-drinkers, ‘younger’ age at menarche, multiparous, and had prior SABs. The 
associations between NVP and its possible predictors are stronger for women with NVP 
with delayed symptom onset and with longer symptom duration.  
 4 
 
1.2.2 Specific aim 2 
 
Specific aim 2 of this study was to evaluate the relationship between NVP and 
pregnancy loss. Moreover, we examined symptoms of NVP with respect to symptom 
severity and duration.  Covariates of interest included sociodemographic variables, 
maternal health behaviors, reproductive history, and medical history. We tested the 
hypothesis that the absence of NVP in early pregnancy is associated with a higher risk of 
spontaneous abortion, with higher risk associated with women with no symptoms or short 
symptom duration. 
 
1.2.3 Specific aim 3  
 
Specific aim 3 of this study was to apply propensity score methods in studying 
maternal health behaviors and exposures in pregnancy. The goal of many reproductive 
and perinatal epidemiologic studies is to estimate the causal effects of exposures on 
health outcomes. The use of randomized studies is not always justified or ethical; 
consequently, observational data are often used as an alternative to interpret causal 
effects. Traditional covariate adjustments in multivariable analysis may not be sufficient 
to correct the bias in estimation that potentially arises from the systematic differences in 
observed covariates across exposure status. However, propensity score was developed by 
Rosenbaum and Rubin to reduce bias in observational studies.23  
Because pregnancy is a time in which many women modify their behavior for the 
health of the fetus or under the advice of clinicians; therefore, investigators are often 
interested in studying the effects of maternal exposures and behaviors on pregnancy 
health. In specific aim #3, we illustrated the application of propensity score methods in 
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study reproductive health in an extension of an earlier study that evaluated the association 
between caffeine exposure at three time periods and SAB.24 Caffeine provides a useful 
example as it’s consumption around the time of pregnancy is influenced by a number of 
factors and the use of propensity score methods allowed us to compare findings from 
traditional multivariable models with covariate adjustments with propensity score 
models.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
 
2.1 Nausea and vomiting in early pregnancy 
2.1.1 NVP characteristics 
Little is known about the natural history of early pregnancy, and pregnant women 
may not know what to expect with regard to symptoms.25 Nausea and vomiting in early 
pregnancy (NVP) is a common phenomenon that affects 50%-90% of pregnant women.4, 
5, 26
 Symptoms may differ in the timing of onset, duration, and severity, both among 
individual women and among individual pregnancies of the same woman, and some 
women experience symptoms of nausea during pregnancy with or without episodes of 
vomiting. Although the presence of NVP is unpleasant and can be somewhat debilitating, 
they may protect women from ingesting substances that could potentially damage the 
embryo during the crucial stages of embryogenesis or organogenesis.27 Due to its 
common occurrence, the onset of NVP symptoms often is the first indicator to a woman 
that she is pregnant. Any delay in the onset of symptoms may delay a woman’s actions to 
make necessary behavioral changes to protect her embryo.25 In spite of the many theories 
that have been generated to explain early pregnancy symptoms, the etiology of NVP 
remains unclear. The secretion of human chorionic gonadotropin (hCG) and the rapid rise 
in its levels in the first trimester have been proposed as the most likely contributors to 
NVP.2, 28  It was demonstrated that presence of symptoms during early 
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pregnancy has a protective effect on the health of the growing fetus, where various 
mechanisms have been proposed to explain the feto-protective effect of NVP symptoms; 
this included the reduction of fetal exposure to potential teratogens present in the 
mother’s diet, a decrease in energy intake that elicits hormonal changes to stimulate early 
placental and fetal growth, and other nutritional and non-nutritional pathways.29   
In a comprehensive review by Gadsby et al.30 on the timing of onset, duration, 
and severity of NVP, the authors found that symptoms of nausea and vomiting episodes 
in pregnancy began between the fourth and seventh week after the last menstrual period 
(LMP) in 70% of women; however, a small proportion (7%) noted NVP symptoms prior 
to their missed menstrual period. Women in this study population reported symptom 
onset before nine weeks’ gestation, and decrease in symptoms was noted in 30% by the 
10th week, another 30% by the 12th week, and the last 30% by 16th week. An analysis of 
the 24-hour variation in NVP in this study demonstrated that symptoms occurred 
commonly between 6 am and noon, but symptoms were experienced by many women 
throughout the day. While most studies did not examine the natural 24-hour variation in 
NVP symptoms, these studies provided further confirmation that  onset of NVP is early 
in the gestational period; however, the duration and severity of the symptoms varied 
between the studies.8, 31, 32  
While most women’s experiences with NVP symptoms are restricted to early 
pregnancy; approximately 20% of pregnant women continue to experience the symptoms 
beyond 20 weeks gestation.1 Data from an earlier study indicated NVP in late pregnancy 
resulted in lower prenatal weight gains and lower infant birth weight, although this study 
focused only on pregnant teenagers.33 In a small study of Midwestern women receiving 
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care from prenatal care clinics in their first trimester, 70% of women reported 
experiencing symptoms of nausea and vomiting during the early gestational period; 
however, 32% continued to have NVP symptoms past the first 20 weeks. Women with 
late NVP tended to be older, had higher parity, and gained less weight in the pregnancy 
than women who did not experience late NVP.34  
The most severe form of NVP, hyperemesis gravidarum, affects 0.5%-2% of 
pregnancies, and it is one of the most common reason for hospitalization in pregnancy, 
second only to preterm labor.35 Hyperemesis gravidarum is a diagnosis of exclusion 
based on a typical presentation in the absence of other disorders that could explain the 
findings. Despite a lack of uniform definition of hyperemesis gravidarum, persistent 
vomiting, dehydration, ketonuria, electrolyte disturbance, and weight loss greater than 
5% are the usual criteria.36     
2.1.2 Risk factors or markers for NVP 
Symptoms of NVP begin typically at two to four weeks gestation;30, 37 generally 
peak in intensity between 8 and 12 weeks, and subside by 20 weeks’ gestation.37-39 To 
date, no confirmed predictors of NVP has been established; however, a few previous 
studies found that the presence of NVP is associated with older maternal age, occupation 
such as manual or service workers, cigarette smoking, and infant gender.3, 5, 39 However, 
other studies yielded conflicting results on these factors.31, 40 Furthermore, chronic 
illnesses such as hypertension, liver and renal diseases,40 maternal hormones,41vitamin 
use,32 gravidity, plurality, increasing number of prior miscarriages,42 and stress43 have 
also shown to be predictors for NVP.   
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2.2 Nausea and vomiting in early pregnancy & spontaneous abortion 
2.2.1 Spontaneous abortion 
Spontaneous abortion (SAB) or miscarriages are pregnancies that are lost prior to 
20 completed weeks’ gestation from the first day of the LMP. Although between 10%-
12% of pregnancies that are identified resulted in SAB, the proportion of losses that take 
place prior to six weeks’ gestation may be two to three times higher.22 Pregnancy loss can 
be stressful and traumatizing for some women and women who experience a pregnancy 
loss may exhibit symptoms of distress such as depression, anxiety, and prolonged grief.44-
46
 Advanced maternal age and history of previous SABs are the strongest predictors for 
SAB;9, 10 other potential risk factors include the presence of uterine fibroids,47, 48 
incompetent cervix,49 occupational chemicals,15 cigarette smoking,11 caffeine 
consumption,12-14 drinking water disinfection by-products16 
2.2.2 The association between NVP and SAB 
The role of NVP has been examined in a few previous research studies in relation 
to pregnancy outcomes. Several studies have found that symptoms of NVP are strongly 
associated with a decreased risk of SAB.3-5 Tierson et al.4 examined the patterns of NVP 
on pregnancy outcome and reported that while 90% of the study population experienced 
some form of NVP symptoms during pregnancy, the 10% of women who had no 
symptoms of NVP had a higher incidence of SAB. A meta-analysis was performed on 11 
previous studies to examine the effects of NVP on the risk of SAB.8 The authors found 
that the presence of NVP were significantly associated with a decreased risk of 
miscarriage.  
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Although much previous research found consistent association between positive 
pregnancy outcome and the presence of NVP symptoms during pregnancy, one study 
found a difference in pregnancy outcome dependent the severity of NVP. In this 
retrospective cohort study of women in a large city on the West Coast, Weigel and 
Weigel7 did not find any association of NVP with pregnancy outcomes such as perinatal 
death, fetal anomalies, preterm delivery, and low birthweight. However, symptoms of 
nausea and accompanying vomiting episodes were associated with a decreased risk of 
SAB (adjusted OR=0.18, 95%CI: 0.06, 0.53), but women with nausea symptoms without 
any vomiting episodes had a miscarriage risk equal to that in the overall study population 
(adjusted OR=0.32, 95%CI: 0.15, 0.68). Results from a prospective cohort study on 
Ecuadorian prenatal patients confirmed previous findings that women who experienced 
nausea only (adjusted OR= 0.45, 95%CI: 0.22, 0.94) and those who experienced nausea 
with vomiting had a decreased risk of spontaneous abortion (adjusted OR=0.66, 95%CI: 
0.46, 0.99).50 Selected studies on the risk factors of NVP and its association with SAB are 
detailed in Tables 1 and 2. Figure 1 is a Directed Acyclic Graph (DAG) which provides a 
visual diagram on the causal relationship between NVP and SAB, along with covariates 
of interests;51, 52 each linked covariates by arrows represents direct causal effects, either 
protective or causative, of one variable on another. Maternal demographics such as 
race/ethnicity, education, marital status, and age have been known to influence maternal 
health behaviors during pregnancy. Maternal age at the time of pregnancy and parity may 
impact a woman’s symptoms of NVP. Women with certain maternal demographic 
characteristics may be more prone to experience prior pregnancy losses. Prior SABs, 
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woman’s age at menarche, parity, maternal health behaviors may cause SAB in a 
woman’s “current” pregnancy.  
2.3  An application of propensity score methods in studying maternal health 
exposures and behaviors in pregnancy health  
2.3.1 The use of observational study data and propensity score methods 
The goal of many epidemiologic studies is to estimate the causal effect of some 
specific exposures on a health outcome,53 and reproductive and perinatal health studies 
are no exception. Investigators often rely on the use of observational research data for 
estimating causal effects; causal interpretation from observational data is complicated 
because exposure groups may differ systematically with respect to relevant observed 
covariates and, therefore, may not be directly comparable and such differences may lead 
to biased effect estimates. 17-20 Traditional covariate adjustments may not be sufficient to 
correct this bias in estimation; propensity score methods have been named as another 
approach to control confounding and reduce bias in observational data.  
The concept of propensity scores has been used in pharmacoepidemiology and 
other disciplines, but reproductive and perinatal epidemiologic studies have been slow to 
adopt this method. Propensity score was developed by Rosenbaum and Rubin23 to reduce 
bias in observational studies. In theory, the effect of an exposure can be measured among 
individuals with the same probability of being exposed, thus allowing control for 
confounding; individuals with the same propensity score have the same chance of being 
exposed even though in truth some were and some were not. Therefore, this method is 
often conceptualized “virtual randomization” and a useful tool to evaluate maternal 
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exposures and outcome relationships where randomization to specific exposures is not 
ethical. 
2.3.2 Propensity score 
Under the assumption of strongly ignorable treatment or exposure assignment, a 
propensity score is defined as the conditional probability of exposure to a potential risk 
factor given an individual’s set of observed covariates.23 Each individual has a vector of 
observed covariates measured at baseline, Xi and an indicator of exposure, Zi, where Zi 
=1 if exposed and Zi  = 0 if unexposed. The propensity score, e(Xi), is the probability of 
exposure for a person with covariates Xi, that is,  
 
    e(Xi) = P(Zi =1 | Xi = xi), 
 
where we assume that Zi , i =1, and the number of study subjects are independent 
conditional on X. It is a function of the observed covariates X such that the conditional 
distribution of X given the propensity score e(Xi) is the same for subjects with Zi = 1 and 
Zi =0. The propensity score is estimated from observed data using logistic regression.17 
Individuals with the same estimated propensity score are thought to have the same 
probability of being exposed, although they may have different sets of X’s.   
2.3.3 An example: Caffeine and the risk of SAB 
 While most sources of caffeine comes from coffee and that coffee drinking in 
many countries and societies is common, it is considered a harmless habit in many 
countries. However, caffeine is a central nervous system stimulant known to cross 
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placental membranes and the blood-brain barrier during pregnancy,54 slower in 
metabolism later in gestational age during pregnancy,55, 56 potential to influence cellular 
development by increasing cAMP,57 and the interference with utero-placental circulation 
with increased catecholamines.58 Because of the properties of caffeine, its use by 
pregnant women has generated much controversy in the past 30 years. Some earlier 
epidemiologic studies have implicated caffeine as a risk factor for adverse pregnancy 
outcomes such as preterm birth,59 birth defects,26 fetal death (>20 weeks’ or >140 days’ 
gestation),60, 61 and small-for-gestational-age.62 Despite many studies in recent decades 
that evaluated the association between caffeine exposure and SAB,12-14, 60, 63-68 these 
studies and others showed conflicting results due to methodological limitations.21 
Consequently, this poses a major challenge to the interpretation of results from previous 
studies. For example, in a prospective cohort study in New Haven, the researchers found 
that the odds for SAB was 2.6 times (95%CI: 1.3, 5.3) higher for women who consumed 
>300 mg/day than those who were non-consumers.63 Bech60 and Tolstrup 66 found a 
positive association between caffeine exposure and SAB in their respective studies, but 
the magnitude of association was not quite as high that found in the New Haven study. In 
the Danish National Birth Cohort study,60 women who consumed ≥8 cups of coffee had 
1.5 times (95%CI: 1.0, 2.2) and 2.3 times (95%CI: 1.3, 3.9) the average hazard for SAB 
in <140 days gestation and between 140-195 days gestation respectively. A recent 
published study showed very little to no evidence overall that caffeine consumption 
increases the risk of SAB, despite the study’s use of prospective cohort data and 
evaluated caffeine exposure at three time points.24 However, a different study that was 
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published in the same year yielded conflicting results.69 A summary of epidemiologic 
studies that evaluated the association between caffeine and SAB is shown in Table 3. 
 
2.4 Limitations of prior studies 
2.4.1 Limitations in studying SAB 
Early stages of development are crucial to the survival of an embryo developing 
into a healthy fetus; many pregnancies that result in losses typically occur prior to 20 
completed weeks’ gestation with many losses occurring right before a woman is aware of 
her pregnancy. Because of the difficulties in recognizing pregnancies and pregnancy 
losses, many epidemiologic studies that are designed to recruit participants at a later 
gestational age would have missed ascertaining relevant information from women who 
already experienced pregnancy losses. This consequently leads to a major methodological 
issue known as left truncation, which resulted because of a selection process in the study 
design. Left truncation is of special concern when we have subjects who had the event of 
interest (i.e. pregnancy loss) but are not in the study.70, 71 SAB data are often left 
truncated due to the high prevalence of unplanned pregnancies, high proportion of loss 
experienced by the source population prior to enrollment into study, and study subjects 
for SAB studies are commonly recruited after conception; therefore, the true cohort of 
pregnant women cannot be known and many women who experience pregnancy loss 
generally would have lost their pregnancies before they are even aware that they were 
pregnant, or that they first become aware of their pregnancy at the time of the loss. For 
this reason, many women who otherwise would have been eligible in the study are left 
out in the analysis data set because they have already experienced the event. 
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While many methodological limitations are unique to the studies on the effect of 
NVP symptoms on the risk of SAB and the effect of caffeine exposure on SAB, another 
possible limitation to studying SAB is the potential inaccuracy in gestational age dating. 
Estimated gestational age is determined based on the first day of a woman’s LMP or with 
the use of ultrasound. Errors in gestational age dating can occur as a result of recall error, 
where a woman is unable to recall the exact date of her last menstrual period and she 
makes up a date, or she is asked to recall in which week of the month she had her last 
menstrual period. Self-reported or assigned LMP can lead to digit preference.72, 73 Error 
in estimating gestational age can also be influenced by the time in which ultrasound is 
used for pregnancy dating. Because assessment of gestational age using ultrasound is 
shown to be more accurate for a younger pregnancy relative to an older pregnancy, the 
timing in which ultrasound is used for pregnancy dating can influence the assignment of 
gestational age relative to a pregnancy’s true age. Regardless of the sources of errors, 
inaccuracy in the dating of pregnancy age can lead to potential inaccuracy in dating 
exposure or potentially misclassifying an early pregnancy loss that takes place close to 
the cutpoint, by definition of SAB, as a fetal demise. 
 
2.4.2 Limitations of previous NVP studies 
Although findings from some previous research on the effects of NVP on SAB 
showed fairly consistent results, methodological limitations could have potentially biased 
the estimates. Often, these previous research were conducted using retrospective cohort 
and case-control study designs,35-38 with the exception of the Early Pregnancy Study,38 
the Diana Project,74 and the Ecuadorian study,50 where the reproductive outcomes were 
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examined prospectively.  Retrospective cohort and case-control studies are subjected to 
exposure misclassification, especially when studies recruit women in later gestation 
which would bias the effect estimates.  Exposures could also be non-differentially or 
differentially misclassified depending whether women with pregnancy losses recall past 
exposures more accurately in comparison to women with no history of pregnancy losses. 
The variability in the classification of exposure groups in previous studies may introduce 
non-differential misclassification which may generate either an underestimation or an 
overestimation on the effect of NVP symptoms in relation to SAB. 
Analytic techniques used in earlier studies posed additional challenges in studying 
the association between NVP and SAB. Most investigators utilized logistic regression to 
model the odds of NVP and SAB, even in prospective cohort studies;50, 74 while this 
method was suitable for some study designs, the use of logistic regression modeling did 
not take into consideration that women are observed to be at risk for SAB for varying 
lengths of time because they entered the studies at different gestational ages. Because 
logistic regression does not account for left truncation and assumes that follow-up time 
for all subjects are the same, it is especially problematic when the left truncation is 
differential with respect to exposure status; thus using logistic regression to analyze SAB 
data would create a biased estimate of effect. In addition to the limitations from study 
designs and analytic methods, the comparability of study results in earlier studies is 
further compromised, because the operational definitions of NVP varied across studies. 
Some studies utilized a dichotomous approach in categorization of NVP symptoms, while 
other studies categorized NVP ordinally. Those that coded NVP data as “any versus 
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none” did not take into account symptom severity, duration, or timing of onset of the 
symptoms.  
 
2.4.3 Limitations of previous caffeine exposure studies 
Methodological limitations in previous studies on the association between  
caffeine exposure and SAB have hampered the interpretation of earlier findings. Few 
major methodological issues included exposure assessment, quantifying caffeine 
exposure, and identification of pregnancy symptoms.  
 
Exposure assessment 
 Caffeine consumption generally changes drastically when a woman becomes 
pregnant. The decrease in intake may be due to the advice of clinicians or in response to 
an increase in olfactory sensitivity or the presence of pregnancy symptoms such as NVP. 
Consequently, ascertaining information on caffeine intake during pregnancy is inherently 
more difficult. Because many pregnant women modify their behavior during the course 
of the pregnancy, it is not enough to elicit a single measurement to capture true caffeine 
intake; nevertheless, many earlier studies have done so.68, 75-77 Only a handful of studies 
attempted to incorporate temporal changes in caffeine intake. Despite this approach, a 
number of studies ascertained information on change in consumption, if applicable, and 
then computed an average consumption value.14, 64, 76, 78 While this form of exposure 
assessment is a slight improvement over single exposure measurement over the course of 
the pregnancy; nevertheless, this approach is not robust enough to capture multiple 
changes in consumption over the course of the pregnancy. 
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Quantifying caffeine exposure 
 The amount of caffeine present in a beverage depends on the method of 
preparation and the beverage cup size. Only a small number of prior studies took 
caffeinated beverage preparation method65, 76 into consideration and a few studies 
collected information on beverage cup size.65, 76, 79 The range of caffeine assigned to each 
caffeinated beverage has been inconsistent across studies; depending on a study’s 
methods in quantifying caffeine exposure, the absolute caffeine intake of an individual 
based on the reported amount in one study may be different in another. This large 
variability in quantifying caffeine exposure often leads to measurement error and make 
comparing results across studies difficult.  
 
Accounting for pregnancy symptoms 
NVP, a common type of pregnancy symptoms, often causes pregnant women to 
develop aversions toward specific foods, drinks, tastes, or smells, leading to potentially 
drastic lifestyle and behavioral modification during the course of viable pregnancy, while 
women with non-viable pregnancies may carry on with pre-pregnancy behavior because 
such behavior is not deterred by pregnancy symptoms. Caffeine exposure assessments, in 
most studies, are likely to take place after changes have already been made under the 
influence of NVP; women who retained their pre-pregnancy behavior (i.e. caffeine 
intake) in light of the absence of NVP symptoms could be interpreted as causally linked 
to SAB. Therefore, it is unclear to what extent is caffeine exposure truly affecting the 
pregnancy outcome or if the exposure-outcome relationship is an artifact of NVP. One 
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review21 uncovered studies on caffeine exposure and SAB often did not take NVP into 
consideration because data 1) were not collected 63, 66, 75, 80, 81, 2) were collected but were 
incomplete60, or 3) were not incorporated into the analysis.64, 79 While many studies that 
examined caffeine exposures and SAB often failed to take into consideration NVP 
symptoms, those that attempted only had done so simplistically. Because of 
methodological limitations in earlier studies, particularly in failing to address 
confounding by NVP symptoms, the interpretation of results from previous studies on the 
effects of caffeine and SAB is further limited.  
    
2.5 Contribution of the proposed research 
The proposed study addressed some of the limitations in prior research by using 
data from the Right from the Start (RFTS) study to 1) identify potential risk factors for 
NVP, 2) examine the association between NVP and spontaneous abortion, and 3) 
examine the effect of caffeine exposure at three time points and SAB. Because most 
pregnancy losses are concentrated in the earlier weeks of gestation, studies of SAB are 
often challenging, primarily due to the difficulty in identifying women early in 
pregnancy. The protocol of RFTS called for the identification of women early in their 
pregnancy (<12 completed weeks gestation) or women who were trying to conceive; 
therefore, we were able to successfully track the course of pregnancy events and 
outcomes for all study participants. With a prospective study design, we were able to 
collect detailed information on maternal behaviors and exposures in early weeks of 
gestation. We were able to follow-up and confirm pregnancy losses through participant 
self-report and medical record abstraction, and for other pregnancy outcomes via 
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participant self-report, medical record abstraction, and linkages of vital fetal death 
records.   
Nausea and vomiting in early pregnancy was classified based on symptom 
severity, time of onset, and duration. Caffeine exposure was classified as caffeine from 
coffee only and caffeine from caffeinated coffee, caffeinated iced and hot tea, and 
caffeinated sodas. Pregnancy outcomes, including SABs, were ascertained in the parent 
study through three mechanisms which included participant self-report, medical record 
abstraction, and matching of vital records data. Estimated gestational age was assigned 
based on the women’s last menstrual period or assessed with the use of endovaginal 
ultrasound dating.  
Modified Poisson regression with robust variance was used to model the log risk 
of maternal age, maternal race/ethnicity, marital status, education, smoking, alcohol use, 
pregnancy loss history, plurality, parity, and age at menarche as potential risk factors for 
NVP. Discrete hazard models were fitted to examine the association between NVP and 
SAB, with maternal age, maternal race/ethnicity, education, marital status, education, 
smoking, alcohol use, age at menarche, parity, plurality, and SAB history as potential 
effect measure modifiers and/or potential confounders. We used the example of caffeine 
intake and SAB to illustrate the application of propensity score methods in observational 
study data. These improved study features and the application of more sophisticated and 
appropriate analytic methods allowed us to produce a more valid magnitude of 
association and for us to account for the time-varying outcome that was not considered in 
the analyses of earlier research studies.  
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Table 1. Selected literature on studies of risk factors or markers influencing nausea and vomiting in early pregnancy 
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Risk factors or 
markers examined for 
NVP 
Assessment of NVP 
symptoms 
Main findings 
O’Brien 
(1995) 
Design: Cross-sectional 
Population: pregnant  
women who sought 
prenatal care <16 weeks in 
three Midwestern clinics  
Study subjects: 147 
Maternal age, 
Education, 
Parity, 
Occupation, 
Cigarette smoking, 
Other demographic 
characteristics (not 
reported) 
Measurement collected via 
questionnaire on NVP: 
Occurrence, 
Duration,  
Frequency, 
Amount,  
 
Maternal age,  
Occupation (working 
outside home), 
Parity, 
Cigarette smoking, 
Infant gender 
 
 
 
 
 
Zhang 
(1999) 
Design: Case-control 
Population: Sample of 29 
hospitals in Shanghai, 
China. Cases-perinatal 
deaths; controls-live births 
born around time of the 
case  
Study subjects: 1,875 
cases, 1,875 controls 
Chronic hypertension, 
Chronic liver disease, 
Chronic renal illness, 
Passing smoking, 
Maternal age, 
Gravidity 
 
Measurement of vomiting 
only; ascertained from 
prenatal care card 
Chronic hypertension, 
Chronic liver disease, 
Chronic renal illness, 
Passing smoking 
 
 
 
 
 
Zhou 
(1999) 
Design: Secondary data 
analysis from a RCT 
Population: Volunteers 
recruited through 
newspaper advertisement 
for RCT to evaluate the 
efficacy of P6 acupressure 
on NVP 
Study subjects: 103  
Maternal age, 
Previous SAB, 
Parity, 
Employment status, 
Infant gender, 
Infant birthweight 
Measurement on NVP 
severity from mail 
questionnaire   
Infant birthweight  
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Table 1 (cont). Selected literature on studies of risk factors or markers influencing nausea and vomiting in early pregnancy 
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Risk factors or 
markers examined for 
NVP 
Assessment of NVP 
symptoms 
Main findings 
Källén 
(2003) 
Design: Prospective cohort 
Population: Women 
seeking care in prenatal 
care clinic in Sweden 
Study subjects: 3,675 
women  
Maternal age,  
Parity, 
Cigarette smoking, 
Occupation, 
Vitamin use 
Measured via questionnaire 
for NVP severity (none, 
nausea only, both), number 
of times per day, and 
symptom duration 
Maternal age, 
Parity, 
Occupation (worked 
outside home), 
Vitamin use 
 
 
   
Lagiou  
(2003) 
Design: Prospective cohort 
Population: Boston women 
who participated in study 
on breast cancer among 
White and Asian women 
Study subjects: 402 
Prolactin, 
Estradiol,  
E3, 
Sex hormone-binding 
globulin, 
Progesterone 
Measured via self-report 
interview on NVP severity 
(none, nausea only, both) 
 
 
 
Prolactin, 
Estradiol 
 
 
 
 
 
Louik 
(2006) 
Design: Case-control 
Population: Birth defects 
surveillance of The Slone 
Epidemiology Center at 
Boston University. Cases-
women with infants with 
congenital malformations; 
controls-women with live 
birth in greater 
metropolitan areas of 
Boston, Philadelphia, 
Toronto, and San Diego 
Study subjects: 17,158 
cases, 5,329 controls 
Plurality, 
Gravidity, 
Planned pregnancy, 
Education, 
Maternal age, 
Maternal race/ethnicity, 
Income ($/year), 
Cigarette smoking, 
Pre-pregnancy weight, 
Obstetrics 
characteristics 
 
Measured via interview 
where  
1)  NVP asked as 
single event   (1988-
1992) 
2) Nausea and 
vomiting asked as 
separate entity (>1992)  
 
in terms of occurrence 
(yes/no), duration, and time 
of onset 
Maternal age, 
Maternal race/ethnicity, 
Gravidity, 
Pre-pregnancy weight 
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Table 2. Summary of selected epidemiologic studies examining the association between nausea and vomiting in early pregnancy and spontaneous 
abortion.  
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of NVP 
symptoms  
Covariates adjusted for in 
multivariable model(s) 
Main findings 
Adjusted ORs or RRs 
(95%CI) 
Klebanoff 
(1985) 
Design: Prospective cohort  
Population: 56,000 
pregnancies from 
Collaborative Perinatal 
Project 
Study subjects: 9,098 
primiparous women 
enrolled in CPP within 14 
weeks’ gestation   
Measured occurrence 
of vomiting since LMP 
Maternal age, 
Maternal race, 
Education, 
Gravidity, 
Cigarette smoking, 
Pre-pregnancy weight 
OR=0.7, p=0.002  
(no 95% CI reported) 
 
 
 
 
 
 
Tierson 
(1986) 
Design: Prospective cohort 
Population: Women with 
singleton pregnancies in 
Albany, NY 
Study subjects: 414 
Measured occurrence 
of NVP, onset and stop 
dates, and time of day 
in occurrence during 
interviews that took 
place at 12, 16, 20, 30, 
and 38 weeks 
None reported Study reported that 
women with no 
symptoms of nausea 
and/or vomiting 
experienced 
significantly greater 
proportion of SABs 
(p<0.0015). No 
adjusted estimates 
reported.   
 
 
 
 
 
Weigel 
(1985) 
 
Design: Meta-analysis 
Population: N/A  
Study subjects: 10 
previous studies 
N/A N/A OR=0.4 (0.3, 0.4) 
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Table 2 (cont). Summary of selected epidemiologic studies examining the association between nausea and vomiting in early  
pregnancy and spontaneous abortion.  
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of NVP 
symptoms  
Covariates adjusted for in 
multivariable model(s) 
Main findings 
Adjusted ORs or RRs 
(95%CI) 
Weigel 
(1989) 
Design: Retrospective 
cohort 
Population: Women with 
singleton births and 
delivered at UCLA 
Study subjects: 873 
Measured occurrence 
of NVP since LMP at 
intake interview, and 
NVP since last visit at 
subsequent interviews 
Maternal age, 
Maternal race/ethnicity, 
Housewife status, 
Anti-emetic medication 
Nausea only: 
OR=0.32 (0.2, 0.7) 
 
Nausea with vomiting: 
OR=0.2 (0.1, 0.5) 
 
 
   
Weigel 
(2006) 
Design: Prospective cohort  
Population: Women in 1st 
trimester of pregnancy and 
planned to have prenatal 
care and delivery at the 
Hospital Patronato 
Municipal San Jose in 
Quito, Ecuador 
Study subjects: 849  
Measurement 
occurrence, timing, 
intensity, peak and 
duration for nausea and 
vomiting at two time 
intervals (~11 weeks 
and weeks 24 to 28)  
Maternal age, 
Neighborhood altitude, 
Cigarette smoking, 
Alcohol consumption, 
Antiemetic drugs, 
Vitamin-mineral 
supplements 
Nausea only: 
OR=0.5 (0.2, 0.9) 
 
Nausea with vomiting: 
OR=0.7 (0.5, 1.0) 
 
Did not examine NVP 
with respect to its 
timing, intensity, peak, 
and duration 
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Figure 1. Directed Acyclic Graph showing causal relationship between nausea and vomiting in early pregnancy and spontaneous 
abortion, Right from the Start (2000-2004)  
 
 
 
 
 
Symptoms of NVP during 
early pregnancy 
Spontaneous abortion 
Maternal 
age 
Maternal health 
behaviors  
-smoking 
-alcohol use 
? 
Race & 
ethnicity 
Marital 
status 
Age at 
menarche 
Parity 
Previous 
SAB 
Education 
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Table 3. Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.  
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of NVP 
symptoms 
Covariates adjusted 
for in multivariable 
model(s) 
Main findings 
Adjusted ORs or RRs 
(95%CI)  
Axelsson 
(1989) 
Design: Retrospective 
cohort 
Population: Women 
employed at Swedish 
hospital between 1980 and 
1984 
Study subjects: 769 
Coffee consumption 
ascertained in cups for 
before and during 1st 
trimester of pregnancy 
None collected  Coffee before 
pregnancy: 
>3 cups/day 
OR=1.3 (1.0, 1.8) 
Coffee during 1st 
trimester: 
>3 cups/day 
OR=1.6 (1.1, 2.3) 
 
 
    
Fenster 
(1991) 
Design: Case-control 
Population: Residents of 
Santa Clara, CA with SAB 
by 20 weeks’ gestation 
Study subjects: 607 cases, 
1,284 controls   
Cases asked of events 
during entire 
pregnancy; controls for 
the first 20 weeks 
 
Caffeine consumption 
(coffee, tea, and soda) 
Measured as “any” 
versus “none” 
 
Did not incorporate into 
analysis 
Maternal age, 
Maternal race, 
Marital status, 
Insurance coverage, 
Cigarette smoking, 
Alcohol 
consumption, 
Previous SAB,  
Previous therapeutic 
abortion 
Total caffeine: 
>300 mg/day 
OR = 1.2 (0.8, 1.9)   
 
 
 
 
  
Kline 
(1991) 
Design: Case-control 
Population: Cases-
identified in both public 
and private facilities of 
NYC hospital; controls-
women registered for 
prenatal care in same 
facilities 
Study subjects: 899 cases, 
1,462 controls 
Information collected 
during interview on 
caffeine consumption 
(coffee, tea, cocoa, and 
sodas) for “during 
pregnancy” and “peri-
fertilization” (2 mos 
before and 1 mos after 
LMP).  
Collected but did not 
specify symptom 
classification 
 
Did not incorporate into 
analysis 
Maternal age, 
Maternal ethnicity, 
Cigarette smoking, 
Alcohol consumption 
Total caffeine: 
>225mg/day during 
preg 
(normal karyotype) 
OR=1.9 (1.3, 2.6) 
 
>225mg/day during 
preg 
(abnormal karyotype) 
OR=1.6 (1.1, 2.3) 
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Table 3 (cont). Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.   
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of NVP 
symptoms 
Covariates 
adjusted for in 
multivariable 
model(s) 
Main findings 
Adjusted ORs or RRs 
(95%CI)  
Parazzini 
(1991) 
Design: Case-control 
Population: Cases with ≥2 
SABs and no term 
pregnancy; controls were 
women admitted for normal 
delivery 
Study subjects: 94 cases, 
176 controls 
Single assessment of 
coffee intake during 
pregnancy  
None collected  Coffee 
during  pregnancy: 
Any coffee 
OR=1.4 (0.7, 2.6) 
 
 
    
Infante-Rivard 
(1993) 
Design: Case-control 
Population: Cases-fetal 
loss and controls with 
normal pregnancy in 
obstetric & pediatric 
hospital in Montréal, 
Quebec  
Study subjects: 331 cases, 
993 controls 
Information on caffeine 
consumption (coffee, 
tea, and cola) before 
pregnancy and during 
pregnancy collected via 
in-person interview of 
both cases and controls 
None collected Period of 
pregnancy, 
Maternal age, 
Education, 
Cigarette smoking, 
Alcohol 
consumption,  
Uterine 
abnormality, 
Work schedule 
Total caffeine 
 (before preg): 
48 to 162 mg/day 
OR = 1.3 (0.9, 2.0) 
163 to 321 mg/day 
OR=1.4 (0.9, 2.0) 
>321 mg/day 
OR =1.9 (1.2, 2.9) 
 
(during preg): 
48 to 162 mg/day 
OR = 1.2 (0.8, 1.6) 
163 to 321 mg/day 
OR=2.0 (1.3, 2.9) 
>321 mg/day 
OR =2.6 (1.4, 5.0) 
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Table 3 (cont). Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.   
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of NVP 
symptoms 
Covariates adjusted 
for in multivariable 
model(s) 
Main findings 
Adjusted ORs or 
RRs (95%CI)  
Dlugosz 
(1996) 
Design: Prospective cohort 
Population: Women 
planning to deliver at Yale-
New Haven Hospital 
Study subjects: 2,849 
Caffeine consumption 
(coffee, tea, and soda) 
collected via interview 
before 16 weeks’ 
gestation 
 
Total caffeine derived 
by: 
-107mg/cup (coffee) 
-34 mg/cup (tea) 
-47 mg/can (soda) 
None collected Maternal age, 
Maternal race/ethnicity, 
Education, 
Gravidity, 
Parity, 
Cigarette smoking, 
Alcohol consumption, 
Prior SAB, 
Prior TAB, 
Pre-pregnancy weight, 
Age at menarche 
Total caffeine: 
1-150 mg/day 
OR=0.81 (0.5,1.2) 
151-300 mg/day 
OR=0.89 (0.5,1.6) 
>300 mg/day 
OR=1.8 (0.9, 3.5) 
 
Coffee: 
≥3 cups/day: 
OR = 2.6 (1.3, 5.3) 
      
Fenster 
(1997) 
Design: Prospective cohort 
Population: Women 
receiving health care at 3 
Kaiser Permanente facilities 
in CA  
Study subjects: 5,144 
pregnant women 
1st trimester interview on 
caffeine consumption 
(coffee, tea, and soda, 
cups or cans/day) before 
and during pregnancy 
 
Total caffeine derived 
by: 
-107mg/cup (coffee) 
-34 mg/cup (tea) 
-47 mg/can (soda) 
Measured as “any” 
versus “none” 
 
Did not incorporate 
into analysis 
Maternal age, 
Maternal race, 
Pregnancy history, 
Cigarette smoking, 
Alcohol consumption, 
Employment, 
Gestational age at 
interview, 
Marital status, 
Socioeconomic status 
Total caffeine: 
>300mg/day during 
preg 
OR=1.3 (0.8, 2.1) 
>300mg/day before 
preg. 
OR=1.3 (0.9, 1.7) 
 
Coffee: 
2 cups/day before preg 
OR=1.1 (0.8, 1.5) 
≥3 cups/day before 
preg 
OR=1.1 (0.8, 1.6) 
2 cups/day after preg 
OR=1.5 (1.0, 2.2) 
≥3 cups/day after 
preg 
OR=0.8 (0.4, 1.7) 
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Table 3 (cont). Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.   
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of 
NVP symptoms 
Covariates adjusted 
for in multivariable 
model(s) 
Main findings 
Adjusted ORs or 
RRs (95%CI)  
Parazzini 
(1998) 
Design: Case-control 
Population: Cases-admitted 
for SAB in Milan; controls-
women who gave birth at 
term in same hospitals where 
cases were identified 
Study subjects: 782 cases, 
1,542 controls   
Caffeine consumption 
(coffee, tea, and cola) 
was collected during 
interview 
Measured in terms 
of occurrence and 
intensity (none, low, 
moderate, or 
serious); only ~50% 
of study population 
had NVP data 
because collection 
started midway 
through study period 
Maternal age, 
Education, 
Previous live births, 
Previous SAB, 
Alcohol consumption, 
Cigarette smoking, 
Nausea intensity in 1st 
trimester 
Coffee: 
2-3 cups/day in 1st 
trimester 
OR=1.8 (1.2, 2.3) 
 
≥4 cups/day in 1st 
trimester  
OR=4.0 (2.6, 6.2) 
 
 
    
Cnattingius 
(2000) 
Design: Case-control 
Population: Cases-identified 
from Dept. OB/GYN at 
Uppsala University, Sweden; 
controls—antenatal clinics in 
Uppsala County 
Study subjects: 562 cases, 
953 controls 
Information on weekly 
caffeine consumption 
(coffee, tea, cocoa, 
chocolate, sodas, and 
medications), starting 4 
weeks before LMP until 
most completed week 
gestation  
Nausea (never, 
sometimes but not 
daily, daily but not 
all day, daily all 
day) 
 
Vomiting (never, 
sometimes but not 
daily, daily) 
 
Scores were 
assigned based on 
responses; 
multivariable 
analysis adjusted for 
presence/absence of 
NVP symptoms  
 
 
Maternal age, 
Cigarette smoking, 
Alcohol consumption,  
Gravidity 
History of SAB,  
NVP 
 
 
No overall main 
results 
 
Total caffeine 
among non-smokers: 
(normal karyotype) 
300-499 mg/day 
OR = 1.8 (0.8, 3.8) 
≥500 mg/day 
OR= 2.2 (0.8, 6.4) 
 
(abnormal karyotype) 
300-499 mg/day 
OR = 0.9 (0.5, 1.7) 
≥500 mg/day 
OR= 1.8 (0.8, 3.9) 
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Table 3 (cont). Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.   
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of NVP 
symptoms 
Covariates adjusted 
for in multivariable 
model(s) 
Main findings 
Adjusted ORs or 
RRs (95%CI)  
Wen 
(2001) 
Design: Prospective cohort 
Population: Women enrolled 
in HMO in Twin Cities, MN 
Study subjects: 650   
Caffeine consumption 
(coffee, tea, soda, hot 
chocolate, other foods 
with chocolate)  was 
collected via mailed-in 
monthly food frequency 
questionnaire 
 
-139.2 mg/cup (coffee) 
-64.0 mg/cup (tea) 
-46.0 mg/can (cola)  
Measured as nausea status 
“yes” vs. “no” and its 
duration (days) 
 
No measurement for 
vomiting episodes 
Found  no differences in 
association between 
unadjusted and adjusted 
analysis, only unadjusted 
RRs were presented 
Total caffeine 
With or without nausea: 
100-299 mg/day 
RR = 2.0 (1.0, 4.1) 
≥300 mg/day 
RR =2.5 (1.0, 6.4) 
 
With nausea: 
20-99 mg/day 
RR = 2.5 (0.5, 11.3) 
≥100 mg/day 
 RR =0.6 (0.1, 3.9) 
Without nausea: 
20-99 mg/day 
RR = 1.1 (0.4, 2.8) 
≥100 mg/day 
 RR =1.6 (0.6, 4.2) 
 
 
    
Giannelli 
(2003) 
Design: Case-control 
Population: Cases-nulliparous 
women with confirmed SAB 
in UK; controls-nulliparous 
women attended prenatal care 
Study subjects: 160 cases, 
314 controls 
Cases, on average, were 
interviewed 3 weeks after 
controls 
 
Measured caffeine 
consumption (coffee, tea, 
and cola) before and 
during pregnancy 
Measured occurrence and 
classified by severity: 
mild, moderate, or severe 
Maternal age, 
Nausea severity,  
Gestational age 
Total caffeine 
(during pregnancy): 
301-500 mg/day 
OR=1.9 (1.0, 3.6) 
>500 mg/day 
OR = 2.2 (1.1, 4.4) 
 
Coffee  
(during pregnancy): 
107-321 mg/day 
OR=2.2 (1.3, 3.6) 
>321 mg/day 
OR = 2.3 (1.2, 4.4) 
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Table 3 (cont). Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.   
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of NVP 
symptoms 
Covariates adjusted 
for in multivariable 
model(s) 
Main findings 
Adjusted ORs or 
RRs (95%CI)  
Tolstrup 
(2003) 
Design: Nested case-
control 
Population: Random 
sample from general 
population of Copenhagen, 
Denmark 
Study subjects: 303 cases, 
1,381 controls   
Caffeine consumption 
(coffee and tea) before 
pregnancy was 
collected at enrollment 
interview  
None collected Maternal age, 
Marital status, 
Cigarette smoking, 
Pregnancy history 
Total caffeine 
(before pregnancy): 
75-300 mg/day  
OR=1.3 (0.8, 2.1) 
300-500 mg/day 
OR= 1.5 (0.9, 2.4) 
501-900 mg/day 
OR= 1.4 (0.9, 2.4) 
>900 mg/day 
OR= 1.7 (1.0, 3.0) 
 
 
 
 
  
Bech 
(2005) 
Design: Prospective cohort 
Population: Danish 
National Birth Cohort 
Study subjects: 88,482 
Coffee consumption 
(number of cups 
drank/day) was 
collected during 
interview 
 
 
None collected Maternal age, 
Parity, 
Pre-pregnancy BMI, 
Cigarette smoking, 
Alcohol 
consumption, 
Socio-occupational 
status 
Coffee  
(during pregnancy): 
4-7 cups/day: 
HR=1.2 (0.9, 1.6) 
≥8 cups/day: 
HR =1.5 (1.0, 2.2) 
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Table 3 (cont). Summary of selected epidemiologic studies examining the association between caffeine consumption and spontaneous abortion.   
Reference 
(Year) 
Study design, study 
population, and data 
collection 
Assessment of caffeine 
consumption 
Assessment of 
NVP symptoms 
Covariates adjusted for 
in multivariable 
model(s) 
Main findings 
Adjusted ORs or RRs 
(95%CI)  
Savitz 
(2008) 
Design: Prospective cohort 
Population:  Women 
recruited from three US 
cities who were early in 
pregnancy or trying to 
conceive a pregnancy 
Study subjects: 2,407 
women with singleton 
pregnancies 
Caffeinated coffee, caffeinated 
iced tea, caffeinated hot tea, 
and caffeinated soda were 
collected at time of interview 
(number of cups, cup size, 
brewing methods, timing of 
change in consumption, 
consumption amount after 
change) 
 
Assessment at three time 
points: pre-pregnancy, four 
weeks post-LMP, and around 
time of telephone interview 
Symptoms of 
nausea and 
vomiting were 
collected 
separately for 
severity (NVP 
status), time of 
onset and stop 
dates 
Maternal age 
Maternal education 
Maternal race/ethnicity 
Marital status 
Alcohol use 
Vitamin use 
NVP 
Coffee 
(at time of interview) 
>0 to <200.8mg/day 
OR=1.2 (0.7, 1.9) 
≥200.8 mg/day  
OR=1.0 (0.6, 1.6) 
>372.9 mg/day 
OR=0.7 (0.3, 1.8) 
 
Total caffeine 
(at time of interview) 
>0 to <144.3 mg/day 
OR=1.0 (0.7, 1.4) 
≥144.3 mg/day 
OR=1.2 (0.9, 1.7) 
>273.2 mg/day 
OR=1.3 (0.9, 1.9) 
 
 
    
Weng 
(2008) 
Design: Population-based 
prospective cohort  
Population: Kaiser 
Permanente Medical Care 
Program members who 
resided in the San Francisco 
areas and who had a positive 
pregnancy test in a Kaiser 
facility 
Study subjects: 1.063 
Caffeinated coffee, caffeinated 
tea, caffeinated soda at the time 
of the in-person interview 
(types of drinks, timing of 
initial drink, frequency and 
amount of intake, whether 
changed consumption patterns 
since pregnancy, intake amount 
after change) 
NVP (yes/no) Maternal age 
Maternal race 
Maternal education 
Household income 
Marital status 
Smoking 
Alcohol use 
Jacuzzi use 
EMF 
NVP 
Caffeine 
<200mg/day 
aHR=1.4 (0.9, 2.2) 
≥200mg/day 
aHR=2.2 (1.3, 3.7) 
 
Coffee only 
<200mg/day 
aHR=1.2 (0.6, 2.2) 
≥200mg/day 
aHR =2.5 (1.2, 5.1) 
  
CHAPTER 3: METHODS 
 
3.1 Overview of Right from the Start study 
The Right from the Start (RFTS) study was a multi-site, prospective 
epidemiologic cohort study that recruited pregnant women and women, who were 
planning a pregnancy between 2000 and 2004 from three distinct metropolitan areas in 
three states, in prenatal care clinics and directly from the communities. The primary study 
aim of RFTS was to examine the effects of drinking-water disinfection by-products on 
SAB.82, 83 In the parent study, endovaginal ultrasound was used to collect information on 
the health of the fetus and telephone interviews were conducted at two time intervals to 
ascertain behavioral and relevant pregnancy-related information. Fibroid sub-study 
participants received additional endovaginal ultrasounds and participated in an additional 
telephone interview; whereas women in the blood trihalomethane biomarker study each 
completed a 24-hour water activity diary and provided the study with 12 mL of tap water 
from their residence and 10 mL of blood during a home visit.  
This study included 2,430 women whose pregnancies started between 2000 and 
2004 based on the LMP. Women included in this analysis were those who completed at 
least the baseline interview and had a valid last menstrual period date.   
Data on NVP symptoms were collected in the telephone interviews, before 16 
weeks’ and between 22-26 weeks’ gestation. All study participants were asked by 
telephone about their experiences with nausea symptoms. Information on vomitin
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episodes, if any, was ascertained only from women with symptoms of nausea. Symptom 
duration was recorded independently for nausea and vomiting and severity was asked in 
regard to vomiting episodes. Participant self-reports, medical records abstraction, and 
linkages with vital records were use to determine and to confirm pregnancy outcomes.  
Also, at the time of the telephone interview, information on daily consumption for 
“a typical week” was collected on coffee, iced and hot tea, and sodas. Questions were 
asked about all sources, including the number of cups consumed daily, beverage sizes, 
and brewing methods for coffee. We also collected information regarding changes in 
intake on each caffeinated beverage, if applicable, with respect to the timing of change 
and consumption amount prior to the change. 
 
3.2 Overview of proposed research using Right from the Start data 
With the data from RFTS study, we examined the risk factors or markers for the 
occurrence of NVP and evaluate the association between NVP and SAB. Additionally, 
we used this data to illustrate the application of propensity score models in pregnancy 
health research by applying the data and methods in studying the effects of maternal 
caffeine consumption and SAB. Maternal age, maternal race/ethnicity, marital status, 
education, cigarette smoking, alcohol use, parity, plurality, pregnancy loss history, and 
age at menarche were assessed as potential risk factors or markers for NVP. These 
predictors were chosen because they were shown in the literature as some of the known 
risk factors for NVP. Modified Poisson regression with robust error variance was applied 
to examine potential risk factors for NVP. Discrete-time hazard models were employed to 
describe the association between NVP and SAB, with covariates maternal age, maternal 
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race/ethnicity, marital status, education, cigarette smoking, alcohol use, age at menarche, 
parity, and previous pregnancy loss considered as potential effect measure modifiers or 
potential confounders. Finally, in the propensity score analysis, a subset of the covariates 
listed above was used to estimate the probability of caffeine use at three time points: pre-
pregnancy, four weeks post-LMP, and around the time of telephone interview. We then 
evaluated the association between caffeine exposure at three time points and the risk for 
SAB by using discrete-time hazard models. 
  
3.3 Study sites selection and participant recruitment 
3.3.1 Selection of study sites and study eligibility criterion 
Study sites for RFTS were chosen because of their differences in drinking water 
disinfection by-products (DBPs) characteristics. Women from three U.S. metropolitan 
cities (Raleigh, North Carolina; Memphis Tennessee; and Galveston, Texas) who were 
eligible to participate in this research study must have been 18 years of age or older and 
less than 12 completed weeks pregnant, or women between the ages of 18 to 45 and who 
were trying to become pregnant for less than six months. All participants lived within the 
city limits of the study sites and did not plan to move out of the study areas prior to 
delivery. For participants who were pregnant, they must have had a positive pregnancy 
test and must not have taken any medications prescribed to become pregnant. If she did 
not have a positive pregnancy test, she was not considered pregnant by the study until she 
notified the study staff with a positive pregnancy result. Additionally, participants must 
be able to speak, read, and write in English. If a participant met all eligibility criteria but 
had unknown date of LMP (last menstrual period), an ultrasound EGA (estimated 
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gestational age) was used to determine her eligibility. Summary of participant recruitment, 
enrollment, and women who are included in the final analysis are shown in Figures 2 to 4.83 
 
 
Figure 2. Recruitment and enrollment summary, Right from the Start (2000-2004)                     
Adapted from AwwaRF report (Savitz et al., 2005) 
 
 
 
 
 
Total Women Screened (n= 4066) 
Site 1 (n=1923)  
Site 2 (n=1479) 
Site 3 (n=664) 
 
Unknown Pregnancy  
Status (n=7) 
Site 1 (n=5) 
Site 2 (n=2) 
Pregnancy at Screening (n=2514) 
Site 1 (n=1068) 
Site 2 (n=961) 
Site 3 (n=485) 
 
Trying to Become Pregnant 
(n=611) 
Site 1 (n=325) 
Site 2 (n=217) 
Site 3 (n=69) 
Eligible for Interview 
n =2766 
Converted to Pregnancy (n=252) 
Site 1 (n=164) 
Site 2 (n=70) 
Site 3 (n=18) 
Completed Modified 
Baseline Interview (n=89) 
 
Completed Baseline Interview 
(n=2418) 
Others: 
Declined Interview (n=70) 
Contact Window Closed  (n=44) 
Excluded (n=113) 
Completed Modified 
Follow-Up Interview 
(n=196) 
Completed Follow-Up Interview 
(n=2066) 
Others: 
Declined Interview (n=18) 
Contact Window Closed 
(n=129) 
Excluded (n=9) 
Enrolled at Screening (n=3132) 
Site 1 (n=1398) 
Site 2 (n=1180) 
Site 3 (n=554) 
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Figure 3. Construction of analysis data set for aim 1 and aim 2 analyses: Right from the Start (2000-
2004). Adapted from AwwaRF report (Savitz et al., 2005)  
 
 
Figure 4. Construction of analysis data set for aim 3 analysis: Right from the Start  
(2000-2004). Adapted from AwwaRF report (Savitz et al., 2005) 
Invalid LMP (n=1) 
Of 2,507 Participants: 
-Completed Baseline Interview (n=2,418) 
-Completed Modified Baseline Interview (n=89) 
2,506 Participants: 
-Had valid LMP date 
Excluded because of multiple gestations 
(n=23) 
Repeated (2nd or 3rd) RFTS pregnancies 
(to maintain independence of 
observations) (n=69) 
Incomplete information on critical 
variables (n=7) 
2,407 unique 
participants included in 
analysis 
Of 2,507 Participants: 
-Completed Baseline Interview (n=2,418) 
-Completed Modified Baseline Interview (n=89) 
2,430 unique 
participants included in 
analysis 
Invalid LMP (n=1) 
Repeated (2nd or 3rd) RFTS 
pregnancies (to maintain 
independence of observations) 
(n=69) 
Incomplete information on critical 
variables (n=7) 
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3.3.2 Recruitment of potential study participants 
Several strategies were developed to facilitate the identification of potential 
participants and recruitment of participants—recruitment through medical practices and 
community-based recruitment. Cumulative result of RFTS recruitment strategies is shown in 
Figure 583 
Health 
department or 
medical center
(n=1,013, 
32.3%)
Referred by 
friend/family
(n=214, 6.8%)
Re-enrolled
(n=113, 3.6%)
Community 
promotion
(n=250, 8.0%)
Mailed letters
(n=97, 3.1%)
Drug stores
(n=212, 6.8%)
Prenatal care 
practices
(n=1,942, 
62.0%)
 
Figure 5. Recruitment sources for all study sites*, Right from the Start (2000-2004)                     
*Participants can be recruited from multiple avenues. Adapted from AwwaRF report (Savitz 
et al., 2005) 
 
Recruitment through medical practices  
Through collaborative relationships with 50 private obstetrics and gynecology clinics, 
public prenatal care sites including county health department clinics and university medical 
centers, RFTS study staff was able to identify and recruit women who sought preconception 
counseling, prenatal care services, or pregnancy testing, into the study. Study coordinators 
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worked with each medical practice to develop individualized plans for recruitment and 
collaboration to best accommodate the differences in clinic flow and patient populations 
amongst the practices. Brochures and fliers with information about the study were posted 
in the waiting rooms and examination rooms, and contact information for interested 
women was collected and then transferred to The University of North Carolina at Chapel 
Hill (UNC). In addition to displaying promotional materials, many clinics discussed 
RFTS with their patients; clinic staff collected contact information for all interested 
women to be faxed to the study office or forwarded their patient calls directly to the study 
office if a woman were interested in learning more about the study. Regardless of the 
mode of contact, study staff further explained the study and invited interested women to 
complete the screening interview. 
  
Community-based recruitment 
RFTS utilized multiple avenues in the communities to generate awareness about 
the study throughout the three study sites. Fliers with tear-off tables were regularly posted 
at local childcare facilities, grocery stores, public libraries, churches, drug stores, book 
stores, retail stores, beauty salons. Brochures and information cards were displayed at the 
waiting and examination rooms of pediatric and family practices, and promotional 
materials were also distributed by study coordinators at local health fairs and community 
events. Rebate coupons for home pregnancy test kits were available at local drug stores 
and eligible women who contacted RFTS and enrolled into the study redeemed a $5 
coupon. Letters describing the study and pregnancy test rebate were mailed to two target 
groups: new home owners in the study areas and women who delivered a child within the 
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past three years. All study-related promotional and information materials included the 
study’s toll-free telephone number and the study’s web site address for potential 
participants to contact the study staff. When women contacted RFTS study office, study 
staff provided information about the study, explained the study protocol and invited them 
to complete a screening interview to determine eligibility. 
 
3.4 Data collection 
3.4.1 Screening interview 
A short telephone screening interview was conducted with potential study 
participants to gather information (e.g. women’s date of birth, residential address, LMP, 
pregnancy status, pregnancy-related medication use) that was necessary to establish 
eligibility for RFTS study. If a woman was deemed eligible to participate in the study and 
she agreed to participate in RFTS, additional information was collected and an 
endovaginal ultrasound was scheduled.  
3.4.2  Participant consent 
The RFTS research team employed a vigorous consent process to ensure that all 
study protocols was explained thoroughly and that all potential study participants 
understood all parts of the study activities. All study participants provided a signed 
consent prior to their first trimester ultrasound or participating in any study activities. 
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3.4.3 Monetary and non-monetary participant incentives 
Study participants were eligible to receive numerous incentives from the study. 
The amount of incentives varies depending on the type of study activity completed by 
each participant in the main study and/or in one of the sub-studies. Incentives included 
six free pregnancy test kits for women who enrolled into the study while trying to 
conceive, one free endovaginal ultrasound to all newly pregnant women, and monetary 
incentives in varying amount for the completion of one and both telephone interviews 
($10 for baseline or $20 for modified baseline interview and $10 for follow-up or 
modified follow-up interview). An additional $10 was given to women who completed 
all study activities in the main study.  
3.4.4 First trimester endovaginal ultrasound 
 First trimester endovaginal ultrasounds were conducted around eight weeks’ 
gestation (median gestational age at ultrasound=9.3 weeks) by ARDMS® certified 
clinical sonographers, using state-of-the-art ultrasound technology. All clinical 
sonographers were required to attend study-specific training and a trained study staff 
reviewed all data collection forms and still images prior to data entry. We collected 
measurements on the gestational sac, yolk sac, fetal pole, and fetal heart rate for use in 
clinical pregnancy dating.  
3.4.5 Study telephone interviews 
Some sociodemographic information (e.g. maternal age, mother’s highest 
educational attainment, maternal race) were obtained during the screening interview. As 
part of the study activities, participants were asked to complete two telephone interviews 
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that took place at two different time intervals in the course of the study. The baseline 
interview took place around one to two weeks after the screening interview and no later 
than 16 completed weeks’ gestation. This interview ascertained information on a range of 
topics such as: 
 
 Employment history 
 Health behaviors (water, alcohol and caffeine consumption, tobacco and 
illicit drug use, physical activity, and time in pool, hot tubs, and Jacuzzi) 
 Water exposure characteristics 
 Current and previous reproductive histories (menstrual history, previous 
pregnancy history, time to conception, NVP, vaginal bleeding, infections, 
diabetes, medications taken to prevent pregnancy complications, and 
prenatal care) 
 Physical and sexual violence 
 Vitamin and mineral supplement use 
 Other social, household, and income information.  
 
Participants were contacted between 22 to 26 weeks of their pregnancy for the follow-up 
telephone interview. This interview gathered additional information on the following 
topics: 
 
 Changes in health behaviors and water exposures
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 Current and past pregnancy and medical histories (diseases and injuries, 
surgical procedures, fever, and other health problems) 
 Pregnancy-related symptoms and information regarding prenatal care and 
delivery choices, and partner information.  
 Paternal information (age, race/ethnicity, education) 
 
Study participants who had been identified as having pregnancy losses during either 
phase of the telephone interviews were asked to complete the modified version of the 
baseline or follow-up interview. The modified interviews ascertained identical 
information as those in the “regular” interviews, but the language of the modified version 
took into account the sensitivity of the recent pregnancy loss. Figure 6 shows a flow 
diagram of RFTS study activities.83   
Flow Diagram of Study Activities 
 
 
 
                                                                                                           Medical records 
                                         Ultrasound                                                                        abstraction 
  Baseline Follow-up  
                                                                                                                                                      
 
 
Weeks EGA/ 2     4      6     8     10    12   14    16   18    20   22    24   26    28   30    32 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Diagram of study activities, Right from the Start (2000-2004) 
*Adapted from AwwaRF report (Savitz et al., 2005) 
IDEAL TIME FRAMES AND DEADLINES FOR ULTRASOUNDS AND CATI 
All Participants 
First Trimester Ultrasound ideal time: 6 2/7 – 7 5/7 weeks; no later than 14 0/7 weeks 
Baseline CATI: preferably within 2 weeks of enrolling and no later than 16 0/7 weeks 
Follow-up CATI: 20 0/7 – 25 0/7 weeks 
 
cut off for enrollment 
12 6/7 weeks 
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3.4.6 Medical record reviews and vital record linkages 
Participants’ medical records were reviewed and relevant information was 
abstracted at the end of pregnancy, whether it resulted in a loss or in a live birth. 
Information such as first day of the LMP, gestational age at delivery, pregnancy outcome, 
and other maternal demographic status from the medical chart abstraction was used to 
clarify discordance and to supplement the data collected during the telephone interviews. 
Additionally, vital and fetal death records were linked with existing participant data to 
confirm and/or to provide supplemental information on pregnancy outcomes. Infant’s 
birthweight, date of birth, and gender were key pieces of information abstracted from the 
vital records and similar information on the infant was obtained from the fetal death 
records.  
Because of the comprehensive nature of RFTS, multiple sources including 
participant self-report, vital records, and medical records, were used to gather participant 
and pregnancy-related information; information collected such as pregnancy outcome and 
pregnancy outcome date, abstracted data from medical records took precedence over data 
from vital records, which took precedence over self-reported data.  
 
3.5  Collection of NVP information  
3.5.1 NVP assessment 
Information on NVP was collected via self-report from all eligible participants at 
two time intervals, the baseline (Appendix A) and follow-up (Appendix B) telephone 
interviews. For this study, symptoms of nausea was defined as ‘nausea or feeling sick to 
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their stomach at any time’ during the index pregnancy and a vomiting episode was 
defined as a woman who ‘had nausea so bad that she vomited’.  
Information regarding the date of onset and stop date for nausea during pregnancy 
was collected on all women at the baseline and follow-up telephone interviews. Similarly, 
information on the date of onset and stop date on vomiting was also gathered during the 
same two time intervals; however, questions pertaining to vomiting episodes were 
ascertained only from women who experienced symptoms of nausea.  
Onset and stop dates for NVP symptoms were collected down to the specific 
month, day, and year for each woman, and separately for symptoms of nausea and for 
vomiting episodes. If the women were unsure of their “day” of event, they were asked 
one additional question to describe the timing of occurrence with respect to the “week in 
the month”. For women who experienced vomiting along with nausea symptoms, two 
more questions were used to collect information on the number of times per day and per 
week she vomited when her “vomiting was the worst” to provide further indication on the 
intensity of NVP. 
Additionally, women who experienced symptoms of NVP were asked about 
changes in their health behaviors during their pregnancy such as coffee, soft drinks, and 
water consumption, physical activity level, change in intake of prenatal vitamin or 
supplements, cigarette smoking, etc. as a direct result of NVP symptoms at the baseline 
telephone interview. These questions on health behavioral changes were tailored 
specifically to each woman based on her reported activities and/or consumption of 
beverages reported in the earlier sections of the interview. For example, if a woman who 
experienced NVP symptoms and reported consuming coffee during her pregnancy, her 
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health behavior modification questions included one on whether her coffee intake 
increased or decreased as a direct result of her NVP symptoms. Similarly, a non-
consumer with NVP symptoms was not asked about her changes in coffee consumption.  
3.5.2 Variable creation and coding for NVP 
Information collected on symptoms of NVP from the telephone interviews was 
used for the coding and creation of variables to indicate NVP characteristics in this study 
population.  
 
Symptom severity  
Severity of women’s experience with NVP symptoms was categorized into three 
levels of “no symptoms”, “symptoms of nausea only”, and “symptoms of nausea and 
vomiting episodes”. Women were considered to have no symptoms if they did not 
experience any symptoms of nausea and any vomiting during the pregnancy. They were 
classified into the second group, “having symptoms of nausea only”, if they reported 
experiencing symptoms of nausea, without any vomiting episodes as a result of the 
nausea symptoms. Lastly, women were classified as having “symptoms of nausea and 
vomiting episodes” if they reported experiencing both symptoms of nausea and vomiting 
during their pregnancy.  
 
Assigning timing of onset and stop date  
As noted in the earlier section of this proposal, information pertaining to NVP 
symptoms was ascertained at both telephone interviews; nevertheless, these questions 
asked women to make references back to the symptoms that they experienced during the 
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early gestational period. That is, women were asked to report the exact dates of 
symptoms onset and the exact stop dates for nausea and/or for vomiting episodes that 
occurred during early pregnancy at Time 1 (baseline interview) and they were 
subsequently asked to best recall the same information in regard to their NVP symptoms 
for the early pregnancy period at Time 2 (follow-up interview).   
Because the primary focus were symptoms of nausea and vomiting during the 
period of early pregnancy (approximately four weeks after the LMP), we made the 
assumption that dates of onset and stop dates given at Time 1 were reported more 
accurately than those given for the same events at Time 2. Therefore, dates of onset and 
stop dates for each symptom reported at the baseline interview took precedence over the 
dates reported in the follow-up interview, in order to minimize misclassification and 
recall bias. An exception was made to use the date(s) reported in the follow-up interview 
if a woman reported experiencing either nausea or vomiting episodes, but was unable to 
provide the corresponding dates of onset and/or stop dates at the baseline interview but 
one was provided during the follow-up interview.  
The onset and stop dates for nausea symptoms and vomiting episodes were 
collected not only in calendar year and the month of occurrence but also for the “day” of 
the month, so we were able to almost pinpoint the date of onset and stop dates for these 
symptoms with respect to the gestational period, down to the number of days from the 
LMP. To further reduce misclassification in the assignment for timing of NVP, women 
were asked to report the week in the month in which they experienced either nausea 
symptoms or vomiting episodes if they were not able to provide the exact “day” of 
symptom occurrence. In scenarios where the “day” of event was unknown but the “week 
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in month” estimate was reported, we were able to impute the “day” of the month 
according to the week (1st, 2nd, 3rd, 4th, and 5th) in the month. This allowed us to 
approximate the onset and stop dates of NVP in relation to the LMP and to classify the 
dates relative to the gestational period. Using an algorithm, the “day” of the month 
corresponding to the “week in the month” is imputed as follow:  
  First week = Day 4 
  Second week = Day 11 
  Third week = Day 18  
  Fourth week = Day 25 
  Fifth week = Day 30 
  Unknown week= Day 15  
 
Time of symptom onset and symptom duration.  
Time of onset was subdivided into “typical onset”, defined into out study as symptom 
onset that took place prior to the start of the second trimester (≤13 weeks gestation) and 
“delayed onset”, which was defined as symptom that commenced after the first trimester 
(>13 trimester gestation). Symptom duration was calculated using dates of symptom 
onset and stop dates for nausea and vomiting episodes.  Using the available information, 
duration was categorized as “symptoms restricted within first trimester” and “symptoms 
lasting beyond first trimester” in Manuscript 1 or “short”, “moderate”, and “severe” in 
Manuscript 2. We considered gestational weeks 0 to 12 as first trimester, weeks 13 to 26 
as the second trimester, and week 27 and greater was assigned as the third trimester.   
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3.6 Collection of caffeine intake information  
Information on the daily consumption of caffeine from coffee and from non-
coffee beverages for a typical week (study participant not on vacation or experience 
unusual event(s) or circumstance(s) that would affect caffeine consumption) was 
ascertained during the telephone interview (Appendix C). Detailed questions were asked 
of caffeinated coffee, with respect to the number of cups consumed daily on a typical 
week, beverage sizes, and brewing method (brewed versus instant). We considered cup 
sizes for caffeinate coffee and caffeinated hot tea to be small (7oz), medium (13oz), and 
large (20oz).  Iced tea was categorized as small (7 oz), medium (16 oz), and large (28 oz), 
and sodas as small (10 oz), medium (18 oz), and large (29 oz). Daily caffeine exposure 
(mg) was calculated based on amount consumed (according to the number of cups and 
cup sizes) and brewing methods. Bunker’s caffeine contents were then applied to the 
amount consumed to determine the total daily exposure value. We applied Bunker’s 
parameter of caffeine content 84 to calculate the total exposure value (mg/day). Caffeine 
contents (mg/oz) for each type of caffeinate beverage were assigned as follow:  
 
Brewed caffeinated coffee =28.6869 mg/oz 
 
             Instant caffeinated coffee =13.0108 mg/oz 
             
Half brewed and instant caffeinate coffee = 20.8489 mg/oz 
 
Unknown caffeinated coffee = 26.7688 mg/oz 
 
Hot and iced caffeinated tea = 9.7581 mg/oz 
 
Caffeinated sodas = 3.4881 mg/oz 
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In addition to collecting data on women’s “current consumption” during the interviews, 
we also considered changes in consumption, if any, since their LMP on each caffeinated 
beverage. If changes in consumption occurred, timing of changes in month, date, and 
year were determined via women’s self-report. Because we collected information on 
changes in consumption not only in calendar year and the month of occurrence but also 
for the “day” of the month, we were able to almost pinpoint the date of change with 
respect to the gestational period, down to the number of days from the LMP. In scenarios 
where the “day” of event was unknown but the “week in month” estimate was reported, 
we imputed the “day” of the month accordingly and unknown week was assigned the 
mid-month value, using the same algorithm that was used to assign the “day” of the 
month for the date of onset and stop date for NVP.  
 
3.7 Collection of SAB information 
SAB is typically defined as pregnancy loss prior to 20 completed weeks’ 
gestation. In RFTS, SAB is classified as loss of pregnancy if the end of pregnancy 
occurred on or before 140 days gestation as calculated by the last menstrual period. The 
RFTS cohort (n=2,430) had 88.8% (n=2,158) live births, 0.5 % fetal deaths (n=12), and 
10.7% (n=260) resulted in SAB. Regardless of the pregnancy outcome, the outcome 
information was obtained through participant self-report, review of medical records 
abstraction from prenatal care provider offices, university hospitals, emergency rooms, 
and other health care settings, and through data linkages to vital records to document live 
birth or fetal death.  
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3.7.1 Calculation of gestational age  
Whether for a loss or a delivery, the first step in assigning outcomes was to 
estimate gestational age at pregnancy outcome. In the RFTS cohort, we found self-
reported LMP to be highly reliable in dating pregnancy onset; therefore, gestational age 
in this study population was primarily determined based on women’s self-reported LMP 
and secondarily with the use of ultrasound dating. If both self-reported LMP and LMP 
from ultrasound dating were available and the two dates agreed within seven days, the 
self-reported LMP was used to calculate gestational age; however, information from 
ultrasound dating was used if they differed for more than seven days or if a woman’s 
LMP were unknown or were deemed unreliable.   
         
3.8 Measurement of covariates of interest 
Maternal age, maternal race/ethnicity, marital status, education, cigarette 
smoking, alcohol use, age at menarche, parity, plurality, and pregnancy loss history were 
examined as potential risk factors or markers for NVP in the analysis for Manuscript 1. 
Manuscript 2 examined the association between NVP and spontaneous abortion; many 
covariates were evaluated as effect measure modifiers or potential confounders and the 
DAG51 (Figure 1) was drawn to provide a visual assessment on the covariates of interest. 
Manuscript 3 focused on the association between caffeine exposure and SAB. A list of 
covariates, similar to those used in Manuscripts 1 and 2, was used in Manuscript 3 as 
potential confounders in the traditional covariate adjustment analysis and to estimate 
individual propensity score for the propensity score analysis. Covariates of interest that 
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were used in the analysis of Manuscripts 1, 2, and 3 and the respective variable coding 
schemes are shown in Tables 4, 5, and 6.  
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Table 4. Variables included in the analysis for Manuscript 1: Risk factors or markers for nausea and 
vomiting in early pregnancy 
Variable Name Description Variable Coding 
Study Outcome     
Nausea and 
vomiting during 
early pregnancy 
Self-reported experiences with NVP 
during the baseline and follow-up 
telephone interviews  
 Severity: 0= Any symptoms 
  1= No symptoms 
   
 Time of symptom onset: 0=Typical onset 
  1=Delayed onset 
   
 Duration: 0=Symptoms restricted to first trimester 
  1=Symptoms lasting past first trimester 
Predictors   
Age Maternal age at study enrollment 1= 18-24 years old 
  2= 25-29 years old 
  3= 30-34 years old 
  4= ≥ 35 years old 
   
Race/ethnicity Mother's race/ethnicity 0= Non-Hispanic White 
  1= Non-Hispanic Black 
  2= Hispanic 
  3= Asian/Other 
   
Education Maternal education 0= <12 years 
  1= 12 to <16 years 
  
2= ≥16 years 
   
Smoking Cigarette smoking 0= Non-smoker 
  1= Smoked any 
   
Alcohol  Alcohol use during pregnancy 0= No alcohol use 
  1= Any alcohol use 
   
Marital status Marital status 0= Married 
  1= Other 
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Table 4 (cont). Variables included in the analysis for Manuscript 1: Risk factors or markers for nausea 
and vomiting in early pregnancy 
Variable Name Description Variable Coding 
Predictors   
Parity Parity 0= 0 (nulliparous) 
  1= 1 
  2= 2+ 
   
SAB history Pregnancy loss history 0= No prior SAB 
  
1= ≥1 prior pregnancy with no prior 
SAB 
  
2= ≥1 prior pregnancy with ≥1 prior 
SAB 
   
Age at menarche Mother's age at menarche 0= <11 years old 
    1= 12 to 13 years old 
  
2= ≥14 years old 
   
Plurality Plurality for index pregnancy 0= Singleton 
  1= Multiple 
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Table 5. Variables included in the analysis for Manuscript 2: Symptoms of nausea and vomiting in 
early pregnancy and spontaneous abortion  
Variable Name Description Variable Coding 
Study Outcome     
Spontaneous abortion 
Pregnancy loss at <20 completed 
weeks gestation 0= No SAB 
  1= SAB 
Main Exposure   
Nausea and vomiting 
during early 
pregnancy 
Self-reported experiences with 
NVP during the baseline and 
follow-up telephone interviews  
 Severity: 0= Both nausea and vomiting 
  1= Nausea symptoms only 
  2= No symptoms 
   
 Duration 0= Short 
  1= Moderate 
  2= Long 
Covariates   
Age Maternal age at study enrollment 1= 18-24 years old 
  2= 25-29 years old 
  3= 30-34 years old 
  
4= ≥ 35 years old 
   
Race/ethnicity Mother's race/ethnicity 0= Non-Hispanic White 
  1= Non-Hispanic Black 
  2= Hispanic 
  3= Asian/Other 
   
Marital status Marital status 0= Married 
  1= Other 
   
Education Maternal education 0= <12 years 
  1= 12 to <16 years 
  
2= ≥16 years 
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Table 5 (cont). Variables included in the analysis for Manuscript 2: Symptoms of nausea and 
vomiting during early pregnancy and spontaneous abortion  
Variable Name Description Variable Coding 
Covariates   
Smoking Cigarette smoking 0= Non-smoker 
  1= Smoked any 
   
Alcohol  Alcohol use during pregnancy 0= No alcohol use 
  1= Any alcohol use 
   
Age at menarche Mother's age at menarche 0= <11 years old 
    1= 12 to 13 years old 
  
2= ≥14 years old 
   
Parity Parity 0= 0 (nulliparous) 
  1= 1 
  2= 2+ 
   
SAB history Pregnancy loss history 0= No prior SAB 
  
1= ≥1 prior pregnancy with no prior SAB 
  
2= ≥1 prior pregnancy with ≥1 prior 
SAB 
   
Plurality Plurality for index pregnancy 0= Singleton 
  1= Multiple 
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Table 6. Variables included in the analysis for Manuscript 3: Exposure of caffeine intake and 
spontaneous abortion: An application of propensity score methods  
Variable Name Description Variable Coding 
Study Outcome     
Spontaneous abortion 
Pregnancy loss at <20 completed weeks 
gestation 0= No SAB 
  1= SAB 
Main Exposure   
Caffeine exposure 
from coffee and total 
caffeine 
Calculated by self-reported daily 
consumption applied to Bunker’s 
parameters for caffeine contents for 
caffeinated beverages.   
 Pre-pregnancy 
Calculated pre-pregnancy 
consumption (mg/day)   
 Early pregnancy 
Calculated consumption 
(mg/day) at four weeks after 
LMP 
 Current 
Calculated consumption 
(mg/day) at the time of 
telephone interview 
Covariates   
Maternal age Maternal age at study enrollment 1= 18-24 years old 
  2= 25-29 years old 
  3= 30-34 years old 
  
4= ≥ 35 years old 
   
Race/ethnicity Mother's race/ethnicity 0= Non-Hispanic White 
  1= Non-Hispanic Black 
  2= Hispanic 
  3= Asian/Other 
   
Marital Marital status 0= Unmarried 
  1= Married 
   
Education Maternal education 0= ≤12 years 
  1= >12 - <16 years 
  2= 16+ years 
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Table 6 (cont). Variables included in the analysis for Manuscript 3: Exposure of caffeine intake and 
spontaneous abortion: An application of propensity score methods 
Variable Name Description Variable Coding 
Covariates   
Smoking Cigarette smoking 0= Non-smoker 
  1= Smoked any 
   
Alcohol  Alcohol use during pregnancy 0= No alcohol use 
  1= Any alcohol use 
   
Vitamin use Vitamin use 0= No 
  1= Yes 
   
NVP symptoms 
Symptoms of nausea and vomiting during 
pregnancy 0= both symptoms 
  1= nausea only 
  2= no symptoms 
   
Parity Parity 0= 0 
  1= 1 
  2= 2+ 
   
SAB history Pregnancy loss history 0= No prior pregnancy 
  
1= Prior pregnancy with no 
prior pregnancy loss 
    
2= Prior pregnancy with 
prior pregnancy loss 
 
 
3.9 Missing values  
 
To increase the precision of our estimates, multiple imputation was considered as a 
tool to systematically impute values for covariates with missing values in some observations. 
Multiple imputation, in SAS PROC MI and PROC MIANALYZE,85-87 was sought if 
covariate patterns of missing data were found to be “missing at random” (MAR) and where 
covariates of interest were missing greater than five percent of in the observation. If the data 
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were concluded to be “missing completely at random” (MCAR), complete case analysis 
was employed where observations with missing values were dropped from the final 
model.  
3.10 Data analysis  
3.10.1 Data management 
RFTS employed a rigorous protocol for data collection and cleaning by the 
telephone interviewing staff and computer programmer. The screening interview was 
conducted in-house at UNC where each potential participants was assigned a unique 
study identification number; CATI (computer-assisted telephone interviewing) system 
was used for both baseline and follow-up interviews where this method of collecting 
telephone interview data minimized “false skip-patterns” and potential human errors 
associated with questionnaire skip patterns. Data collected from the completed baseline 
and follow-up telephone interviews were concatenated from ASCII files to SAS data sets 
in batches weekly from Battelle Centers for Public Health Research and Evaluation in 
Durham, NC. Descriptive statistics (frequencies and cross-tabulations) were performed to 
further detect any error in data coding and data entry.    
3.10.2 Statistical methods 
3.10.2.1 Analytic plan for study aim 1 
Various maternal characteristics, health behaviors before and during pregnancy, 
and reproductive and medical histories have potential influences on the presence or 
absence of NVP symptoms. Logistic regression is a commonly used analytic technique in 
epidemiology to estimate the odds of an exposure of interest to an outcome of interest, 
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and results from logistic regression are easily interpretable for both case-control and 
cohort studies. The more prevalent the outcome, the adjusted odds ratio (OR) 
overestimates the risk ratio (RR) when it is greater than one or underestimates the RR 
when it is less than one.88  
Aim 1 applied modified Poisson regression with robust error variance89 models to 
model the log-risk between independent variables or possible risk factors for NVP. 
Although binomial regression, or log-binomial model, is generally preferred and more 
widely used; nevertheless, it has the tendency to be less stable than logistic regression90 
and has the potential problem with model non-convergence.91 The use of Modified 
Poisson regression with robust error variance as an analytic technique reduces the 
problems often seen in logistic regression and binomial regression, and this allows for a 
direct an estimate of an association that best represented the true relative risk. We 
examined maternal characteristics including maternal age, race/ethnicity, marital status, 
and education. Maternal health behaviors included cigarette smoking and alcohol use; 
reproductive and medical histories consisted of age at menarche, parity, and previous 
pregnancy loss. As the main outcome variable of interest, NVP was categorized into 
subgroups to assess the association of the independent variables on symptom-specific 
NVP. A separate analysis was done to assess the effects of individual predictors on the 
time of symptom onset (typical or delayed) and duration (symptoms restricted within the 
first trimester or symptoms lasting beyond the first trimester) of NVP. Bivariate analyses 
were first performed to examine each covariate and outcomes in order to reduce the list 
of potential risk factors for NVP. Covariates were entered into the final models if they 
were found to be statistically significant (α ≤0.20) or have risk ratios (RR) greater than 
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two. Because we examined a highly prevalent outcome from a prospective cohort study, 
the β coefficient from the modified Poisson regression was a direct estimate of the log 
risk and the exponentiation of the β coefficients can directly produce a risk ratio, 
allowing the risk ratio to be the primary effect measure for the predictors and NVP.  
3.10.2.2 Analytic plan for study aim 2   
Aim #2 examined the association between nausea and vomiting in early 
pregnancy and spontaneous abortion. Because of the methodological sensitivity in 
studying spontaneous abortion, survival analysis was a well-suited analytic tool to handle 
the concerns with left truncation and to account for delay entry.  
We used a discrete-time survival model with a logit link (a.k.a. discrete-time 
continuation ratio logistic survival model) to estimate week-specific odds ratios for the 
conditional probability of having SAB in a given week,92-94 given that a woman was still 
pregnant at the beginning of that time. The main exposure of interest, NVP, was coded as 
a three-level ordinal categorical variable (with the understanding that linearity 
assumption is met) where the presence of both nausea symptoms and vomiting episodes 
was considered the referent category, and “no NVP symptoms” and “nausea only” are the 
other two index categories. It was also categorized into “short”, “moderate”, and “long” 
to evaluate the effects of NVP symptom duration and early pregnancy loss. Similar to 
study aim #1, maternal characteristics included maternal age, race/ethnicity, marital 
status, and education. Maternal health behaviors included cigarette smoking and alcohol 
use; reproductive and medical histories consisted of age at menarche, parity, plurality, 
and previous pregnancy loss. Effect measure modification was assessed by comparing 
stratum-specific estimates of each covariate of interest and with the likelihood ratio test 
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(p<0.10). Covariates that were deemed to be non-modifiers were assessed to determine 
whether they were confounders.  
We modeled the probability of having a pregnancy loss at a given week j, 
conditional on a subject not experiencing a loss prior to week j. Equation 3.1, defined as 
the hazard at time tj, is the conditional probability of pregnancy loss for subject i at week 
j, where Ti is the gestational week of loss for subject i, j is the gestational week of 
pregnancy, and xij is the set of covariates of interest (the presence or absence of NVP) for 
subject i at gestational week j.   
 
              h(tij) = Pr(Ti = j | Ti ≥ j, xij).                                                                   (3.1) 
 
 
In turn, we expressed the odds of NVP and SAB as (Equation 3.2) 
    
 
              logit(h(tij) = αj + β1x1ij’ + β2x2ij’ + β3x3ij’ + …..+ βnxnij’,                       (3.2)  
 
 
where β describes the log odds between NVP and SAB, xij’ is the effects of each 
covariate for subject i at week j, and αj is the week-specific intercepts to account for the 
varying probabilities of SAB as pregnancy progresses. This model essentially treats time 
as a discrete factor by introducing one parameter αj for each possible time of having a 
pregnancy loss at tj. Exp(β) represents the odds ratio for having the outcome of interest 
given a one-unit increase in the predictor.  
 
3.10.2.3 Analytic plan for study aim 3 
 Estimating propensity scores 
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Using logistic regression models, we first estimated the probability of coffee 
consumption (yes/no) and consumption of any caffeinated beverages (yes/no) for pre-
pregnancy, four weeks post-LMP, and around the time of interview. Covariates that were 
selected to enter the logistic regression model included maternal age, maternal 
race/ethnicity, education, marital status, smoking, alcohol use, parity, symptoms of NVP, 
and pregnancy loss history. We then subclassified all propensity scores into propensity 
score quintiles, as proposed by D’Agostino,17 and propensity score quintiles were used in 
discrete-time survival model to estimate the effects of caffeine intake at three time points 
and SAB.  
 
Discrete-time survival model 
For both traditional covariate adjustment and propensity score analyses, discrete-
time survival models 93, 94 with a logit link (Equations 3.1 and 3.2) were also used to 
estimate week-specific odds ratios for the conditional probability of having SAB in a 
given week, given that a woman was still pregnant at the beginning of that time, with 
caffeine exposure from coffee only and from total caffeine at three time points as the 
main exposures of interest.  
Caffeine exposure (mg/day) was examined as a categorical variable, with 
cutpoints in caffeine use set at “none”, “>0 to <median”, “≥median”, and “>75th 
percentile”. Potential confounders that were used in the traditional models included 
maternal age, maternal race/ethnicity, education, marital status, alcohol use, and vitamin 
use.  
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In the propensity score models, we first examined caffeine effects within each 
propensity score quintile and used an interaction test to determine whether stratification 
was needed, based on p=0.05 as the significance level of interest. Propensity scores were 
kept as the main effects in the models if the test of interaction for each time window did 
not meet our criteria of <0.05; otherwise, stratification was necessary to examine quintile-
specific estimates. Because of the properties of propensity score models, we did not 
include additional covariates in the propensity score models.   
  
3.11 Software use 
 
Data cleaning, data manipulation (e.g. variable recoding), and data analysis were 
conducted using SAS 9.1 (SAS Institute, Inc., Cary, NC) 
 
3.12 IRB approval 
 
As determined by The Public Health Institutional Review Board (IRB), this research 
does not constitute as human subjects research as defined under federal regulations, and 
therefore, this research does not required by IRB approval (Study # 06-0285).   
 
 
 
 
  
CHAPTER 4: MANUSCRIPTS 
 
4.1 Manuscript 1: Factors influencing the characteristics of nausea and vomiting in 
early pregnancy  
 
Abstract 
Background: The risk factors or markers for symptoms of nausea and vomiting 
in early pregnancy (NVP) have not been well established and no study focused on early 
pregnancy has examined potential risk factors for the subclasses of NVP. We examined 
potential risk factors (maternal demographic, behavioral, reproductive and medical 
histories) for the characteristics of NVP symptoms involving symptom severity, time of 
onset, and duration. Methods: Our study population consisted of 2,430 newly pregnant 
women (≤ 12 weeks’ gestation) or women planning a pregnancy, who participated in a 
prospective cohort study on early pregnancy health, from 2000 to 2004 in three U.S. 
cities. Detailed data on NVP and other participant health information were collected 
through telephone interviews, ultrasound, and medical records. Modified Poisson 
regression with robust error variance models were used to generate the risk ratios for 
potential risk factors to NVP characteristics. Results: Most characteristics, with the 
exception of plurality, were not associated with having NVP. Dose-response gradient for 
increasing risk for delayed symptom onset with maternal age; increased risks were also 
found among Non-Hispanic Blacks [Risk ratio (RR): 4.3, 95% confidence interval (CI): 
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1.6, 11.6)], Hispanic women (RR=2.3, 95%CI: 0.4, 11.5), and women who began 
menstruating between 12 and 13 years old (RR=2.6, 95CI: 0.8, 8.7). Our findings also 
indicated that older maternal age and Non-Hispanic Black women were less likely to 
experience NVP symptoms lasting beyond the first trimester. Conclusions: Maternal age 
and maternal race/ethnicity were found to be associated with most aspects of NVP, while 
other factors were associated with selected characteristics of NVP. Further investigation 
is warranted in order to provide better understanding underlying biological and 
endocrinological mechanisms that may promote the onset of NVP symptoms.  
 
 
4.1.1 Introduction  
 
The onset of symptoms of nausea and vomiting during early pregnancy (NVP) 
often is the first indicator to a woman that she is pregnant. NVP is common, affecting 
50% to 90% of pregnant women some time prior to 20 completed weeks’ gestation.1, 2 
Timing of NVP onset, duration and severity of symptoms differ among women and 
among individual pregnancies of the same women. Hyperemesis gravidarum, the most 
severe form of NVP, affects 0.5% to 2% of pregnancies and is one of the most common 
reasons for hospitalization among pregnant women.35 While there is no uniform 
definition for hyperemesis gravidarum, the usual diagnostic criteria are persistent 
vomiting, dehydration, ketonuria, electrolyte disturbance, and weight loss greater than 
five percent, with the absence of other disorders.36  
Although having NVP is unpleasant and can be debilitating to pregnant women’s 
daily lives, these symptoms have been hypothesized to act as a deterrent for maternal 
exposure from harmful substances that could potentially damage the embryos during the 
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critical stages of embryogenesis.27 The etiology of NVP remains unclear. The secretion of 
human chorionic gonadotropin (hCG) and its rapid increase during the first trimester are 
considered by many to be the most likely contributor to NVP symptoms.2, 28 Increased 
secretion of thyroxine, prostaglandin E2,30 estrogens,1 prolactin and estradiol41 have been 
proposed as contributing factors. Furthermore, two studies have found evidence that 
pregnancies of multiple gestation tend to exhibit higher levels of hCG, thus causing these 
women to experience more severe NVP.95, 96  
NVP symptom characteristics can vary. Time of symptom onset typically begins 
at four to eight weeks’ gestation, generally peaks in intensity between eight and twelve 
weeks, and then subsides by twenty weeks’ gestation.30, 37-39 Although NVP symptoms 
for most women are restricted to early pregnancy, some studies found 20% to 30% of 
pregnant women continued to be affected by these symptoms beyond 20 weeks’ 
gestation.1, 34  
No risk factors or markers for NVP symptoms have been established. Some 
previous studies have found that the presence of NVP is associated with older maternal 
age, occupation such as manual or service workers, parity, cigarette smoking, and infant 
gender,32, 40, 43 although other studies have not replicated these associations.31, 39, 40, 97 
Chronic illnesses such as hypertension, liver and renal diseases,40 maternal hormones,41 
vitamin use,32 and stress43 have been shown to be related to the risk of NVP. Finally, 
reproductive history including increasing gravidity, plurality (singleton or multiple 
births), and increasing number of prior miscarriages have also been found to increase the 
risk for NVP.97  
  68 
One study reported that cigarette smoking or marijuana use was associated with 
delay the onset of NVP symptoms.25 Another study found that compared to women with 
early onset, women who reported late onset of NVP symptoms that began after the first 
trimester were more likely to be less educated and to be African-Americans.97 Another 
study34 found late onset to be more common among women who are older, had higher 
parity, and gained less weight during pregnancy. Few have examined risk factors and 
markers for long symptom duration, but one study found that long symptom duration, 
defined as symptoms that lasted more than four months (independent of timing of onset), 
was more common among younger women, with multiple gestation, and among 
multigravidae.97  
As part of a prospective pregnancy cohort study, we examined potential risk 
factors for the characteristics of NVP symptoms involving severity, time of onset and 
duration. 
 
4.1.2 Methods  
 
Data for this study were collected from 2000 to 2004 as part of a prospective 
cohort epidemiologic study (Right from the Start or RFTS) on drinking water disinfection 
by-products and spontaneous abortion (SAB). Details of this study are described 
elsewhere.82, 83, 98 Briefly, we recruited pregnant women, from the communities and 
prenatal care clinics in three cities (Raleigh, North Carolina; Memphis, Tennessee; and 
Galveston, Texas), who 1) were ≥18 years old and were ≤12 weeks’ gestation or 2) were 
between 18 and 45 and trying to conceive a pregnancy for no more than six months. 
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Participants were asked to take part in an endovaginal ultrasound assessment to confirm 
the gestational age and the viability of the fetus around eight weeks’ gestation. Two 
telephone interviews were conducted, no later than 16 weeks’ and between 22 and 26 
weeks’ gestation to ascertain information on maternal health behavior and current and 
past medical and reproductive histories, including NVP symptoms.  
A woman was considered to have experienced symptoms of nausea if she reported 
having had “nausea or feeling sick to her stomach at any time” during the index 
pregnancy and she experienced vomiting episodes if she “had nausea so bad that she 
vomited”. Time of onset, that is, start of NVP symptoms, and stop dates were collected 
separately for symptoms of nausea and vomiting episodes. Onset and stop dates were 
collected, noting the month, day, and year. Using the midpoint of the week, we imputed 
“days” for women who were unable to recall the exact days.   
For the purposes of this study, symptom severity was classified into “nausea 
symptoms only”, “nausea with vomiting episodes”, and “no symptoms”. Time of onset 
was subdivided into “typical onset”, defined in our study as symptom onset that took 
place prior to the start of the second trimester (≤ 13 weeks gestation), and “delayed 
onset”, which was defined as symptoms that started after the first trimester (>13 weeks 
gestation). Symptom duration was defined as symptoms restricted to the first trimester 
only and symptoms lasting beyond one trimester. Data relating to the onset and duration 
of NVP symptoms are presented in gestational weeks, as calculated based on a woman’s 
last menstrual period (LMP).   
Information on a wide range of potential risk factors for NVP was collected 
during the telephone interviews. Maternal characteristics included maternal age (<25 
  70 
years, 25 to 29 years old, 30 to 34 years, ≥35 years), maternal race/ethnicity (non-
Hispanic White, non-Hispanic Black, Hispanic, and Asian/other), marital status (married, 
other), and education (<12 years, >12 to <16 years, ≥16 years). Maternal health behaviors 
were cigarette smoking during pregnancy (none, any) and alcohol use during pregnancy 
(none, any); reproductive and medical histories included age at menarche (≤11 years, 12 
to 13 years, ≥14 years), plurality (singleton, multiple), gravidity (primigravida, 2, 3, ≥4) 
and pregnancy loss history (no prior SAB, ≥1 pregnancy with no SAB, ≥1 pregnancy 
with ≥1 SABs). 
 
Statistical analysis 
With NVP symptoms being a prevalent outcome in our study population, we 
estimated risk ratios (RRs) instead of odds ratios (ORs), because the ORs would 
overestimate the RRs when greater than one or underestimate the RRs when it is less than 
one.88 Log-binomial91 and Poisson regression99 are the recommended procedures 
estimating risk ratios, though log-binomial models have the tendency to be less stable 
than logistic regression.90 To eliminate problems with model non-convergence with log-
binomial regression,91 we used the modified Poisson regression with robust error 
variance89 models to generate the RRs for risk factors in relation to the timing of onset 
and two NVP symptoms outcomes.  
Bivariate analyses were first conducted to examine each covariate and outcomes 
in order to reduce a list of potential risk factors for NVP; covariates were entered into the 
final models if they were found to be statistically significant (alpha ≤ 0.2) or have risk 
ratios (RR) greater than two. Based on our strategies, risk factors retained in the various 
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final analysis models included maternal age, maternal race and ethnicity, education, 
marital status, smoking, alcohol use, age at menarche, pregnancy loss history, plurality, 
and gravidity.  
 
4.1.3 Results  
   We included a total of 2,430 women in the final analysis, with the majority of the 
study participants recruited from Raleigh (45.2%) or Memphis (37.3%). The mean age at 
enrollment was 27.8 years and the mean gestational age at enrollment was 54.8 days. 
Non-Hispanic White  women made up over 50% of the study population and 32% were 
Non-Hispanic Black; nine percent were of Hispanic ethnicity with the majority of those 
(75.6%) from the Galveston area. Our study population consisted mostly of women who 
were college graduate (48.8%), married (66.0%), non-smokers (94.5%) or non-drinkers 
(97.6%), and first time mothers (49.5%). Only 23 women (0.9%) carried multiple 
gestation. Because of the similarities in characteristics between the two groups and the 
small number of women carrying multiples, we included these women with women 
carrying singletons.  
The majority of the study participants (88.5%) reported experiencing some form 
of NVP symptoms with 35.3% having nausea symptoms only and 53.2% having nausea 
symptoms with vomiting episodes. Characteristics were similar in many respects for 
women who experienced any NVP symptoms and those who experienced no symptoms. 
Most maternal sociodemographic and behavioral characteristics, reproductive and 
medical histories were not associated with having either form of NVP symptoms, with 
the exception of plurality. Symptoms were more likely to occur among women carrying 
  72 
multiple gestations (RR = 1.3, 95%CI: 1.2, 1.5 for experiencing nausea only and RR=1.2, 
95%CI: 1.2, 1.3 for experiencing nausea with vomiting episodes) (Table 7).  
Among women with NVP symptoms, the median time of onset for nausea 
symptoms was five gestational weeks and the median time of onset for vomiting episodes 
was seven weeks. Among women with any NVP, 1.1% (n = 23) reported delayed onset of 
symptoms, defined as any NVP symptoms that began after the first trimester (>13 weeks 
gestation). We then examined the time of onset in gestational weeks with respect to 
plurality of the study’s index pregnancy. Regardless of plurality, onset for nausea 
symptoms and for vomiting episodes took place for most women within the first 
trimester. Women carrying multiple fetuses had a slight delay (in gestational weeks) of 
nausea symptom onset compared to women carrying singletons; nevertheless, the start of 
symptoms mostly concentrated between second and ninth week gestation (Figures 7 and 
8).   
A dose-response gradient was detected for increasing maternal age in relation to 
an increased risk of delayed symptom onset (Table 8), compared to women with typical 
symptom onset. The risk for delayed symptom onset was elevated, but imprecise, for 
Non-Hispanic Black women (RR = 4.3, 95% CI: 1.6, 11.6) and among Hispanic women 
(RR = 2.3, 95% CI: 0.4, 11.5). High school graduates were less likely than women with 
at least college degree to experience delayed symptom onset; however, there was a 
suggestion that women with some years of college were at an increased risk (RR =1.8, 
95% CI: 0.6, 5.2) for delayed onset. Women who began menstruating at 12 and 13 years 
old were almost three-times (RR = 2.6, 95% CI: 0.8, 8.7) as likely as women who began 
menstruating at a later age (≥14 years old) to have their symptom onset delayed. 
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Compared to primigravidae, each additional pregnancy was shown to have an inverse 
relationship with delayed symptom onset.   
The median duration for NVP symptoms was eight weeks. Few characteristics 
were associated with symptoms lasting beyond the first trimester (Table 9). The 
regression analysis showed that older (≥35 years old) (RR=0.8, 95% CI: 0.6, 1.0), Non-
Hispanic Black women (RR=0.8, 95%CI: 0.7, 1.0), and women who consumed alcohol 
during their pregnancy (RR=0.6, 95%CI: 0.3, 1.1) were less likely to experience 
symptoms that lasted beyond the first trimester.  Additionally, we saw suggestive 
evidence for increase in risk for longer duration with each successive pregnancy among 
multigravidae when compared to primigravidae.  
 
4.1.4 Discussion 
Eighty-nine percent of our study cohort reported having experienced symptoms of 
nausea with or without vomiting, which is higher than previously reported in prospective 
or retrospective cohort6, 7, 41 and case-control studies.97 This may be because the study 
recruited women trying to conceive and those very early in pregnancy, which better 
captured early pregnancy conditions.   
We found little to no association between most characteristics we examined and 
the risk for having symptoms of NVP, inconsistent with some earlier studies3, 5, 39, 97 but 
in agreement with others.31, 39, 40, 97   
For majority of RFTS women, symptom onset for either nausea symptoms or 
vomiting episodes began at some point within the first trimester, primarily between the 
second and tenth week gestation, regardless of plurality. Among women with NVP 
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symptoms, we found increased, but imprecise, risk for delayed symptom onset among 
Non-Hispanic Blacks and among women of Hispanic ethnicity, which agree with findings 
from an earlier study;97 however, our findings on decreasing risk with each additional 
previous pregnancy did not confirm findings from the same study. Our findings also 
suggested that women with some college education and among women who had at least 
one previous pregnancy with no prior spontaneous abortion to have a higher risk for 
delayed onset.  While no earlier studies examined a woman’s age at menarche and time 
of symptom onset, our findings suggested a modest increase in risk of delayed symptom 
onset for women who began their menarche at 12 and 13 years old. This evidence merits 
further investigations to uncover possible determinants for menarche within this age 
range and how these roles ultimately influence late symptom onset during pregnancy.  
We divided NVP symptom duration into “symptoms restricted to the first 
trimester” and “symptoms lasting beyond the first trimester”. Notably, older (≥35 years 
old) and Non-Hispanic Black women were found to have decreased risks for 
experiencing symptoms that lasted beyond the first trimester. Our findings of elevated 
risk among multigravidae (≥2) and among younger women (<25 years old), though 
marginal, supported the findings of one,97 but not all studies.34       
One strength of this study is the use of data from a prospective cohort study of 
reproductive age women who were identified early in their pregnancies or who were 
trying to conceive. We were able to collect information on potential risk factors and 
markers such as maternal behaviors, reproductive and medical histories, and information 
on symptoms of nausea and vomiting early in pregnancy. Unlike most previous studies, 
we were able to more precisely define the date the start and end for NVP symptoms 
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because we collected onset and end dates independently for symptoms of nausea and 
vomiting episodes, by the month, day, and year.  
The information we collected allowed us to examine risk factors and markers for 
specific NVP symptom characteristics including severity, timing, and duration. We were 
able to examine effects of potential risk factors within the NVP subgroups, potentially 
providing clues to biologic and physiologic etiologic pathways for NVP symptoms. 
Furthermore, we found a tendency for young maternal age to increase the risk and a 
tendency for Non-Hispanic Black and older maternal age to decrease the risk for long 
symptom duration, but the opposite was indicated on these maternal characteristics for 
delayed symptom onset; in addition to the other characteristics and behaviors that were 
found to be more strongly associated with long symptom duration and delayed symptom 
onset.   
Despite our enhanced protocol and intense effort to recruit women early into our 
study from communities and prenatal care clinics, limitations still exist with regard to 
data collection. Although we interviewed 97% of all study cohort to assess NVP 
information prospectively and 3% retrospectively due to pregnancy loss, we still had to 
impute the “day” for approximately one-fourth of women with NVP symptoms for either 
their onset and/or stop dates based on the responses provided for the “week in the 
month”. With the inclusion of the imputed dates, the effect estimates for time of onset 
and symptom duration were unlikely to have differed greatly than if we were to generate 
these estimates using actual dates provide by the women. This is because we had asked 
them to recall these dates around events in their lives (i.e.: birthdays, holidays, etc.); 
therefore, information given in the “week of the month” ideally would approximate the 
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recall date(s). NVP information was collected from telephone interviews based on 
women’s recall, rather than from daily diaries. Therefore, inaccurate participant self-
report on timing of NVP and its characteristics cannot be ignored. A woman’s experience 
with nausea symptoms is generally more subjective while her experience with vomiting 
episodes is more objective. Therefore, some women with nausea symptoms may have 
been misclassified as having no symptoms and vice versa, though these classification 
errors for experiencing any vomiting seem unlikely.  
In RFTS, no biological specimens were collected so we were unable to measure 
the concentration of hCG and other hormone levels in maternal blood at the point of 
conception or from the point of a clinically recognized pregnancy, or to monitor its 
pattern throughout the entire gestation period. Consequently, we were unable to compare 
the overall hCG profile between singleton and multiple pregnancies. Furthermore, our 
study did not measure the changes in NVP symptoms; once a woman reported having 
either nausea only or nausea symptoms with accompanying vomiting episodes we made 
the assumption that her symptom severity to be constant (i.e.: always nausea only or 
always both symptoms). This assumption would have prohibited us from finding out 
other potential risk factors or markers or generating more precise estimates for the risk 
factors already measured because of its variability in its natural cycle and characteristics.  
In this study, we collected a limited amount of information concerning medical 
treatment and weight loss and weight gain as a result of NVP; thereby we were unable to 
evaluate hyperemesis gravidarum. From our data, only 20% of 2,149 women with NVP 
symptoms self-reported having contacted their clinicians and 30 reported being 
hospitalized for NVP symptoms, thus considered severe enough symptoms to warrant 
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medical attention. Some of these cases may have been classified as hyperemesis 
gravidarum.  
 Our study found that maternal age and maternal race/ethnicity were associated 
with most aspects of NVP examined in this study, while other characteristics were found 
to be associated with only specific characteristics of NVP. While many hypotheses have 
been proposed, the etiology of this common pregnancy symptom remains unknown. 
Future studies should focus on further refinements in measuring NVP in order to provide 
a better understanding of the biological and endocrinological mechanisms between the 
characteristics evaluated in this study and other potential risk factors and markers to NVP 
symptoms.  
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Table 7. Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom severity: Right from the Start (2000-2004), n=2,430 
 
 
 
  
 
Symptom severity 
 
  
No symptoms 
 Having nausea only  
Having both symptoms of nausea and 
vomiting 
 
 n (%) 
 n (%) Adj. RR†‡ (95% CI)  n (%) Adj. RR†‡ (95% CI) 
Maternal age         
<25 years old  76 (27.2)  160 (18.7) 1.0 (0.8, 1.3)  497 (38.5) 1.1 (1.0, 1.2) 
25 to 29 years old  84 (30.1)  284 (33.1) 1.0  383 (29.7) 1.0 
30 to 34 years old  70 (25.1)  279 (32.5) 1.0 (0.8, 1.2)  308 (23.9) 1.0 (0.9, 1.1) 
≥35 years old  49 (17.6)  135 (15.7) 0.9 (0.8, 1.2)  103 (8.0) 0.8 (0.7, 0.9) 
 
  
  
 
   
Race/ethnicity         
Non-Hispanic White  137 (49.1)  558 (65.1) 1.0  662 (51.3) 1.0 
Non-Hispanic Black  112 (40.1)  215 (25.1) 0.9 (0.8, 1.0)  444 (34.4) 0.9 (0.9, 1.0) 
Hispanic  22 (7.9)  57 (6.7) 1.0 (0.8, 1.1)  130 (10.1) 1.0 (0.9, 1.1) 
Asian/Other  8 (2.9)  27 (3.2) 1.0 (0.8, 1.2)  30 (2.3) 1.1 (1.0, 1.2) 
 
  
  
 
   
Education         
<12 years  94 (33.7)  174 (20.3) 0.9 (0.8, 1.0)  455 (35.3) 1.0 (1.0, 1.1) 
>12 to <16 years  47 (16.9)  161 (18.8) 1.0 (0.9, 1.1)  313 (24.3) 1.1 (1.0, 1.2) 
≥16 years  138 (49.5)  523 (61.0) 1.0  522 (40.5) 1.0 
 
  
  
 
   
Marital status         
Married  169 (60.6)  663 (77.4) 1.0  770 (59.6) 1.0 
Other  110 (39.4)  194 (22.6) 0.9 (0.8, 1.0)  321 (40.36) 1.0 (0.9, 1.0) 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, marital status, alcohol use, age at menarche, pregnancy loss history, and plurality 
‡Compared to women with no nausea and vomiting symptoms 
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Table 7 (cont). Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI) on maternal 
characteristics in relation with symptom severity: Right from the Start (2000-2004), n=2,430 
 
 
 
  
 
Symptom severity 
 
  
No symptoms 
 Having nausea only 
 Having both symptoms of nausea and 
vomiting 
 
 n (%) 
 n (%) Adj. RR†‡ (95% CI)  n (%) Adj. RR†‡ (95% CI) 
Smoking         
Any  16 (5.8)  31 (3.6) -  87 (6.7) - 
None  263 (94.3)  827 (96.4) -  1,204 (93.3) - 
         
Alcohol use         
Any  11 (4.0)  22 (2.6) 0.8 (0.7, 1.1)  25 (1.9) 0.9 (0.7, 1.1) 
None  266 (96.0)  836 (97.4) 1.0  1,266 (98.1) 1.0 
 
  
  
  
  
Age at menarche         
≤11 years old  59 (21.5)  177 (20.8) 1.1 (1.0, 1.2)  298 (23.2) 1.1 (1.0, 1.1) 
12 to 13 years old  132 (48.0)  464 (54.6) 1.1 (1.0, 1.2)  674 (52.5) 1.1 (1.0, 1.1) 
≥14 years old  84 (30.6)  209 (24.6) 1.0  312 (24.3) 1.0 
 
  
  
 
   
Pregnancy loss (SAB) history         
No prior SAB  88 (31.5)  246 (28.7) 1.0  391 (30.3) 1.0 
≥1 pregnancy with no SAB  150 (53.8)  429 (50.0) 1.0 (1.0, 1.1)  609 (47.2) 1.0 (1.0, 1.1) 
≥1 pregnancy with ≥1 SAB  41 (14.7)  183 (21.33) 1.1 (1.0, 1.2)  291 (22.5) 1.1 (1.1, 1.2) 
*NVP: Nausea and vomiting during early pregnancy 
†
 Model adjusted for maternal age, race/ethnicity, education, marital status, alcohol use, age at menarche, pregnancy loss history, and plurality 
‡Compared to women with no nausea and vomiting symptoms 
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Table 7 (cont). Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom severity: Right from the Start (2000-2004), n=2,430 
 
 
 
  
 
Symptom severity 
 
  
No symptoms 
 Having nausea only 
 Having both symptoms of nausea and 
vomiting 
 
 n (%) 
 n (%) Adj. RR†‡ (95% CI)  n (%) Adj. RR†‡ (95% CI) 
Plurality         
Singleton  279 (100.0)  852 (99.3) 1.0  1,274 (98.7) 1.0 
Multiple  0 (0.0)  6 (0.70) 1.3 (1.2, 1.5)  17 (1.3) 1.2 (1.2, 1.3) 
 
  
  
 
   
Gravidity         
Primigravid  93 (33.3)  253 (29.5) -  408 (31.6) - 
2  89 (31.9)  283 (33.0)   377 (29.2) - 
3  45 (16.1)  171 (19.9) -  256 (19.8) - 
≥4  52 (18.6)  151 (17.6) -  250 (19.4) - 
*NVP: Nausea and vomiting during early pregnancy 
†
 Model adjusted for maternal age, race/ethnicity, education, marital status, alcohol use, age at menarche, pregnancy loss history, and plurality 
‡Compared to women with no nausea and vomiting symptoms 
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Figure 7. Onset of nausea symptoms by plurality                    
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Figure 8. Onset of vomiting episodes by plurality 
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Table 8. Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom time of onset: Right from the Start (2000-2004), n=2,430 
 
 
 
 
Time of onset  
  Typical onset  Delayed onset 
  n (%)  n (%) Adj. RR†‡ (95% CI) 
Maternal age      
<25 years old  647 (30.5)  7 (30.4) 0.9 (0.3, 3.0) 
25 to 29 years old  658 (31.0)  7 (30.4) 1.0 
30 to 34 years old  581 (27.4)  6 (26.1) 1.3 (0.4, 4.2) 
≥35 years old  235 (11.1)  3 (13.0) 1.7 (0.4, 6.9) 
      
Race/ethnicity      
Non-Hispanic White  1,211 (57.2)  8 (34.8) 1.0 
Non-Hispanic Black  643 (30.3)  13 (56.5) 4.3 (1.6, 11.6) 
Hispanic  185 (8.7)  2 (8.7) 2.3 (0.4, 11.5) 
Asian/Other  80  (3.8)  0 (0.0) - § 
      
Education      
<12 years  621 (29.3)  5 (21.7) 0.7 (0.2, 2.7) 
>12 to <16 years  464 (21.9)  9 (39.1) 1.8 (0.6, 5.2) 
≥16 years  1,035 (48.8)  9 (39.1) 1.0 
      
Marital status      
Married  1,418 (66.9)  14 (63.6) - 
Other  703 (33.1)  8 (36.4) - 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, smoking, age at menarche, pregnancy loss history, plurality, and gravidity 
‡Compared to women with typical symptom onset 
§Cannot estimate due to small sample size 
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Table 8 (cont). Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom time of onset: Right from the Start (2000-2004), n=2,430 
 
 
 
 
Time of onset 
  Typical onset  Delayed onset 
  n (%)  n (%) Adj. RR†‡ (95% CI) 
Smoking      
Any  115 (5.4)  1 (4.4) 1.1 (0.1, 8.2) 
None  2,006 (94.6)  22 (95.6) 1.0 
      
Alcohol use      
Any  46 (2.2)  1 (4.4) - 
None  2,075 (97.8)  22 (95.7) - 
      
Age at menarche      
≤11 years old  471 (22.4)  3 (13.6) 1.0 (0.2, 5.1) 
12 to 13 years old  1,118 (53.1)  16 (72.7) 2.6 (0.8, 8.7) 
≥14 years old  518 (24.6)  3 (13.6) 1.0 
      
Pregnancy loss (SAB) history      
No prior SAB  629 (29.7)  6 (26.1) 1.0 
≥1 pregnancy with no SAB  1,024 (48.3)  13 (56.5) 1.6 (0.4, 6.5) 
≥1 pregnancy with ≥1 SAB  468 (22.1)  4 (17.4) 1.2 (0.2, 7.5) 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, smoking, age at menarche, pregnancy loss history, plurality,  
    and gravidity 
‡Compared to women with typical symptom onset 
§Cannot estimate due to small sample size 
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Table 8 (cont). Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom time of onset: Right from the Start (2000-2004), n=2,430 
 
 
 
 
Time of onset 
  Typical onset  Delayed onset 
  n (%)  n (%) Adj. RR†‡ (95% CI) 
Plurality      
Singleton  2,098 (98.9)  23 (100.0) 1.0 
Multiple  23 (1.1)  0 (0.0) - § 
      
Gravidity      
Primigravid  653 (30.8)  6 (26.1) 1.0 
2  652 (30.7)  8 (34.8) 0.9 (0.5, 2.6) 
3  420 (19.8)  5 (21.7) 0.8 (0.2, 2.6) 
≥4  396 (18.7)  4 (17.4) 0.7 (0.1, 4.2) 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, smoking, age at menarche, pregnancy loss history, plurality,  
    and gravidity 
‡Compared to women with typical symptom onset 
§Cannot estimate due to small sample size 
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Table 9. Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom duration: Right from the Start (2000-2004), n=2,430 
 
 
 
 
Symptom duration  
  Symptoms restricted to 1st trimester  Symptoms lasting beyond 1st trimester 
  n (%) Adj. RR*† (95% CI)  n (%) Adj. RR†‡ (95% CI) 
Maternal age       
<25 years old  486 (28.8) 1.1 (1.0 1.1)  167 (36.9) 1.2 (1.0, 1.3) 
25 to 29 years old  530 (31.4) 1.0  133 (29.4) 1.0 
30 to 34 years old  474 (28.1) 1.0 (1.0, 1.1)  113 (24.9) 1.0 (0.9, 1.2) 
≥35 years old  198 (11.7) 0.9 (0.9, 1.0)   40 (8.8) 0.8 (0.6, 1.0) 
       
Race/ethnicity       
Non-Hispanic White  986 (58.5) 1.0  233 (51.6) 1.0 
Non-Hispanic Black  491 (29.1) 0.9 (0.9, 1.0)  163 (36.1) 0.8 (0.7, 1.0) 
Hispanic  141 (8.4) 1.0 (0.9, 1.1)  45 (10.0) 0.9 (0.8, 1.1) 
Asian/Other  69 (4.0) 1.0 (1.0, 1.1)  11 (2.4) 0.9 (0.6, 1.4) 
       
Education       
<12 years  442 (26.2) 1.0 (0.9, 1.0)  182 (40.2) 1.1 (0.9, 1.3) 
>12 to <16 years  368 (21.8) 1.0 (1.0, 1.1)  104 (23.0) 1.2 (1.0, 1.4) 
≥16 years  877 (52.0) 1.0  167 (36.9) 1.0 
       
Marital status       
Married  1,171 (69.4) 1.0  259 (57.2) 1.0 
Other  516 (30.6) 1.0 (0.9, 1.0)  194 (42.8) 1.0 (0.9, 1.1) 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, marital status, alcohol use, age at menarche, and gravidity 
‡Compared to women with no nausea and vomiting symptoms 
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Table 9 (cont). Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom duration: Right from the Start (2000-2004), n=2,430 
 
 
 
 
Symptom duration 
  Symptoms restricted to 1st trimester  Symptoms lasting beyond 1st trimester 
  n (%) Adj. RR*† (95% CI)  n (%) Adj. RR†‡ (95% CI) 
Smoking       
Any  86 (5.1) -  30 (6.6) - 
None  1,602 (94.9) -  423 (93.4) - 
       
Alcohol use       
Any  41 (2.4) 0.9 (0.8, 1.0)  6 (1.3) 0.6 (0.3, 1.1) 
None  1,647 (97.6) 1.0  447 (98.7) 1.0 
       
Age at menarche       
≤11 years old  355 (21.2) 1.0 (1.0, 1.1)  118 (26.3) 1.2 (1.0, 1.4) 
12 to 13 years old  906 (54.0) 1.0  228 (50.9) 1.1 (1.0, 1.3) 
≥14 years old  417 (24.9) 1.0 (1.0, 1.1)  102 (22.8) 1.0 
       
Pregnancy loss (SAB) history       
No prior SAB  514 (30.5) -  118 (26.1) - 
≥1 pregnancy with no SAB  810 (48.0) -  227 (50.1) - 
≥1 pregnancy with ≥1 SAB  364 (21.6) -  108 (23.8) - 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, marital status, alcohol use, age at menarche, and gravidity 
‡Compared to women with no nausea and vomiting symptoms 
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Table 9 (cont). Selected maternal characteristics by NVP* symptoms, adjusted risk ratios (RR) and 95% confidence interval (CI)  
on maternal characteristics in relation with symptom duration: Right from the Start (2000-2004), n=2,430 
 
 
 
 
Symptom duration 
  Symptoms restricted to 1st trimester  Symptoms lasting beyond 1st trimester 
  n (%) Adj. RR*† (95% CI)  n (%) Adj. RR†‡ (95% CI) 
Plurality       
Singleton  1,670 (98.9) -  448 (98.9) - 
Multiple  18 (1.1) -  5 (1.1) - 
       
Gravidity       
Primigravid  537 (31.8) 1.0  119 (26.3) 1.0 
2  521 (30.9) 1.0 (1.0, 1.0)  139 (30.7) 1.1 (1.0, 1.2) 
3  334 (19.8) 1.0 (1.0, 1.1)  91 (20.1) 1.2 (1.1, 1.3) 
≥4  296 (17.5) 1.1 (1.0, 1.1)  104 (23.0) 1.3 (1.1, 1.5) 
*NVP: Nausea and vomiting during early pregnancy 
†Model adjusted for maternal age, race/ethnicity, education, marital status, alcohol use, age at menarche, and gravidity 
‡Compared to women with no nausea and vomiting symptoms 
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4.2 Manuscript 2: Severity and duration of nausea and vomiting symptoms in early 
pregnancy and spontaneous abortion 
 
Abstract 
 Background: Previous studies have shown an inverse association between the 
presence of nausea and vomiting in pregnancy (NVP) and spontaneous abortion (SAB). 
We evaluated this phenomenon more closely by examining the effects of symptom 
severity and duration on SAB. Methods: Our analysis included 2,430 women who 
participated in a prospective cohort study on pregnancy health between 2000 and 2004 in 
three U.S. cities. Detailed data on NVP and other participant health information were 
collected through telephone interviews, ultrasound assessments in early gestation, and 
medical records abstractions. Discrete-time continuation ratio logistic survival models 
were used to estimate week-specific pregnancy loss associated with the subclasses of 
NVP. Results: Having no NVP symptoms was found to increase risk for SAB [Adjusted 
odds ratio (OR) =3.2, 95% confidence interval (CI): 2.4, 4.3], compared to having any 
symptoms. Increasing maternal age was found to strengthen the risk for SAB among 
women without any symptoms. Reduced risks for SAB was found across all maternal age 
groups for those with longer symptom duration, but the effects were much stronger in the 
oldest maternal age group (OR=0.38, 95%CI: 0.24, 0.61 for moderate duration and 
OR=0.15, 95%CI: 0.06, 0.37 for long duration). Conclusions: Our results confirm that 
the absence of NVP symptoms is associated with early pregnancy loss. They also clearly 
indicate that longer symptom duration is protective against early loss, especially among 
women in the oldest maternal age group.  
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4.2.1 Introduction 
Pregnancy is a time of many changes; these changes are hormonal and 
physiological, as a woman’s body prepares for the growth of a fetus. Nausea and 
vomiting in early pregnancy (NVP) affects 50 to 90 percent of women,4, 5, 26 and  usually 
presents as one of the first signs of pregnancy.  
The severity of symptoms experienced by women differs; some women may only 
experience symptoms of nausea, while other women experience both nausea and 
vomiting. Timing of symptom onset and duration vary both among women and across 
multiple pregnancies of a woman. Symptoms can begin as early as two to four weeks’ 
gestation30, 37 and end for most women by 20 weeks’ gestation.30, 100 However, 20% of 
women continue to experience symptoms beyond 20 weeks’ gestation.100 Hyperemesis 
gravidarium is the most severe form of NVP, in which women have prolonged NVP 
symptoms that cause maternal weight loss, electrolyte imbalance, and dehydration.29  
The pathogenesis of NVP is poorly understood but has been attributed to the rise 
in the hormone hCG, human chorionic gonadotropin, and the trophoblastic activity and 
gonadotropin production in the early phases of pregnancy.3 A number of maternal 
characteristics, including primiparity, younger maternal age, and lower education, have 
been associated with NVP, and higher maternal BMI has been identified as a risk factor 
for vomiting.5  
Spontaneous abortion (SAB) is defined as a pregnancy loss before 20 completed 
weeks’ gestation. Though it affects approximately 10% of all clinically-recognized 
pregnancies,22 the actual rate of pregnancy loss is about two to five times higher, most 
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not clinically recognized.101 SAB typically affects women of all ages and across all 
sociodemographic characteristics. Current knowledge on the causes of SAB is limited, 
but two consistent risk factors are older maternal age and history of previous SABs. 
Other potential risk factors found in epidemiologic studies have included occupational 
chemical exposures,15 maternal stress, caffeine consumption,12-14 uterine fibroids, 47, 48, 102, 
103
 incompetent cervix,49 and drinking water disinfection by-products.16  
Earlier epidemiologic studies have shown an inverse association between NVP 
and SAB.3-8 The absence of NVP may be indicative of an impending pregnancy loss, 
where the presence of symptoms serves as a predictor of healthy pregnancy outcome. 
Additionally, an earlier analysis104 found a dose-response pattern between the presence of 
nausea alone and the presence of nausea symptoms with vomiting episodes and decreased 
risk of SAB. However, many of these studies reveal methodologic limitations including 
differences in study design, selection criteria, sample size, ascertainment of NVP 
information and classification of NVP symptoms, and analytical approach.  
As part of a prospective cohort study on drinking water disinfection by-products 
and early pregnancy loss, we obtained detailed information on symptoms of nausea and 
vomiting. Because we recruited women quite early in gestation or before they conceived, 
we were able to collect detailed prospective data on the pregnancy, onset of nausea 
symptoms and vomiting episodes, behavioral factors and other maternal characteristics. 
In this study, we focused on symptom severity and duration of NVP to evaluate whether 
different sub-classifications of NVP are associated with an increased risk of early 
pregnancy loss.  
  
  92 
4.2.2 Methods 
Participant recruitment 
We identified and recruited women who were newly pregnant and women who 
were trying to conceive from Raleigh, North Carolina; Memphis, Tennessee; and 
Galveston, Texas. Women were recruited from public and private prenatal care providers 
and the communities between 2000 and 2004 for an epidemiologic study that examined 
the relationship between drinking water disinfection by-products and early pregnancy 
loss. Women were eligible to be in the study if they were at least 18 years old and 
pregnant at less than 12 weeks gestation or if they were between 18-45 years old and had 
been trying to conceive for no longer than six months. A screening interview was used to 
determine whether a pregnant woman was eligible to enroll (or “pre-enroll” for a woman 
who was trying to become pregnant). The recruitment process has been described in 
detail elsewhere.82, 83, 98 An endovaginal ultrasound was performed around eight weeks’ 
gestation (median gestational age at ultrasound = 9.3 weeks) to confirm pregnancy 
viability and to ascertain the gestational age of the fetus. Telephone interviews took place 
in two time intervals, at no later than 16 weeks’ gestation and then between 20 and 25 
weeks’ gestation, to collect information on health behaviors, medical and reproductive 
history, current pregnancy history and symptoms, and water exposure characteristics.   
 
Exposure to symptoms of nausea and vomiting during early pregnancy  
Information on NVP was collected during two telephone interviews. Symptoms of 
nausea was defined as “nausea or feeling sick to your stomach at any time” during the 
index pregnancy, and a vomiting episode was defined as “had nausea so bad that you 
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vomited”. We collected information on the timing of onset and ending dates separately 
for symptoms of nausea and for vomiting episodes. Questions that pertained to vomiting 
episodes were asked exclusively of women who experienced symptoms of nausea. Onset 
and end dates were collected as month, day, and year. For those who were unable to 
recall the exact days, we collected timing information with respect to “week in the 
month”, and we imputed the day as the midpoint of the week. Symptoms had not 
subsided for 13% (164 out of 1,291) of women who had both symptoms of nausea and 
vomiting and 26% (222 out of 858) of women with nausea symptoms only at the time of 
the telephone interviews; therefore, we created a symptom ending date for these women 
at 23 weeks gestation, which was shown in the literature as a time during pregnancy 
when most NVP symptoms commonly end.37  
We described symptoms of NVP using two categories: symptom severity and 
symptom duration. Absence or presence of NVP symptoms, whether nausea alone or with 
the addition of vomiting episodes, was used to classify symptom severity into 1) no 
symptoms, 2) nausea only, and 3) nausea symptoms with vomiting episodes. The length 
of symptoms in weeks was calculated separately for nausea symptoms and vomiting 
episodes. The length of these intervals were used to denote short (<50th percentile), 
moderate (>50th to <75th percentile), and long symptom duration (≥75th percentile), in 
weeks for nausea symptoms and vomiting episodes.    
 
Health characteristics, health behavior, and pregnancy outcome assessment 
Using the telephone interviews, a wide range of risk factors for early pregnancy 
loss were collected and considered as potential effect measure modifiers and 
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confounders. These covariates included maternal age, race and ethnicity, maternal 
education, marital status, smoking, alcohol use, age at menarche, parity, SAB history, and 
plurality. We found, in the main study,82, 83 that the self-reported last menstrual period 
(LMP) in this cohort to be highly reliable; therefore, self-reported LMP was used to date 
the onset of pregnancy. Pregnancy outcome data were ascertained via participant self-
report, with confirmation via medical records abstraction and/or with the presence or 
absence of corresponding vital records for the pregnancy. Early pregnancy loss or 
spontaneous abortion is defined in this study as a loss of a pregnancy before 20 
completed weeks’, or 140 days, gestation calculated from the self-reported LMP.  
 
Multiple imputation   
We determined the level of missing data by evaluating the data three ways: 1) the 
number of missing observations observed for each covariate, 2) the amount of 
“missingness” for each covariate cross-classified by the main exposure, and 3) the 
amount of “missingness” for each covariate cross-classified by the outcome. If 
missingness for any covariates of interest occurred in greater than five percent of the total 
observations and the covariate patterns of the missing data were found to be “missing at 
random” (MAR), then the missing values were imputed as a function of the existing data 
using multiple imputation (PROC MI and PROC MIANALYZE).85-87 It was determined 
that the level of data “missingness” did not exceed our pre-determined criteria. As a 
result, complete case analysis was conducted for all analyses with less than two percent 
of women dropped due to missingness.  
 
  95 
Statistical analysis 
We used a discrete-time continuation ratio logistic survival model to estimate 
week-specific pregnancy loss in relation to symptoms of nausea and vomiting in early 
pregnancy. Adjusted odds ratios and the 95% confidence intervals were generated for the 
conditional probability of having a pregnancy loss in a given gestational week, 
conditional on a woman’s pregnancy having survived to the beginning of that gestational 
week. Our cohort was followed from the time of enrollment into the study until 20 
weeks’ gestation, with possible pregnancy outcomes being a viable pregnancy that went 
on past 20 weeks, pregnancy loss, or participant dropout. Pregnancies that survived 
passed 20 completed gestational weeks were included for the entire period, and women 
whose pregnancies ended for other reasons (i.e.: ectopic pregnancies, molar pregnancies) 
or those who were lost-to-follow-up were censored at the end of the risk period.  
Two distinct discrete-time survival models were used to estimate the sub-classes 
(severity and duration) of symptoms of NVP in relation to early pregnancy loss. The 
covariates that we considered were known to be predictors of pregnancy loss, including 
maternal age, race and ethnicity, maternal education, marital status, smoking, alcohol use, 
age at menarche, parity, pregnancy loss history, and plurality. Effect measure modifiers 
were evaluated by comparing stratum-specific estimates of each covariate of interest 
along with examination of the likelihood ratio test (p<0.15). Covariates that were deemed 
to be non-modifiers were then tested for confounding. Evaluation of potential 
confounders was conducted first by examining the association of each covariate of 
interest by the main exposure among all subjects and also by examining each covariate 
with the outcome among the unexposed group, along with using the change-in-estimate 
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approach, where covariates were retained in the final models if they changed the effect 
estimates for the exposure of interest by greater than 10% when removed from the model. 
In each model, maternal race and ethnicity, maternal education, marital status, alcohol 
use, age at menarche, parity, and pregnancy loss history were evaluated as potential 
confounders; maternal age was included as an effect measure modifier.     
 
4.2.3 Results 
A total of 2,430 women were included in the final analysis (78% of all eligible 
and enrolled) in the study, with majority of the study participants recruited from the 
Raleigh or Memphis study areas (82.4%). The mean age at enrollment for this study 
population was 27.8 years (SD=5.5) and the mean gestational age at enrollment was 54.8 
days (SD=14.0). Although non-Hispanic White women made up over 50% of the study 
population, substantial proportions (31.8%) of study participants were non-Hispanic 
Black. Very few women in our study population self-identified as smokers or consumers 
of alcohol during pregnancy. Approximately 37% were considered as overweight or 
obese by the Institute of Medicine classification.105 Almost half of the study participants 
were primigravida and 21% reported having a prior early pregnancy loss. Only 23 women 
had multiple gestations in this index pregnancy (Table 10). Because of the small number 
of women carrying multiples and the similar characteristics between the two groups, the 
analyses presented here combined women with singleton and multiple pregnancies. There 
were 260 (10.7%) SABs in this study population.  
Eighty-eight percent of the women in this cohort experienced some form of NVP, 
with more than half (53.2%) reported experiencing symptoms of nausea accompanied by 
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vomiting episodes (Table 10). Onset for NVP symptoms was more likely to occur in 
early pregnancy, with 99.0% of initial nausea symptoms and 95.3% of initial vomiting 
episodes taking place in the first trimester. The median onset time for nausea symptoms 
was 5.7 weeks and that for vomiting episodes was 7.0 weeks from LMP.  
    Table 11 highlights the maternal sociodemographic characteristics, behavioral, 
and reproductive characteristics of the study population, stratified by sub-classes of NVP. 
Women who reported experiencing both symptoms of nausea and vomiting episodes 
tended to be younger (<30 years old), of Hispanic origin, and had completed fewer years 
of education. Reproductive characteristics were similar for women with any form of 
NVP, but women who reported experiencing no nausea symptoms at this index 
pregnancy tended to begin menstruating at a later age (≥14 years old), were nulliparous, 
or had no history of prior SAB if they had ≥1 prior pregnancy.   
In our study cohort, most women with any form of NVP symptoms reported 
having either  short (32.7%) or moderate (28.4%) length of symptom duration, where 
these intervals are equivalent to six weeks or less and between seven to ten gestational 
weeks, respectively, with an overall mean symptom duration of eight gestational weeks. 
Those who reported having long symptom duration tended to be younger (<30 years old), 
Black or of Hispanic ethnicity, had fewer years of education, and began menstruating at 
an early age (≤11 years old). Women with either short or moderate length of symptom 
duration were likely to be older (≥30 years old), White, have completed at least college, 
began menstruating between 12-13 years old, and had no prior SAB.  
Overall, women with no symptoms of NVP had three times the odds for having a 
SAB (OR=3.2, 95% CI: 2.4, 4.3) compared to women with any form of NVP symptoms. 
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The remaining results of modeling the week-specific odds of a woman having an early 
pregnancy loss for the different forms of NVP symptoms are shown in Table 12. The 
association between NVP and pregnancy loss was strengthened with increasing maternal 
age, from OR=4.04 (95%CI: 2.14, 7.61) for women <25 years old to OR=10.92 (95%CI: 
4.47, 26.67) for women 35 years and older. A more moderate pattern of association was 
found across maternal age groups for having nausea symptoms only. Maternal age also 
modified the association between duration and pregnancy loss. Longer symptom duration 
was found to have a much reduced odds for SAB for all maternal age groups, but the 
association was much stronger among the oldest maternal age group (OR=0.38, 95%CI: 
0.24, 0.61 for moderate duration and OR=0.15, 95%CI: 0.06, 0.37 for long duration).    
 
4.2.4 Discussion 
We examined the associations between the subgroups of symptoms of nausea and 
vomiting and spontaneous abortion in a population of women recruited early in their 
pregnancy or women who were planning a pregnancy. The incidence of NVP (35.3% for 
nausea symptoms only, 53.2% for both symptoms) was within the range for nausea 
symptoms only (20% to 50%) and for both symptoms (48% to 80%) reported by previous 
cohort studies.6, 32, 41 However, the incidence for experiencing nausea only and for 
experiencing both nausea symptoms and vomiting episodes are higher than those reported 
in other cohort studies in which recruitment took place in prenatal clinics.6, 30 This may 
be the result of our study design, which collected symptom data early in pregnancy, 
increasing the completeness of reporting.  
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The effects of symptom severity and duration were found to be different across 
maternal age groups. It is known that the rate of spontaneous abortion begins to increase 
for women between ages 30 to 35, resulting from chromosomally aberrant and/or 
chromosomally normal losses,106 and the absence of NVP symptoms is a marker for an 
increased risk in early pregnancy. Thus the effect of NVP appears to be magnified with 
advancing maternal age. Some of the odds ratios were imprecise within maternal age 
categories, and caution in interpretation is warranted.  
To our knowledge, no previous study has evaluated the effects of NVP symptom 
duration on early pregnancy loss. Studies that evaluated symptom severity often 
classified symptoms of nausea and vomiting together as a single dichotomous factor. 
Additionally, no other studies have acquired such detailed information on symptom 
duration distinctively for nausea symptoms and for vomiting episodes. The few studies 
that collected such information have done so by either gathering descriptive data on 
duration exclusively for nausea with or without the presence of vomiting episodes or for 
the presence of both symptoms. Because we collected detailed information, we have been 
able to more accurately determine symptom duration. Furthermore, our assignment of a 
symptom ending date at 23 weeks gestation (for women whose symptoms had not 
subsided by the time of the telephone interview) should have minimal impact on the 
reported results because we later categorized symptom duration as short, moderate, and 
long. The duration of symptoms for our study cohort was found to be within the range for 
mean symptom duration (eight to twelve gestational weeks) found in the literature;31, 32 
nevertheless, a sizable proportion of our cohort reported their symptoms lasting for six 
  100 
weeks or less, which may be attributed to our enhanced collection methods where 
misclassification of exposure was minimized.   
Studies of SABs are subject to left truncation because women tend to enter the 
study at different gestational ages and women without a viable pregnancy prior to study 
enrollment, who would have otherwise been eligible to participate, are missing from the 
study population.70, 71 Prenatal clinic recruitment, as conducted in many previous studies, 
allowed for rapid identification of pregnant women; however, a proportion of the source 
population would have been excluded due to pregnancy losses prior to recruitment. Effect 
estimates based on such data may introduce bias because study participation is 
differential by outcome. Data for this study came from a study population that was 
recruited early in pregnancy or as they were planning pregnancies, instead of from solely 
a population of women seeking prenatal care. Because we were able to identify these 
women early and follow them through their pregnancies, we prospectively collected 
detailed information on maternal behaviors, reproductive and medical histories, and other 
maternal characteristics at an earlier gestational age than previous studies; consequently, 
differential misclassification due to recall bias was minimized. Despite these 
improvements, limitations still exist in our study regarding the information collected on 
NVP symptoms. Our study did not attempt to collect NVP information daily, and errors 
on the timing of NVP and its characteristics could have occurred. Misclassification 
introduced by recall bias, could bias the association with early pregnancy loss; however, 
because NVP assessment took place prior to 71% of all pregnancy losses (the remaining 
29% interviewed after loss), the potential for recall error would be limited. Furthermore, 
we imputed symptom stop dates for 18% of women with any NVP symptoms who 
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reported that their symptoms had not subsided at the time of the interviews; even if 
symptom duration for those women were calculated from an actual symptom stop date, 
the effect estimate for symptom duration would not have changed substantially, because 
we chose an end point in the gestational period that reflected a time when most symptoms 
would subside on average. Even though our study recruited women who were early in 
their gestation period and women who were not yet pregnant, we still could have missed 
capturing a small proportion of women with early pregnancy loss; thereby potentially 
producing more imprecise estimates (with wider confidence intervals) and 
underestimating the magnitude of effect on the exposures with respect to the outcome.  
The mechanisms by which NVP predicts favorable pregnancy outcome are not 
known; nevertheless, several different mechanisms have been postulated to explain the 
reported feto-protective effect of NVP. These include reducing fetal exposure to potential 
teratogens present in the maternal diet,7 improving the quality of maternal diets to favor 
the consumption of certain nutrients, increasing energy expenditure that alter hormonal 
balance in favor of maternal and fetal tissue growth,7, 29 along with other nutritional and 
non-nutritional pathways. In our study, we were able to confirm previous findings that 
the absence of NVP symptoms is associated with pregnancy loss. We also were able, for 
the first time, to provide evidence that longer symptom duration is protective against 
early pregnancy loss. In addition to a more refined protocol and a large study population, 
our statistical methods accounted for left censoring by time of study entry, allowing us to 
generate more valid estimates of the associations between the exposures and early 
pregnancy loss. Along with complete assessment into the timing and occurrence of NVP, 
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a better understanding into the biological and physiological mechanisms of this common 
pregnancy phenomenon may help further explain this present association.  
 
 
4.2.5 References 
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Table 10. Sociodemographic characteristics, selected maternal  
behavior, and reproductive histories of women in analysis: Right from the Start  
(2000-2004), n=2,430 
   N % 
Study site    
Raleigh  1,097 45.1 
Memphis  907 37.3 
Galveston  426 17.5 
    
Maternal age    
<25 years old  733 30.2 
25 to 29 years old  752 31.0 
30 to 34 years old  658 27.1 
≥35 years old  287 11.8 
    
Race/ethnicity    
Non-Hispanic White  1,359 56.0 
Non-Hispanic Black  771 31.8 
Hispanic  209 8.6 
Asian/Other  89 3.7 
    
    
Education    
<12 years  723 29.8 
>12 to <16 years  521 21.5 
≥16 years  1,185 48.8 
    
Marital status    
Married  1,604 66.0 
Other  825 34.0 
    
Income    
≤$40,000/year  1,017 43.6 
$40,001 to $80,000/year  773 33.2 
>$80,000/year  541 23.2 
    
Smoking    
None  2,296 94.5 
<10 cigarettes/day  87 3.6 
≥10 cigarettes/day  47 1.9 
    
Alcohol use    
Any  58 2.4 
None  2,370 97.6 
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Table 10 (cont). Sociodemographic characteristics, selected maternal  
behavior, and reproductive histories of women in analysis: Right from the Start  
(2000-2004), n=2,430 
  N % 
BMI*    
Underweight ( <19.8)  250 10.6 
Normal weight (19.8-26.0)  1,235 52.2 
Overweight (<26.0-29.0)  310 13.1 
Obese (>29.0)  572 24.2 
    
Age at menarche    
≤11 years old  534 22.2 
12 to 13 years old  1,272 52.8 
≥14 years old  605 25.1 
    
Parity    
Nulliparous/none  1,202 49.5 
1  766 31.5 
2+  462 19.01 
    
Pregnancy loss history    
No prior SAB  726 29.9 
≥1 pregnancy with no SAB  1,189 48.9 
≥1 pregnancy with ≥1 SAB  515 21.2 
    
NVP† symptom severity    
No symptom  279 11.5 
Nausea symptoms only  858 35.3 
Nausea and vomiting  1,291 53.2 
    
NVP symptom duration    
Short  701 32.7 
Moderate  607 28.4 
Long  833 38.9 
    
Plurality    
Singleton  2,407 99.1 
Multiple  23 0.9 
*BMI: Body Mass Index, based on Institute of Medicine classifications 
†NVP: Nausea and vomiting during pregnancy 
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Table 11. Selected maternal characteristics by NVP* symptoms: Right from the Start (2000-2004), n=2,430 
 
 
 
  
Symptom 
severity    
Symptom 
duration  
  No symptom Nausea only 
Nausea and 
vomiting Short Moderate Long 
  n (%) n (%) N (%)  n (%) n (%) n (%) 
Maternal age‡§         
<25 years old  76 (27.2) 160 (18.7) 497 (38.5)  179 (26.1) 131 (27.2) 182 (36.8) 
25 to 29 years old  84 (30.1) 284 (33.1) 383 (29.7)  226 (32.9) 140 (29.1) 155 (31.4) 
30 to 34 years old  70 (25.1) 279 (32.5) 308 (23.9)  206 (30.0) 151 (31.3) 105 (21.3) 
≥35 years old  49 (17.6) 135 (15.7) 103 (7.9)  76 (11.1) 60 (12.5) 52 (10.5) 
         
Race/ethnicity‡         
Non-Hispanic White  137 (49.1) 558 (65.1) 662 (51.3)  410 (59.8) 308 (63.9) 258 (52.2) 
Non-Hispanic Black  112 (40.1) 215 (25.1) 444 (34.4)  205 (29.9) 113 (23.4) 156 (31.6) 
Hispanic  22 (7.9) 57 (6.7) 130 (10.1)  53 (7.7) 36 (7.5) 58 (11.7) 
Asian/Other  8 (2.9) 27 (3.2) 54 (4.2)  18 (2.7) 25 (5.2) 22 (4.4) 
         
Education‡§         
<12 years  94 (33.7) 174 (20.3) 455 (35.3)  167 (24.3) 107 (22.2) 158 (32.0) 
>12 to <16 years  47 (16.9) 161 (18.8) 313 (24.3)  150 (21.9) 105 (21.8) 117 (23.7) 
≥16 years  138 (49.5) 523 (61.0) 522 (40.5)  369 (53.8) 270 (56.0) 219 (44.3) 
*NVP: Nausea and vomiting during pregnancy 
†SAB: Spontaneous abortion 
‡p<0.05 for severity 
§p<0.05 for duration 
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Table 11 (cont). Selected maternal characteristics by NVP* symptoms: Right from the Start (2000-2004), n=2,430 
 
 
 
  
Symptom 
severity    
Symptom 
duration  
  No symptom 
Nausea 
only 
Nausea and 
vomiting  Short Moderate Long 
  n (%) n (%) n (%)  n (%) n (%) n (%) 
Marital status‡§         
Married  169 (60.6) 663 (77.4) 770 (59.6)  481 (70.1) 355 (73.7) 329 (66.6) 
Other  110 (39.4) 194 (22.6) 521 (40.4)  205 (29.9) 127 (26.4) 165 (33.4) 
         
Smoking‡         
None  263 (94.3) 827 (96.4) 1,204 (93.3)  652 (94.9) 460 (95.4) 466 (94.3) 
<10 cigarettes/day  8 (2.9) 21 (2.5) 58 (4.5)  26 (3.8) 15 (3.1) 18 (3.6) 
≥10 cigarettes/day  8 (2.9) 10 (1.2) 29 (2.3)  9 (1.3) 7 (1.5) 10 (2.0) 
         
Alcohol use§         
Any  11 (4.0) 22 (2.6) 25 (1.9)  13 (1.9) 13 (2.7) 5 (1.0) 
None  266 (96.0) 836 (97.4) 1,266 (98.1)  674 (98.1) 469 (97.3) 489 (99.0) 
         
Age at menarche§         
≤11 years old  59 (21.5) 177 (20.8) 298 (23.2)  128 (18.8) 105 (21.9) 129 (26.4) 
12 to 13 years old  132 (48.0) 464 (54.6) 674 (52.5)  380 (55.7) 264 (55.1) 243 (49.7) 
≥14 years old  84 (30.6) 209 (24.6) 312 (24.3)  174 (25.5) 110 (23.0) 117 (23.9) 
*NVP: Nausea and vomiting during pregnancy 
†SAB: Spontaneous abortion 
‡p<0.05 for severity 
§p<0.05 for duration 
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Table 11 (cont). Selected maternal characteristics by NVP* symptoms: Right from the Start (2000-2004), n=2,430 
 
 
 
  
Symptom 
severity    
Symptom 
duration  
  No symptom 
Nausea 
only 
Nausea and 
vomiting  Short Moderate Long 
  n (%) n (%) n (%)  n (%) n (%) n (%) 
Parity§         
Nulliparous/none  147 (52.7) 409 (47.7) 645 (50.0)  358 (52.1) 219 (45.4) 228 (46.2) 
1  83 (29.8) 300 (35.0) 382 (29.6)  206 (30.0) 174 (36.1) 168 (34.0) 
2+  49 (17.6) 149 (17.4) 264 (20.5)  123 (17.9) 89 (18.5) 98 (19.8) 
         
Pregnancy loss history§         
No prior SAB  88 (31.5) 246 (28.7) 391 (30.3)  227 (33.0) 151 (31.3) 137 (27.7) 
≥1 pregnancy with no SAB  150 (53.8) 429 (50.0) 609 (47.2)  308 (44.8) 236 (49.0) 235 (47.6) 
≥1 pregnancy with ≥1 SAB  41 (14.7) 183 (21.3) 291 (22.5)  152 (22.1) 95 (19.7) 122 (24.7) 
         
Plurality         
Singleton  279 (100.0) 852 (99.3) 1,274 (98.7)  677 (98.5) 479 (99.4) 487 (98.6) 
Multiple  0 (0.0) 6 (0.7) 17 (1.3)  10 (1.5) 3 (0.6) 7 (1.4) 
         
SAB†‡§         
Yes  76 (27.7) 114 (13.7) 70 (5.6)  87 (12.9) 60 (10.3) 33 (4.0) 
No  198 (72.3) 720 (86.3) 1,185 (94.4)  589 (87.1) 522 (89.7) 790 (96.0) 
*NVP: Nausea and vomiting during pregnancy 
†SAB: Spontaneous abortion 
‡p<0.05 for severity 
§p<0.05 for duration 
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Table 12.  Unadjusted and adjusted odds ratio on the association between NVP* symptom severity and duration and risk of pregnancy loss and 
adjusted odds ratios stratified by maternal age: Right from the Start (2000-2004)  
 Main effects model    Models with an interaction term (maternal age) 
    <25 years old  25 to 29 years old  30 to 34 years old  ≥ 35 years old 
NVP characteristics 
Unadj. OR† 
(95% CI)‡ 
Adj. OR 
(95% CI)  Adj. OR (95% CI)  Adj. OR (95% CI)  Adj. OR (95% CI)  Adj. OR (95% CI) 
Symptom severity§           
No symptoms 5.58 (3.99, 7.81) 5.05 (3.56, 7.18)  4.04 (2.14, 7.61)  3.89 (1.89, 7.99)  6.47 (3.16, 13.24)  10.92 (4.47, 26.67) 
Nausea only 2.34 (1.72, 3.17) 2.46 (1.79, 3.37)  2.01 (1.46, 2.76)  1.97 (1.37, 2.83)  2.54 (1.78, 3.64)  3.30 (2.11, 5.16) 
           
Symptom duration║           
Moderate 0.74 (0.52, 1.04) 0.72 (0.51, 1.02)  0.68 (0.48, 0.97)  0.70 (0.48, 1.02)  0.48 (0.31, 0.75)  0.38 (0.24, 0.61) 
Long 0.31 (0.20, 0.46) 0.30 (0.20, 0.45)  0.46 (0.23, 0.94)  0.50 (0.23, 1.05)  0.38 (0.24, 0.61)  0.15 (0.06, 0.37) 
*NVP: Nausea and vomiting during pregnancy 
†OR: Odds ratio 
‡CI: Confidence interval 
§Compared to symptoms of both nausea and vomiting; models stratified by maternal age and adjusted for maternal race and ethnicity, education, marital status,    
alcohol use, age at menarche, parity, and pregnancy loss history 
║Compared to short symptom duration; models stratified by maternal age and adjusted for maternal race and ethnicity, education, marital status, alcohol use, age 
at menarche, parity, and pregnancy loss history 
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4.3 Manuscript 3: Studying the effects of maternal health behaviors in pregnancy: 
An application of propensity score methods  
 
 
Abstract 
 Background: Caffeine is readily available and widely consumed in most 
countries. Issues surrounding caffeine consumption for pregnant women have generated 
much attention and controversy since the 1980’s because of its potential negative impact 
during pregnancy. Most epidemiologic studies have relied on the use of observational 
data to estimate causal effects; however, this poses a challenge when inherent differences 
may exist across the exposure groups. Propensity score methods have been proposed as a 
well-suited alternative approach in reducing the limitations that often plague 
observational study data. We illustrated the use of propensity score methods in studying 
pregnancy health using a study that evaluated the association between caffeine exposure 
at three time points and spontaneous abortion (SAB). Results from propensity score 
models were also compared to estimates from traditional covariate adjustment models.   
Methods: We included 2,407 women with singleton pregnancies, who participated in a 
prospective cohort study on early pregnancy health between 2000 and 2004 in three U.S. 
cities. Information on caffeine consumption and other health data were collected 
extensively through participant telephone interviews, ultrasound assessments in early 
gestation, and medial records abstraction. Logistic regression model was used to estimate 
individual propensity scores. Week-specific pregnancy loss associated with caffeine 
exposure was estimated with discrete-time hazard models. Results: There were no 
overall meaningful differences in estimates from the traditional covariate adjustment 
models and those from the propensity score models. In the analysis of full study 
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population, there was little evidence for an increase in risk for SAB in coffee and caffeine 
exposure around the time of the telephone interview. When we restricted analysis to 
women who reported intake prospectively, pre-pregnancy and around time of interview 
consumptions were found to increase the risk for SAB. Among women who reported 
intake prospectively, no evidence for increase risk of SAB was found across three time 
points. Conclusions: This study was the first, to our knowledge, to apply propensity 
score methods in studying health behaviors in pregnancy. Given our results using both 
traditional and propensity score models, this indicates that our original models were 
robust enough to detect the differences on the risk of SAB across exposure groups. 
Moreover, this provides additional confirmation that our results from traditional covariate 
adjustment analysis were not as a result of biased estimation often found from using 
observational study data.  
 
 
4.3.1 Introduction  
 
Use of observational studies of maternal health exposures in pregnancy 
The goal of many epidemiologic studies is to estimate the causal effect of broadly 
defined exposures on a health outcome,53 and reproductive and perinatal health research 
is no exception. The use of randomized studies is not always justified or ethical in 
studying pregnancy health (e.g. randomizing pregnant women to receive potentially 
harmful exposures). Consequently, investigators often rely on observational research as 
an alternative for estimating causal effects. The causal interpretation from observational 
data is complicated because exposure groups may differ systematically with respect to 
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relevant observed covariates and, therefore, may not be directly comparable and such 
differences may lead to biased effect estimates.17-20 Traditional covariate adjustment may 
not be sufficient to correct this bias in estimation due to a limited number of covariates 
for adjustment that can be used. Recently, attention has been paid to another approach to 
the control of confounding through the use of propensity scores.17, 23  
 
The utility of propensity score methods in studying pregnancy health 
Propensity score methods have been used in pharmacoepidemiology and other 
disciplines, but reproductive and perinatal epidemiologic studies have been slow to adopt 
this method. The concept of propensity scores estimated at baseline was developed by 
Rosenbaum and Rubin23 to reduce bias in observational studies. In principle, the effect of 
an exposure can be measured among individuals with the same probability of being 
exposed, thus allowing control for confounding. Under the assumption that all relevant 
predictors of exposure have been adequately accounted for, the use of propensity scores 
to reduce bias is attractive, because individuals with the same propensity score have the 
same chance of being exposed even though in truth some were and some were not. 
Therefore, propensity score methods are often conceptualized as mimicking randomized 
trials (e.g. randomizing pregnant women to consume or not consume caffeine).20 
In this paper we illustrate the use of propensity scores for studying the effects of 
health behaviors in pregnancy, a period of time in which many women may more 
carefully modulate their behaviors and exposures. We illustrate its application as an 
extension of an earlier study that evaluated the association between caffeine exposure at 
three time points and SAB.24 Caffeine provides a useful example as it’s consumption 
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around the time of pregnancy is influenced by a number of factors. Epidemiologic studies 
on caffeine consumption during pregnancy and risk of spontaneous abortion (SAB) have 
generated substantial public health interest since the 1980s; however conclusive evidence 
for or against an association has not been established.21 SAB, which affects 
approximately 10% of all clinically-recognized pregnancies,22 is defined as a pregnancy 
loss before 20 completed weeks’ gestation. The concern about caffeine consumption 
during pregnancy is based on caffeine’s ability to cross the placental membranes freely,54 
its decreased clearance rate in second and third trimesters,55, 56 potential to influence 
cellular development by increasing cAMP,107 and the interference with utero-placental 
circulation with increased catecholamines.58  Methodological limitations in earlier 
epidemiologic studies,21 including differences in measuring and quantifying exposure and 
control of confounding, pose a challenge to the interpretation of results from previous 
studies. To document the approach in estimating propensity scores and its use in 
regression modeling, a series of SAS codes (SAS Institute, Cary, NC) is provided at the 
end (Appendix 4).  
 
Propensity Score 
Under the assumption of strongly ignorable treatment or exposure assignment, a 
propensity score is defined as the conditional probability of exposure to a potential risk 
factor given an individual’s set of observed covariates.23 Each individual has a vector of 
observed covariates measured at baseline, Xi, and an indicator of exposure (or treatment), 
Zi, where Zi=1 if exposed and Zi=0 if unexposed. The propensity score, e(Xi) is the 
probability of exposure for a person with covariates Xi, that is,  
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      e(Xi) = P(Zi=1|Xi = xi),                                                                                     
 
where we assume that the Zi, i =1, and n (number of study subjects) are independent 
conditional on the set of covariates X. 
 
The propensity score is a function of the observed 
covariates X such that the conditional distribution of X given the propensity score e(X) is 
the same for subjects with Zi = 1 and with Zi =0. Individuals with the same propensity 
score should have the same probability of being exposed, although they may have 
different sets of X’s. Under the additional conditions of strongly ignorable treatment 
assignment X, (i.e., no systematic unobserved differences between subjects with Z=1 and 
Z=0), the estimated treatment effect at a fixed value of the propensity score is unbiased.  
The propensity score is generally estimated from the observed data using 
multivariable logistic regression.17 After they are estimated, propensity scores are used to 
control for selection bias or confounding. The three most common techniques that use 
propensity score include matching on propensity score, stratified analysis with propensity 
score as the stratification variable, and combining the use of conventional multivariable 
modeling with propensity scores.17, 20 Matching is an approach that matches each exposed 
individual to at least one unexposed individual with similar propensity scores. 
Stratification is a modeling approach in which the investigator controls for propensity 
scores in propensity score-disease relationship, and the third approach allows the 
investigators to include the propensity score along with additional predictors for the 
outcome in the model.17, 20 Because the use of propensity score methods allow 
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simultaneous control for confounding by several covariates, it is unnecessary to adjust for 
the same set of covariates that was used in propensity score estimation.  
 
4.3.2 Methods  
 
Study population 
Data for this study came from a prospective cohort study on drinking water 
disinfection by-products and SAB (Right from the Start, RFTS). RFTS recruited and 
enrolled pregnant women at least 18 years old who were less than 12 weeks’ gestation, 
and women between 18 to 45 years old who were trying to conceive for six months or 
less, from three U.S. cities (Raleigh, North Carolina; Memphis, Tennessee; and 
Galveston, Texas) from 2000 to 2004.  Details of the study protocol can be found 
elsewhere.83, 98 We collected detailed information on maternal characteristics, health 
behaviors, medical and reproductive histories, current pregnancy history, and pregnancy 
symptoms during two telephone interviews that took place at no later than 16 weeks’ 
gestation and then between 20 and 25 weeks’ gestation.  
 
Assessment of caffeine consumption 
Information on daily consumption of caffeinated beverages (coffee, iced tea, hot 
tea, and sodas) for a typical week was assessed during a telephone interview. Detailed 
questions were asked about all sources, including the number of cups consumed daily in a 
typical week, beverage sizes, and brewing method for coffee (brewed versus instant). We 
designated cups of coffee and hot tea as small (4 to 10 oz), medium (12 to 14 oz), large 
(16 to 24 oz); sizes for iced tea were designated as small (4 to 10 oz), medium (12 to 20 
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oz), and large (22 to 34 oz), and for sodas as small (8 to 12 oz), medium (14 to 22 oz), 
and large (24 to 34 oz). Reported consumption of small amounts less than one cup or 
glass was set to a small half cup or glass.  
Information regarding changes in consumption for any caffeinated beverages, if 
any, was also collected as was the timing of changes down to the ‘month’, ‘day’, and 
‘year’ for each beverage. When the ‘day’ was unknown but the “week in month” was 
reported, we imputed the day using the midpoint of the week; mid-point of the month was 
used to impute the day of event when only the month of the event was known. 
 
Determination of caffeine exposure  
With information collected at the time of the telephone interview, caffeine 
exposures from coffee alone and from all sources (mg/day) were calculated based on 
daily amount consumed (number of cups consumed and cup sizes), coffee brewing 
methods, and with the assignment of caffeine content84 based on the midpoints of the cup 
sizes.  
We then generated caffeine exposure (mg/day) at three time points [pre-
pregnancy, four weeks after last menstrual period (LMP), and consumption at the time of 
the interview] for coffee only and total caffeine for each woman based on consumption 
assessed at the time of the interview and if applicable the self-reported consumption, 
prior to any change in consumption and the timing of change in intake. Total caffeine was 
the cumulative intake (mg/day) from caffeinated coffee, caffeinated iced and hot tea, and 
caffeinated sodas.  
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Probability of caffeine consumption during three time windows 
We first estimated the probability of coffee consumption (yes/no) and 
consumption of any caffeinated beverages (yes/no) for three time points using logistic 
regression models. Covariates were selected to enter the logistic regression model 
included known and strong predictors of pregnancy loss, as well as other predictors of 
caffeine use, including maternal age, race and ethnicity, maternal education, marital 
status, smoking, alcohol use, parity, symptoms of nausea and vomiting (NVP), and 
pregnancy loss history. Estimated propensity scores for consumption for each subject 
were predicted probabilities from the logistic regression models.   
After constructing the propensity scores, all individuals were subclassified into 
propensity score quintiles, as suggested by D’Agostino.17 Because the propensity score is 
a scalar summary of the observed background covariates, women in the quintile can have 
different values for specific observed covariates, but, within the same stratum, women 
who consumed coffee or any caffeinated beverages and non-consumers would have 
similar distributions of the covariates. This subclassification was used in subsequent 
analysis models, with time to SAB as the outcome variable and caffeine exposure from 
coffee alone and from all sources as the main exposures.  
  
Gestational age and outcome classifications 
An endovaginal ultrasound was performed around eight weeks’ gestation (median 
gestational age at ultrasound = 9.3 weeks) to confirm pregnancy viability and to ascertain 
the gestational age of the fetus.  
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We found the self-reported LMP in this cohort to be highly reliable and consistent 
with LMP dates assessed by ultrasound;83, 108 therefore, self-reported LMP was used to 
date the onset of pregnancy. Pregnancy outcome data were ascertained via participant 
self-report and confirmed via medical records and/or corresponding vital or fetal death 
records. Early pregnancy loss or SAB is defined in this study as a loss of a pregnancy 
before 20 completed weeks’ gestation as calculated from self-reported LMP.  
 
Statistical analysis 
We constructed discrete hazard models as unconstrained continuation odds ratio 
models to estimate the effects of exposure from coffee (or from all caffeine sources) on 
the odds of having a SAB at each gestational week, conditional on a woman’s pregnancy 
having survived to the beginning of that gestational week.92 We then compared results 
using the traditional approach of adjustment for confounders as covariates to propensity 
score models.  
Caffeine exposure (mg/day) was examined as a categorical variable, with 
cutpoints in caffeine use (none, >0 to median, ≥median, and then separately for >75th 
percentile) generated in order to produce more easily interpretable estimates which 
allowed for comparison of results with earlier studies.  
Potential confounders that were used in covariate adjustments for the traditional 
models included maternal age, race and ethnicity, maternal education, marital status, 
smoking, alcohol use, body mass index, vitamin use, NVP, pregnancy loss history, and 
induced abortion history, where covariates were retained in the final model if they 
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changed the effect estimates for the exposure by 10% or greater or if they were predictive 
of the outcome based on a p-value of <0.20.  
In the propensity score models, we first examined caffeine effects within each 
propensity score quintile and used an interaction test to determine whether stratification 
was needed, based on p=0.05 as the significance level of interest. We found that the test 
of interaction for each time window did not meet our criteria of <0.05 (range: 0.10 to 
0.98); therefore, propensity scores were adjusted as the main effects. Additionally, we did 
not adjust for any covariates in the propensity score models.  
 
4.3.3 Results  
 
We included a total of 2,407 women in the final analysis, of whom 258 (10.7%) 
had a SAB. Among those with pregnancy loss, 74 (29%) of loss occurred prior to the 
telephone interview and 184 (71%) took place after the interview. The majority of the 
study participants recruited were from Raleigh (45.2%) or Memphis (37.3%). The mean 
age at enrollment was 27.8 years and the mean gestational age at enrollment was 54.8 
days. Non-Hispanic White women made up approximately 56% of the study population 
and 32% were Non-Hispanic Black; nine percent were of Hispanic ethnicity with the 
majority of these (76.0%) from the Galveston area. Our study population included many 
women who had completed at least college (49.0%), who were married (66.0%), non-
smokers (94.6%), non-drinkers of alcoholic beverages during pregnancy (97.6%), or first 
time mothers (49.6%). Approximately 45% were considered as overweight or obese by 
the Institute of Medicine classification.105 The majority of the study participants (88.4%) 
reported experiencing some form of NVP symptoms, with 35.4% having nausea 
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symptoms only and 53.0% having nausea symptoms with vomiting episodes. 
Approximately 79% of study population consumed caffeinated beverages prior to 
becoming pregnant, with 41% (n=777) reported consuming coffee. Coffee consumption 
decreased by more than 50% from pre-pregnancy to the time of the interview, whereas 
consumption of non-coffee caffeinated beverages dropped approximately 23% in the 
same time period. Among consumers, the median intake for coffee prior to pregnancy 
was 348.0 mg/day and the median intake declined to 200.8 mg/day by the time of the 
telephone interview. Median caffeine consumption among consumers decreased from 
234.9 mg/day prior to pregnancy to 165.3 mg/day around the time of the telephone 
interview (data not shown).  
In the analysis using the full study population, findings from propensity score 
models showed no substantial differences in the point estimates compared to results from 
the traditional multivariable outcome models, in which we saw that exposures from 
coffee alone and caffeine from all sources mostly showed no increase in risk for SAB. 
Most odds ratios (ORs) from the propensity score models moved closer to the null or 
remained the same as those obtained by the traditional models. Under the traditional 
covariate adjustments, there was little evidence for increase in risk for SAB for low 
(<200.8mg/day; OR=1.2, 95%CI: 0.7, 1.9) coffee exposure and some evidence for higher 
total caffeine exposure (OR=1.2, 95%CI: 0.9, 1.7 for above median and OR=1.3, 95%CI: 
0.9, 1.9 for greater than 75th percentile) at the time of the interview. The ORs elevated 
slightly for total caffeine (1.3 and 1.4 respectively) under propensity score estimation, but 
such shift in the magnitude was minimal (Table 13).  When the analyses were restricted 
to women who reported coffee and caffeine intake retrospectively (pregnancy loss 
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occurred before interview), we saw evidence of increase in risk for SAB in pre-pregnancy 
caffeine intake and for both coffee and total caffeine exposure around the time of the 
interview, though the results were imprecise in the traditional models. Propensity score 
model results also supported findings of a positive association in these time points, but 
the magnitude of effects were similar (Table 14). Among women who reported coffee 
and caffeine consumption prospectively (pregnancy loss occurred after interview), 
propensity score models yielded more precise estimates compared to the ORs from the 
traditional multivariable outcome models. We saw no evidence of an increase in risk for 
SAB with results from both modeling methods, with the exception of an imprecise OR 
(OR=3.0, 95%CI: 0.7, 13.2) for coffee consumption around the time of the interview. 
However, this OR dropped to 0.6 (95%CI: 0.2, 1.8) and precision of point estimates 
increased by 50% when the analysis was conducted using propensity score methods 
(Table 15).   
 
4.3.4 Discussions  
 
To our knowledge, this study is the first to apply propensity score methods in 
studying health behaviors in pregnancy. Pregnancy is a critical time in a woman’s life; 
often a time when modification of health behaviors takes place for the health of the fetus 
or due to the advice of clinicians. Investigators are often interested in evaluating the 
effects of certain behaviors on pregnancy outcomes. Because studies of pregnancy health 
rely heavily on observational research study designs, women with exposure of interest 
may be systematically different than those who are unexposed, leading to potentially 
biased estimates of the maternal behaviors and outcome relationships.   
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We chose to re-visit the example of caffeine exposure and SAB due to its 
potential public health importance and conflicting results found in recent literature.21 
Data on caffeine exposure from observational studies may not be adequate in estimating 
caffeine effects on pregnancy outcome because some pregnant women may drastically 
modify their level of consumption during pregnancy. Because randomizing pregnant 
women to different levels of caffeine exposures cannot be done, the balancing property of 
propensity score method is an especially useful application over traditional multivariable 
analysis approach because this method mimics randomization. We applied the use of 
propensity score methods to our earlier study24 which, like many others, relied on the use 
of traditional covariate adjustment methods to evaluate the caffeine-pregnancy loss 
relationship. With this new application we were able to compare the potentially biased 
estimates obtained from traditional models to the results from propensity score models; 
thereby providing us a glimpse on the effects of coffee and total caffeine on the risk of 
SAB if women were randomized to their exposure status, and that the observed covariates 
in consumers and non-consumers were evenly distributed.  
 Overall, we observed no meaningful differences between the estimates from the 
traditional models and those from the propensity score models. Results from the 
propensity score models supported our earlier findings for an increased risk in SAB for 
consumption of coffee alone and for total caffeine around the time of the interview, in the 
analyses among all women and of losses that took place prior to the interview (Tables 13 
and 14). Nevertheless, in the analysis that was restricted to losses after the interview 
(Table 15), the single but highly imprecise estimate that showed a moderate increase in 
risk for SAB for high coffee consumption around the time of the interview from the 
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traditional model disappeared using the propensity score model that produced a more 
precise estimate not showing a positive association.  
Propensity scores are estimated probabilities, based on each woman’s measured 
characteristics, that she would consume or not consume caffeine; this implies that women 
with the same estimated propensity score have equal probability of ‘becoming exposed’. 
The robust properties of the propensity scores allowed us to examine the association 
between caffeine exposure and SAB under the context of “virtual randomization”, in 
which individuals in the consumer and non-consumer groups had overall similar risk 
factors that predict SAB. This form of grouping eliminated the potential biases as a result 
of the systematic differences between the exposure groups with respect to the observed 
covariates. We first examined the distribution of propensity scores by caffeine variables 
(using proc univariate); we then performed additional checks by examining the 
distribution of the covariates by each exposure group, stratified by propensity score 
quintiles.20 The covariates we used did an adequate job in estimating the propensity of 
coffee and total caffeine consumption at three time points and we were able to confirm 
that balanced covariates were achieved across both groups (consumers and non-
consumers) from the stratified analysis. Given we saw no substantial changes from the 
original results observed using traditional models compared to the estimates from the 
propensity score models, this indicated that our original models were robust enough to 
detect the differences on the risk of SAB among women who consumed caffeine and 
women who did not consume. This makes it less likely that our findings on the lack of 
positive association between caffeine intake and SAB in our earlier study are a result of 
biased estimation that often plagues observational studies.  
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Unlike other studies that recruited their study populations from prenatal care 
clinics, we identified and recruited a population of pregnant women early in gestation and 
women who were trying to conceive. With the use of a prospective cohort study design, 
we collected detailed information as pregnancy progresses to discern patterns of 
caffeinated coffee use and generated exposure for coffee alone and caffeine from all 
sources. Because of our timing in recruitment and collection of maternal health 
information, with caffeine assessment taking place prior to loss among 67% with loss, 
differential misclassification of their exposures due to potential recall bias was 
minimized. In the analysis of loss before interview, the increase in risk for SAB we 
observed for coffee and caffeine consumption around the time of interview could have 
come from reporting bias from early pregnancy loss or a return of pre-pregnancy 
consumption level due to the lack of influence from NVP symptoms.  
Despite improvements in our study design, limitations still exist. Our study did 
not collect coffee, iced tea, hot tea, and soda consumption information weekly; rather, we 
placed assumptions that the reported consumption levels before and after change were 
maintained in the gestational weeks before and after the change. Consequently, we could 
precisely capture multiple changes in consumption that may have occurred throughout 
the pregnancy. A few practical limitations persist, despite the many advantages for 
applying propensity score methods on observational study data. Unlike true 
randomization, where the study design removes bias from both measured and 
unmeasured factors, residual bias may still persist because propensity scores can only be 
estimated from measured data and bias cannot be controlled for unmeasured covariates or 
for variables that were measured poorly.20 Although many current literature addresses the 
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theoretical framework and the advantages of propensity score methods, very few have 
addressed other limitations such as issues with handling missing data and systematic 
variable selection.17, 109  
The use of propensity score methods is a novel approach in studying health 
exposures in pregnancy. While it should not be regard as the sole method in the analyses 
of observational study data,17, 20 its application is an important addition to traditional 
modeling methods for investigators to evaluate exposure and outcome relationships by 
reducing bias in estimates and for improving inferences on causal effects.   
 
4.3.5 References  
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Table 13. Results using traditional and propensity score models. Coffee and caffeine consumption and the risk of  
pregnancy loss, contrasting none, below or equal to the median, above the median, and above the 75th percentile:  
all pregnancy loss (n=258) 
 Traditional models* Propensity score models 
Coffee Exposure 
(mg/day) 
# 
Losses 
Unadj. OR‡ Adj.† OR 95% CI§  Adj. OR 95%CI 
Pre-pregnancy        
   None 176 1.0 1.0 -  1.0 - 
   >0 - <348.0 32 0.8 0.9 (0.6, 1.3)  0.8 (0.5, 1.2) 
   ≥348.0 49 0.9 0.8 (0.5, 1.1)  0.9 (0.6, 1.2) 
   >696.0 18 1.0 0.9 (0.5, 1.5)  1.0 (0.6, 1.7) 
        
Four weeks post LMP#        
   None 189 1.0 1.0 -  1.0 - 
   >0 - <348.0 27 0.8 0.8 (0.5, 1.2)  0.8 (0.5, 1.2) 
   ≥348.0  42 1.0 0.9 (0.6, 1.3)  1.0 (0.7, 1.5) 
   >602.3 15 0.8 0.7 (0.4, 1.2)  0.8 (0.5, 1.4) 
        
Time of telephone 
interview 
       
   None 211 1.0 1.0 -  1.0 - 
   >0 - <200.8 19 1.1 1.2 (0.7, 1.9)  1.2 (0.7, 1.9) 
   ≥200.8 27 1.2 1.0 (0.6, 1.6)  1.1 (0.7, 1.8) 
   >372.9 5 0.8 0.7 (0.3, 1.8)  0.7 (0.3, 1.8) 
*Savitz et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62 
†Model adjusted for maternal age, race/ethnicity, maternal education, marital status, alcohol use, vitamin use, and 
symptoms of nausea and vomiting during early pregnancy 
‡OR: Odds ratio 
§CI: Confidence interval 
#LMP: Last menstrual period 
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Table 13 (cont). Results using traditional and propensity score models. Coffee and caffeine consumption and the risk of  
pregnancy loss, contrasting none, below or equal to the median, above the median, and above the 75th percentile:  
all pregnancy loss (n=258) 
 Traditional models* Propensity score models 
Total Caffeine Exposure 
(mg/day) 
# 
Losses 
Unadj. OR‡ Adj.† OR 95% CI§  Adj. OR 95%CI 
Pre-pregnancy        
   None 52 1.0 1.0 -  1.0 - 
   >0 - <243.7 104 1.0 1.0 (0.7, 1.4)  1.0 (0.7, 1.4) 
   ≥243.7 101 0.9 0.9 (0.6, 1.2)  1.0 (0.7, 1.4) 
   >513.2 48 0.9 0.8 (0.5, 1.2)  0.9 (0.6, 1.4) 
        
Four weeks post LMP§        
   None 70 1.0 1.0 -  1.0 - 
   >0 - <210.3 93 1.1 1.0 (0.7, 1.4)  1.0 (0.8, 1.4) 
   ≥210.3 95 1.1 1.0 (0.7, 1.3)  1.0 (0.8, 1.4) 
   >463.1 47 1.0 0.9 (0.6, 1.3)  1.0 (0.7, 1.4) 
        
Time of telephone 
interview 
       
   None 102 1.0 1.0 -  1.0 - 
   >0 - <144.3 71 1.1 1.0 (0.7, 1.4)  1.1 (0.8, 1.5) 
   ≥144.3 84 1.4 1.2 (0.9, 1.7)  1.3 (1.0, 1.8) 
   >273.2 46 1.5 1.3  (0.9, 1.9)  1.4 (1.0, 2.1) 
*Savitz et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62 
†Model adjusted for maternal age, race/ethnicity, maternal education, marital status, alcohol use, vitamin use, and 
symptoms of nausea and vomiting during early pregnancy 
‡OR: Odds ratio 
§CI: Confidence interval 
#LMP: Last menstrual period 
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Table 14. Results using traditional and propensity score models. Coffee and caffeine consumption and the risk of  
pregnancy loss, contrasting none, below or equal to the median, above the median, and above the 75th percentile:  
pregnancy loss before interview (n=74) 
 Traditional models* Propensity score models 
Coffee Exposure 
(mg/day) 
# 
Losses 
Unadj. OR‡ Adj.† OR 95% CI§  Adj. OR 95%CI 
Pre-pregnancy        
   None 45 1.0 1.0 -  1.0 - 
   >0 - <348.0 11 0.8 0.8 (0.3, 2.0)  0.7 (0.3, 1.7) 
   ≥348.0 17 1.2 1.0 (0.6, 1.9)  1.1 (0.6, 2.1) 
   >696.0 7 1.8 1.5 (0.7, 3.5)  1.5 (0.7, 3.6) 
        
Four weeks post LMP#        
   None 50 1.0 1.0 -  1.0 - 
   >0 - <348.0 11 0.9 1.0 (0.4, 2.2)  0.9 (0.4, 2.1) 
   ≥348.0  13 1.2 1.0 (0.5, 1.9)  1.1 (0.6, 2.2) 
   >602.3 4 0.9 0.8 (0.3, 2.3)  0.9 (0.3, 2.5) 
        
Time of telephone 
interview 
       
   None 53 1.0 1.0 -  1.0 - 
   >0 - <200.8 7 1.7 1.9 (0.8, 4.4)  1.6 (0.7, 3.9) 
   ≥200.8 13 2.3 1.8 (0.9, 3.7)  2.1 (1.0, 4.2) 
   >372.9 2 1.4 1.1 (0.3, 4.5)  1.3 (0.2, 5.3) 
*Savitz et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62 
†Model adjusted for maternal age, race/ethnicity, maternal education, marital status, alcohol use, vitamin use, and  
symptoms of nausea and vomiting during early pregnancy 
‡OR: Odds ratio 
§CI: Confidence interval 
#LMP: Last menstrual period
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Table 14 (cont). Results using traditional and propensity score models. Coffee and caffeine consumption and the risk of  
pregnancy loss, contrasting none, below or equal to the median, above the median, and above the 75th percentile:  
pregnancy loss before interview (n=74) 
 Traditional models* Propensity score models 
Total Caffeine Exposure 
(mg/day) 
# 
Losses 
Unadj. OR‡ Adj.† OR 95% CI§  Adj. OR 95%CI 
Pre-pregnancy        
   None 9 1.0 1.0 -  1.0 - 
   >0 - <243.7 33 1.6 1.6 (0.7, 3.4)  1.6 (0.8, 3.4) 
   ≥243.7 31 1.3 1.2 (0.6, 2.6)  1.3 (0.6, 2.9) 
   >513.2 14 1.2 1.1 (0.4, 2.6)  1.2 (0.5, 2.9) 
        
Four weeks post LMP§        
   None 18 1.0 1.0 -  1.0 - 
   >0 - <210.3 28 1.2 1.2 (0.6, 2.2)  1.3 (0.7, 2.5) 
   ≥210.3 28 1.1 1.0 (0.5, 2.0)  1.1 (0.6, 2.2) 
   >463.1 11 0.6 0.5 (0.2, 1.4)  0.6 (0.2, 1.5) 
        
Time of telephone 
interview 
       
   None 24 1.0 1.0 -  1.0 - 
   >0 - <144.3 18 1.3 1.1 (0.6, 2.2)  1.3 (0.7, 2.5) 
   ≥144.3 31 2.1 1.9 (1.1, 3.5)  1.9 (1.0, 3.5) 
   >273.2 18 2.6 2.3 (1.2, 4.5)  2.2 (1.1, 4.4) 
*Savitz et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62 
†Model adjusted for maternal age, race/ethnicity, maternal education, marital status, alcohol use, vitamin use, and 
symptoms of nausea and vomiting during early pregnancy 
‡OR: Odds ratio 
§CI: Confidence interval 
#LMP: Last menstrual period 
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Table 15. Results using traditional and propensity score models. Coffee and caffeine consumption and the risk of  
pregnancy loss, contrasting none, below or equal to the median, above the median, and above the 75th percentile:  
pregnancy loss after interview (n=184) 
 Traditional models* Propensity score models 
Coffee Exposure 
(mg/day) 
# 
Losses 
Unadj. 
OR‡ 
Adj.† OR 95% CI§  Adj. OR 95%CI 
Pre-pregnancy        
   None 131 1.0 1.0 -  1.0 - 
   >0 - <348.0 21 1.0 1.2 (0.7, 2.1)  0.8 (0.5, 1.3) 
   ≥348.0 32 1.0 0.8 (0.5, 1.3)  0.8  (0.5, 1.2) 
   >696.0 11 1.0 1.1 (0.5, 2.3)  0.8 (0.5, 1.6) 
        
Four weeks post LMP#        
   None 139 1.0 1.0 -  1.0 - 
   >0 - <348.0 16 0.9 1.1 (0.6, 2.1)  0.7 (0.4, 1.2) 
   ≥348.0  29 1.0 0.8 (0.5, 1.2)  1.0 (0.6, 1.5) 
   >602.3 11 1.0 0.6 (0.3, 1.4)  0.8 (0.4, 1.5) 
        
Time of telephone 
interview 
       
   None 158 1.0 1.0 -  1.0 - 
   >0 - <200.8 17 1.0 0.7 (0.3, 1.6)  1.0 (0.6, 1.8) 
   ≥200.8 9 1.0 1.0 (0.5, 1.8)  0.9 (0.5, 1.5) 
   >372.9 3 2.9 3.0 (0.7, 13.2)  0.6 (0.2, 1.8) 
*Savitz et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62 
†Model adjusted for maternal age, race/ethnicity, maternal education, marital status, alcohol use, vitamin use, and 
symptoms of nausea and vomiting during early pregnancy 
‡OR: Odds ratio 
§CI: Confidence interval 
#LMP: Last menstrual period 
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Table 15 (cont). Results using traditional and propensity score models. Coffee and caffeine consumption and the risk of  
pregnancy loss, contrasting none, below or equal to the median, above the median, and above the 75th percentile:  
pregnancy loss after interview (n=184) 
 Traditional models* Propensity score models 
Total Caffeine Exposure 
(mg/day) 
# 
Losses 
Unadj. 
OR‡ 
Adj.† OR 95% CI§  Adj. OR 95%CI 
Pre-pregnancy        
   None 43 1.0 1.0 -  1.0 - 
   >0 - <243.7 71 1.0 1.1 (0.7, 1.7)  0.8 (0.6, 1.2) 
   ≥243.7 70 1.0 1.0 (0.6, 1.6)  0.9 (0.6, 1.3) 
   >513.2 34 1.1 0.8 (0.5, 1.5)  0.8 (0.5, 1.3) 
        
Four weeks post LMP§        
   None 52 1.0 1.0 -  1.0 - 
   >0 - <210.3 65 0.9 1.1 (0.7, 1.7)  1.0 (0.7, 1.4) 
   ≥210.3 67 0.9 0.8 (0.5, 1.3)  1.0 (0.7, 1.5) 
   >463.1 36 0.9 0.8 (0.5, 1.3)  1.1 (0.7, 1.7) 
        
Time of telephone 
interview 
       
   None 78 1.0 1.0 -  1.0 - 
   >0 - <144.3 53 0.8 0.9 (0.6, 1.4)  1.0 (0.7, 1.4) 
   ≥144.3 53 1.1 1.1 (0.7, 1.7)  1.2 (0.8, 1.7) 
   >273.2 28 1.1 1.1 (0.6, 1.8)  1.2 (0.8, 1.9) 
*Savitz et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62 
†Model adjusted for maternal age, race/ethnicity, maternal education, marital status, alcohol use, vitamin use, and 
symptoms of nausea and vomiting during early pregnancy 
‡OR: Odds ratio 
§CI: Confidence interval 
#LMP: Last menstrual period 
 
  
CHAPTER 5: DISCUSSION 
 
 
5.1 Summary of findings 
In this study, we found that most maternal characteristics, with the exception of 
plurality, were not associated with having NVP. There was a dose-response gradient for 
increasing risk for delayed symptom onset with increasing maternal age; increased risk 
for delayed onset was also found among non-Hispanic Blacks, Hispanic women, or 
women who began menstruating between 12 and 13 years old. Additionally, our findings 
indicated that older maternal age and non-Hispanic Blacks were less likely to experience 
NVP symptoms lasting beyond the first trimester.  
Findings of this study provided evidence that the lack of NVP symptoms is 
associated with an increased risk for SAB, compared to having any symptoms. Maternal 
age was found to modify the association between symptom severity and duration and 
SAB, with increasing maternal age found to strengthen the risk for SAB among women 
without any symptoms. Reduced risks for SAB were found across all maternal age groups 
for those with longer symptoms duration, but the effects were much stronger in the oldest 
maternal age group.  
Propensity score methodology was applied in the third manuscript to study the 
effects of caffeine exposure (coffee only and total caffeine from all sources) and SAB. 
We found no overall meaningful differences between estimates from the traditional 
covariate adjustment models and the propensity score models. In the analysis of full study 
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population, there was a suggestion of increased risk for SAB for caffeine exposure from 
coffee alone and from all sources around the time of interview. In the analysis of women 
who reported intake retrospectively, pre-pregnancy and around time of interview 
consumptions were found to increase the risk for SAB. When we restricted analysis to 
women who reported intake prospectively, we saw no evidence for an increase in risk of 
SAB.     
 
5.2 Strengths and limitations 
5.2.1 Prospective data collection on maternal health exposures and behaviors 
One strength of this study is the use of maternal exposure and behavioral data that 
were collected prospectively from women who were early in their pregnancy. Extensive 
information was collected via two telephone interviews and included maternal health 
behaviors (e.g. caffeine consumption), reproductive and medical histories, current 
pregnancy history and symptoms (e.g. NVP symptoms), and water exposure 
characteristics. RFTS collected information on the timing of onset and ending dates 
separately for symptoms of nausea and for vomiting episodes. NVP onset and ending 
dates were collected as month, day, and year, as well as timing information in “week in 
the month”. Detailed information was also collected on consumption of caffeinated 
beverages (coffee, iced tea, hot tea, and sodas). Questions were asked about all four 
sources, including the number of cups consumed daily, beverage sizes, and brewing 
method for coffee. Furthermore, information regarding changes in consumption (timing 
and amount) was also collected.  
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 In this study, we collected information directly from study participants early in 
pregnancy (i.e. when recall is more likely accurate); however, because variation in 
symptoms of NVP is known to exist daily or weekly, one main draw back in this study is 
that NVP data were not collected daily. A more extensive mode of data collection (e.g. 
daily diaries) would have captured the severity, timing of onset, and symptom duration of 
NVP symptoms more accurately. This form of data collection should also be applied to 
caffeine exposure assessments. Given we did not collect coffee, iced tea, hot tea, and 
soda consumption information weekly; rather, we placed assumptions that the reported 
consumption levels before and after change were maintained throughout the pregnancy. 
Consequently, we were unable to precisely capture the variations in consumption that 
may have taken place throughout the pregnancy. 
   
5.2.2 Subclassification of nausea and vomiting symptoms 
With our extensive collection of information on NVP symptoms, another strength 
of this study is our ability to examine NVP with respect to symptom severity, timing of 
symptom onset, and symptom duration. No other study of NVP and SAB to date has 
examined the effects of NVP subgroups, and only one other recent study42 explored 
potential maternal health factors that may potentially influence the NVP subgroups.  
 
5.2.3 Prospective follow-up on study subjects and outcome assessment 
Because of the study design, another strength of this study is the prospective 
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follow-up of each woman to determine pregnancy outcome. Many previous studies have 
solely relied on hospital records or vital records to estimate gestational age and to 
ascertain pregnancy outcomes. Unlike previous studies, we confirmed current pregnancy 
status (e.g. still pregnant, had SAB, etc.) with each woman at the start of each telephone 
interview, and we utilized three different sources (participant self-report, medical chart 
abstraction, and vital and fetal death record linkages) for the confirmation and 
verification of pregnancy outcome. This approach is especially important for the 
identification of SABs in a timely manner. Moreover, first trimester endovaginal 
ultrasounds were used to confirm the viability of pregnancy and to ascertain gestational 
age of the fetus. We found in this study that self-reported LMP to be highly reliable in 
dating pregnancy onset; therefore estimated gestational age in this study population was 
primarily determined based on women’s self-reported LMP and secondarily with 
ultrasound dating. If both self-reported LMP and LMP from ultrasound data were 
available, ultrasound data were available to adjust LMP estimates of gestational age if 
they differed for more than seven days or when LMP dates were unavailable or deemed 
invalid.      
Although this study followed women prospectively through their pregnancies, 
limitations still exist. Our study population, unlike those used in previous studies, 
represents a selective group of women who were very early in their pregnancy or were 
actively trying to conceive a pregnancy. Consequently, they may be more apt to modify 
their behavior and adopt a healthier lifestyle prior to or around the time of study 
enrollment. Although we ascertained information on behavior prior to change (along with 
the date of change), it is possible that this still leads to an underestimation of the true 
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exposure and a bias in estimates. Maternal age of RFTS study participants were found to 
be comparable to the general population in the same geographic location but different in 
other maternal characteristics, where RFTS women were more likely to be highly 
educated (≥ 16 years), non-Hispanic White (Raleigh and Memphis) and Hispanic 
(Galveston), and nulliparous.83  
 
5.2.4 Use of discrete-time continuation ratio logistic survival model 
Studies of SABs are subject to left truncation because women tend to enroll into a 
study at various gestational ages and women without a viable pregnancy prior to study 
enrollment, who would have otherwise been eligible to participate, are missing from the 
study population.70, 71 Analytic techniques used previously in many studies on maternal 
exposures and SAB posed limitations, especially with the use of logistic regression in 
prospective cohort studies. Because logistic regression does not account for left 
truncation and assumes equal follow-up time for all subjects, it is especially problematic 
when the left truncation is differential with respect to exposure status; thus fitting logistic 
regression models would create a biased estimate of effect from SAB data. In this study, 
we used discrete-time continuation ratio logistic regression model (a.k.a. discrete hazard 
model), with is a marked improvement in statistical methods over previous studies. With 
this technique, we were able to handle the concerns with left truncation and to account for 
delay entry by modeling the probability of a woman having a pregnancy loss at a given 
week, conditional on her not having experienced a loss in the previous week. 
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5.2.5 Application of propensity score methods in studying pregnancy health 
The application of propensity score methods in studying pregnancy health is the  
final strength of this study. Although the propensity scores have been widely used in 
pharmacoepidemiology, reproductive and perinatal epidemiologic studies have been slow 
to adopt this method. Because causal interpretation from observational data has 
limitations and the effect estimates using traditional covariate adjustments may be biased, 
propensity score methods allowed for the distribution of the covariates to be balanced 
between exposure groups, mimicking “virtual randomization” to an extent. We illustrated 
the use of propensity scores in examining caffeine exposure and SAB and we were able 
to compare results using propensity scores and findings from traditional multivariable 
regression analysis. Although this method reduces bias known to exist in observational 
data, it is not without limitations. Unlike randomized studies where measured and 
unmeasured covariates are balanced across exposure groups, residual bias may linger 
because propensity scores can only be estimated from measured data; therefore, bias from 
unmeasured covariates cannot be accounted for. Furthermore, other issues concerning 
systematic variable selection and handling of missing data110-112 must be addressed. 
Despite its current limitations, propensity score methods provide a useful addition to 
examine factors in pregnancy health that otherwise would not be appropriate for 
randomization. 
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5.3 Public health implications 
5.3.1 Symptoms of NVP 
Little is known about the natural history of early pregnancy, and pregnant women 
may not know what to expect with regard to symptoms. Symptoms of NVP is a common 
phenomenon that affects majority of pregnant women; symptoms can differ in severity, 
timing of onset, and duration, both among individual women and among each pregnancy 
of the same woman. Secretion of hCG and other hormones, as well as the rapid rise in 
their levels have been proposed as the most likely contributors. Few published studies 
suggested several maternal characteristics as potential risk factors for having NVP, but 
other studies yield conflicting results on these factors.  
The presence of NVP, though it can be unpleasant and potentially be disruptive in 
a pregnant women’s daily life, is a marker for favorable pregnancy outcomes. However, 
NVP may lead to serious consequence for a small percent of pregnant women, as 
evidenced by hyperemesis gravidarum. Our study did not evaluate hyperemesis 
gravidarum or medical treatment for NVP, but our data indicated that 20% of women in 
our study population contacted their clinicians and a handful was hospitalized due to 
NVP. Findings from this study suggest that maternal age and maternal race/ethnicity are 
associated with most aspects of NVP, while other maternal characteristics are associated 
with selected NVP subtypes. Also, our findings confirmed that the risk for SAB increases 
with nausea alone and even more so for women no NVP symptoms; there was additional 
evidence that suggested that longer symptom duration reduced the risk for SAB and 
maternal age may play a vital role in these effects. There are no formal treatments for 
NVP symptoms and clinical management varies depending on the severity of the 
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symptoms; nevertheless, careful management of these symptoms is critical for pregnant 
women and their pregnancies.      
 
5.3.2 Caffeine consumption 
Caffeine is readily available and widely consumed in most countries. Since the 
1980s, issues surrounding caffeine consumption for pregnant women have generated 
much public health attention and controversy. Caffeine is a central nervous stimulant and 
impacts a pregnant woman differently; as evidence by its ability to cross placental 
membranes and decrease in clearance in second and third trimesters. Epidemiological 
data have suggested caffeine consumption may be associated with adverse pregnancy 
outcomes, notably early pregnancy loss. However, due to differences in study designs 
and other methodological limitations in previous epidemiologic studies, the association 
between caffeine exposure and SAB has not been firmly established.  
Most studies to date have not been able to identify whether the effects of caffeine, 
if any, are restricted to certain peri-conceptional or pregnancy time window, or have been 
able to identify a threshold or a “maximum exposure limit” so that caffeine consumption 
does not affect the risk of SAB. We were able to examine a wide range of caffeine 
exposure (coffee alone and total caffeine from coffee, iced and hot tea, and sodas) at 
three time windows using two forms of statistical methods. While an increased risk of 
SAB was suggested for consumption around the time of interview, findings from this 
study showed very little evidence that overall caffeine consumption increases the risk for 
SAB.  
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5.4 Conclusions  
This study addressed two important issues concerning pregnant women. Using a 
prospective cohort study design, exposure and outcome assessment methods were greatly 
improved in many ways over those used in previous studies. The prospective follow-up 
of study participants allowed us to ascertain exposure data early in pregnancy and capture 
information from the study questionnaire in a very detailed manner.  
While many hypotheses have been proposed, the etiology of NVP symptoms 
remains largely unknown. Along with maternal characteristics, behaviors, and daily 
exposures, various intricate biological and physiological processes may be triggered, 
which in turn, could dictate whether a pregnant woman is more prone to NVP symptoms. 
Given its complexity, narrowing down specific causes for the onset of NVP symptoms is 
more challenging. RFTS did not collect biological specimens; nevertheless, our findings 
were able to provide additional insight that women with certain maternal traits were more 
prone to exhibit specific NVP characteristics.  
With our findings, along with results found in previous studies, the most 
definitive conclusion we can make is that the lack of NVP symptoms is associated with 
an increased risk for SAB. Compared to having both symptoms of nausea and vomiting, 
our data also indicated an increased risk for SAB with nausea symptoms alone, but the 
magnitude of effect was not as strong as pregnancies without any symptoms. To our 
knowledge, we were the first study that examined the association between symptom 
duration (length in weeks of gestation) with SAB, and the results provided evidence that 
longer symptom duration decreased the risk for SAB. With the exception of a few notable 
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theories, the mechanisms by which NVP predicts favorable pregnancy outcome are still 
not known. Future studies should focus on further refinement in measuring the timing and 
occurrence of NVP in order to provide a better understanding of the biological and 
endocrinological mechanisms between the characteristics evaluated in this study and 
other potential risk factors to NVP symptoms, and its relationship with pregnancy 
outcomes.   
Finally, our findings in this study of largely null results were based on enhanced 
exposure assessments compared to previous studies where positive associations for 
caffeine exposure and SAB were detected. We then applied propensity score methods to 
further confirm our findings, which suggested that our null findings were not as a result 
of biased estimation from using observational data. Because methodological limitations 
from past and recent studies provide challenges to draw definitive conclusions about the 
effects of caffeine exposure on the risk of SAB, future studies must strive to overcome 
current methodological challenges by integrating detailed exposure assessments (e.g. 
daily diaries) and close follow-up of pregnancy outcomes. Until investigators can find 
ways to overcome these limitations, conclusions about the influence of caffeine exposure 
and SAB would likely remain inconclusive.  
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APPENDIX 1. QUESTIONS ON NAUSEA AND VOMITING DURING EARLY 
PREGNANCY IN THE BASELINE QUESTIONNAIRE: RIGHT FROM THE 
START  
 Questionnaire shown in Appendix 1 was abstracted from the Right from the Start 
Baseline Questionnaire (Section H, Current Pregnancy History, pp. 43-46), as prepared by Savitz 
(co-Principal Investigator) and colleagues at the Department of Epidemiology, The University of 
North Carolina at Chapel Hill (CATI Version 2, October 25, 2001. Text updated to match CATI 
on December 16, 2002). 
Section H Current pregnancy history 
This next set of questions is about your current pregnancy 
 
 
Nausea 
H3a. Some women experience days or weeks of nausea or feeling sick to their 
stomach when they are pregnant while other women don’t. At any time 
during this pregnancy, have you had a feeling of nausea? 
no  skip to H7a.  yes  don't know/refused  
 
H3b.  When did you first notice the nausea? 
month: ____  day: ______ [if doesn’t remember day ask H3c.] year: _______  
 doesn’t remember/refused  
 
H3c. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
H3d.  Has the nausea gotten worse? 
yes skip to H4a.  no  don’t know/refused 
 
H3e. Has this feeling of nausea stopped completely? 
yes   no  Skip to H4a.  don’t know/refused 
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H3f. When did the nausea stop completely? 
month: ____  day: ______ [if doesn’t remember day ask H3c.] year: _______  
 doesn’t remember/refused 
 
H3g. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
Vomiting 
H4a.  During this pregnancy, have you had nausea so bad that you vomited? 
Yes 
No  skip to H5. 
don't know/refused  
 
H4b. When did you start vomiting? 
month: ____  day: ______ [if doesn’t remember day ask H4c.] year: _______  
 doesn’t remember/refused 
 
H4c. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
H4d. When your vomiting was the worst, how many days a week did you vomit? 
_____ # day(s)  
 
H4e. When your vomiting was the worst, how many times each day did you 
vomit? Did you vomit once a day, 2 times a day, 3 times a day or more than 3 
times a day? 
 once a day 
 2 times a day 
 3 times a day 
 more than 3 times a day 
 don’t know 
 
H4f. Has the vomiting stopped completely? 
no  skip to H5.  yes  don’t know/refused 
 
H4g. When did you stop vomiting? 
month: ____  day: ______ [if doesn’t remember day ask H4h.] year: _______  
 doesn’t remember/refused 
 
H4h. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
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 doesn’t remember/refused 
 
H5. Has/did the nausea and/or vomiting caused/cause you to ______________? 
[Program out questions that don’t apply, ie. if she doesn’t drink coffee (C1a. and 
C1e. equal 0) then don’t ask the question about coffee] 
 
a.  change the amount of food you eat Yes  PROBE No Don’t 
know 
 Did it cause you to eat more or less? 
b.  change the amount of coffee you 
drink 
 
Yes    
More or less? 
No Don’t 
know 
c. change the amount of alcohol you 
drink 
Yes    
More or less? 
No Don’t 
know 
d. change the amount of soda you 
drink 
Yes    
More or less? 
No Don’t 
know 
e. change the amount of water you 
drink 
Yes    
More or less? 
No Don’t 
know 
f. change the amount of exercise you 
do 
Yes    
More or less? 
No Don’t 
know 
g. change the number of cigarettes 
you smoke 
Yes    
More or less? 
No Don’t 
know 
h. change the number of hours you 
work 
Yes    
More or less? 
No Don’t 
know 
i.  change your normal daily activities Yes  No Don’t 
know 
j.  not be able to take your prenatal 
vitamin or supplements 
Yes No Don’t 
know 
k.  to change anything else in your 
life? 
Yes  PROBE No Don’t 
know 
 Specify: 
 
 
H6a. Have/Did you contact(ed) a doctor or nurse specifically because of the nausea 
and/or vomiting? [do not count regular prenatal visit, only count if she 
specifically called about the nausea or vomiting] 
no  yes   don’t know/refused 
 
H6b. Did you take/Are you taking any medicine, vitamins, or supplements to help 
stop the nausea and/or vomiting? 
no  skip to H6d.  yes  don’t know/refused  skip to H6d. 
 
H6c. What was/is the name of the medicine you took/are taking? 
______________________________________ 
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H6d. Were you put in the hospital for the nausea and/or vomiting? 
no  yes  don’t know/refused 
 
H6e. During the time [you were experiencing/you’ve been experiencing] the 
nausea and/or vomiting, 
[did you lose weight / have you lost weight],  
[did you fail to gain weight/have you failed to gain weight], or  
[did you gain weight/have you been gaining weight] as desired? 
lost weight 
didn’t gain weight  skip to H7a 
gained  skip to H7a 
don’t know/refused  skip to H7a. 
other: (specify) ______________ 
 
H6f. How many pounds have/did you lost/lose? 
________ #lbs 
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APPENDIX 2. QUESTIONS ON NAUSEA AND VOMITING DURING EARLY 
PREGNANCY IN THE FOLLOW-UP QUESTIONNAIRE: RIGHT FROM THE 
START                               
Questionnaire shown in Appendix 2 was abstracted from the Right from the Start Still-
Pregnant Follow-Up (Section H, Current Pregnancy History, pp. 23-24), as prepared by Savitz 
(co-Principal Investigator) and colleagues at the Department of Epidemiology, The University of 
North Carolina at Chapel Hill (CATI Version 2, October 15, 2001. Text updated to match CATI 
on December 16, 2002). 
Section H Current pregnancy history 
This next set of questions is about your current pregnancy 
 
 
Nausea 
H3a. Some women experience days or weeks of nausea or feeling sick to their 
stomach when they are pregnant while other women don’t. At any time 
during this pregnancy, have you had a feeling of nausea? 
no  skip to H7a.  yes  don't know/refused  
 
H3b.  As best as you can remember, when did you first notice the nausea? 
month: ____  day: ______ [if doesn’t remember day ask H3c.] year: _______  
 doesn’t remember/refused  
 
H3c. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
H3e. Has this feeling of nausea stopped completely? 
yes   no  Skip to H4a.  don’t know/refused 
 
H3f. When did the nausea stop completely? 
month: ____  day: ______ [if doesn’t remember day ask H3c.] year: _______  
 doesn’t remember/refused 
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H3g. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
Vomiting 
H4a.  During this pregnancy, have you had nausea so bad that you vomited? 
Yes  No  skip to H5.  don't know/refused  
 
H4b. As best as you can remember, when was the first time that you vomited? 
month: ____  day: ______ [if doesn’t remember day ask H4c.] year: _______  
 doesn’t remember/refused 
 
H4c. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
H4f. Has the vomiting stopped completely? 
no  skip to H5.  yes  don’t know/refused 
 
H4g. When was the last time you vomited? 
month: ____  day: ______ [if doesn’t remember day ask H4h.] year: _______  
 doesn’t remember/refused 
 
H4h. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
H6a. Have/Did you contact(ed) a doctor or nurse specifically because of the nausea 
and/or vomiting? [do not count regular prenatal visit, only count if she 
specifically called about the nausea or vomiting] 
no  yes   don’t know/refused 
 
H6b. Did you take/Are you taking any medicine, vitamins, or supplements to help 
stop the nausea and/or vomiting? 
no  skip to H6d.  yes  don’t know/refused  skip to H6d. 
 
H6c. What was/is the name of the medicine you took/are taking? 
______________________________________ 
 
H6d. Were you put in the hospital for the nausea and/or vomiting? 
no  yes  don’t know/refused 
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H6e. During the time [you were experiencing/you’ve been experiencing] the 
nausea and/or vomiting, 
[did you lose weight / have you lost weight],  
[did you fail to gain weight/have you failed to gain weight], or  
[did you gain weight/have you been gaining weight] as desired? 
lost weight 
didn’t gain weight  skip to Pain 
gained  skip to Pain 
don’t know/refused  skip to Pain 
other: (specify) ______________ 
 
H6f. How many pounds have/did you lost/lose? 
________ #lbs 
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APPENDIX 3. QUESTIONS ON COFFEE CONSUMPTION IN THE BASELINE 
QUESTIONNAIRE: RIGHT FROM THE START 
 
Questionnaire shown in Appendix 3 was abstracted from the Right from the Start 
Baseline Questionnaire (Section C, Health Behaviors, pp. 9-13), as prepared by Savitz (co-
Principal Investigator) and colleagues at the Department of Epidemiology, The University of 
North Carolina at Chapel Hill (CATI Version 2, October 25, 2001. Text updated to match CATI 
on December 16, 2002). 
 
 
The next questions are about caffeine intake. I will ask you about how much coffee, tea, 
and soda you usually drink per day.  
 
 
Ca. For the questions about caffeine intake, please think about what you drank 
over the past week when answering what you currently drink in a typical 
day. Try to answer these questions about your usual habits even if some days 
you drank a different amount than on other days. 
 
Was this past week a typical week for you, meaning that you weren’t on 
vacation or there wasn’t anything unusual that would affect your coffee, tea 
or soda use? 
Yes 
No  then, for all the following questions please think about a different week that 
you would consider a more typical week for you. 
 
 
Caffeinated coffee 
[interviewer notes: include hot and/or cold coffee] 
C1a. Currently, how many cups of caffeinated coffee do you usually drink per 
day? 
____ # per day ____<1 per day  skip to C1c. none skip to C1c. 
____ don’t know/refused  skip to C1c. 
 
C1asize. Are those cups usually small like a tea cup, about 4-10 oz; medium 
like a coffee mug, about 12-14oz; or large like an travel mug or oversized 
coffee mug, about 16-24oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
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C1b. Do you usually drink instant or brewed coffee? [brewed includes espresso] 
brewed instant  both [only if 50/50]   don’t know/refused  
 
C1c. In the past 4 months, since [date], have you changed the amount of 
caffeinated coffee you drink? 
yes  no  skip to C2a. don’t know/refused  skip to C2a. 
 
C1d. When did you change the amount of caffeinated coffee you drink?  
month:  ____  day: ______ [if doesn’t remember day ask C1e.] year:  ___  
 doesn’t remember/refused 
 
C1e. Do you remember what week in [month] that was, the first, second, third, 
fourth, or fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
 
C1f. Before you changed, how many cups of caffeinated coffee did you usually 
drink per day? 
______ # per day  ____<1 per day  none 
 
C1g. Were those cups usually small like a tea cup, about 4-10 oz; medium like a 
coffee mug, about 12-14oz; or large like an travel mug or oversized coffee 
mug, about 16-24oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
 
 
Hot caffeinated tea 
Now I’m going to ask you about caffeinated tea. 
C2a. Currently, how many cups of hot caffeinated tea do you usually drink per day? 
____ # per day  ____<1 per day  skip to C2b. none  skip to C2b.  
Don’t know/refused  skip to C2b. 
 
C2asize. Are those cups usually small like a tea cup, about 4-10 oz; medium like a 
coffee mug, about 12-14oz; or large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
 
C2b. In the past four months, have you changed the amount of hot caffeinated tea you 
drink? 
yes  no  skip to C3a. don’t know/refused  skip to C3a. 
 
C2c. When did you change the amount of hot caffeinated tea you drink? 
month:  ____  day: ______ [if doesn’t remember day ask C2d.] year:  ___  
 doesn’t remember/refused 
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C2d. Do you remember what week in [month] that was, the first, second, third, fourth, or 
fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
C2e. Before you changed, how many cups of hot caffeinated tea did you usually drink per 
day? 
______ # per day  ____<1 per day  none 
 
C2f. Were those cups usually small like a tea cup, about 4-10 oz; medium like a coffee 
mug, about 12-14oz; or large like an travel mug or oversized coffee mug, about 16-
24oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
 
 
Iced caffeinated tea 
[interviewer notes: both brewed and instant] 
C3a. Currently, how many glasses of iced caffeinated tea do you usually drink per day? 
____ # per day  ____<1 per day  skip to C3b. none  skip to C3b. 
Don’t know/refused  skip to C3b. 
 
C3asize. Are those glasses usually small like a juice glass, about 4-10oz; medium like 
a water glass, about 12-20; or large like a giant size drink at the movies/Fast food, 
about 22-34oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
 
C3b. In the past four months, have you changed the amount of iced caffeinated tea you 
drink? 
yes  no  skip to C4a. don’t know/refused  skip to C4a. 
  
C3c. When did you change the amount of iced caffeinated tea you drink? 
month:  ____  day: ______ [if doesn’t remember day ask C3d.] year:  ___  
 doesn’t remember/refused 
 
C3d. Do you remember what week in [month] that was, the first, second, third, fourth, or 
fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
C3e. Before you changed, how many glasses of caffeinated tea did you usually drink per 
day? 
______ # per day  ____<1 per day  none 
 
C3f. Were those glasses usually small like a juice glass, about 4-10oz; medium like a 
water glass, about 12-20; or large like a giant size drink at the movies/Fast food, 
about 22-34oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
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Decaffeinated drinks 
[interviewer notes: for both C4a and C4b. include hot or cold drinks] 
C4a. Currently, how many cups of decaffeinated coffee do you usually drink per day? 
____ # per day  ____<1 per day skip to C4b. none skip to C4b.  
Don’t know/refused skip to C4b. 
 
C4asize. Are those cups usually small like a tea cup, about 4-10 oz; medium like a 
coffee mug, about 12-14oz; or large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
 
C4b. Currently, how many cups of decaffeinated tea do you usually drink per day? 
____ # per day  ____<1 per day  skip to C5a.  none skip to C5a. 
don’t know/refused skip to C5a. 
 
C4bsize. Are those cups usually small like a tea cup, about 4-10 oz; medium like a 
coffee mug, about 12-14oz; or large like an travel mug or oversized coffee mug, 
about 16-24oz? 
Sm Med  Lg Other: specify _______ don’t know/refused 
 
 
Sodas/soft drinks 
The next questions are about sodas and soft drinks. 
C5a. Currently, do you drink one or more cans, bottles or glasses of soda or soft drinks 
per day, including tonic water, club soda, soda water, seltzer and caffeinated water? 
yes  no  skip to C5g. don’t know/refused  skip to C5g. 
 
C5b. What brand or type of soda do you drink most often? Anything else [Up to 4 brands, 
those she usually/regularly drinks. If store brand, include name of store and type of soda, 
ie. cola.] 
_____________ _____________ _______________ _____________ 
 
C5c. Is (brand) diet? [for each of up to 4  types/brands she drinks ask C5c.] 
yes  no  don’t know/refused  
 
C5d. Is (brand) caffeine free? [for each of up to 4 types/brands she drinks ask C5d.] 
Yes if yes for all sodas skip to C5g  No  Don’t know/refused  
 
 
[for each type/brand she drinks that is caffeinated or if she doesn’t know if it’s caffeinated, ask 
C5e-C5f.] 
C5e. How many cans, bottles or glasses of ______ do you usually drink per day? 
____ # per day  ____<1 per day  skip to C5g. 
 
C5f. Are those usually small like a can of soda, about 8-12oz, medium like a small soda 
bottle about 14-22oz or large like a giant drink at the movies or fast food, about 24-
34oz? 
sm  med  lg  Other _______         don’t know/refused 
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[Ask C5g-C5j about caffeinated drinks as a whole, not for each individual brand.] 
 
C5g. The next questions are only about caffeinated sodas. In the past 4 months, have you 
changed the amount of caffeinated soft drinks/sodas you usually drink? 
yes  no  skip to C6a. don’t know/refused  skip to C6a. 
 
C5h. When did you change the amount of caffeinated soft drinks/sodas you drink? 
month:  ____  day: ______ [if doesn’t remember day ask C5i.] year:  ___  
 doesn’t remember/refused 
 
C5i. Do you remember what week in [month] that was, the first, second, third, fourth, or 
fifth? 
___1st ____2nd ___ 3rd ____ 4th ___ 5th   
 doesn’t remember/refused 
 
C5j. Before you changed, how many cans, bottles or glasses of caffeinated soda or soft 
drinks did you usually drink per day? 
______ # per day ____<1 per day  skip to C6a. none  skip to C6a. 
 
C5k. Were those usually small like a can of soda, about 8-12oz, medium like a small soda 
bottle about 14-22oz or large like a giant drink at the movies or fast food, about 24-
34oz? 
sm  med  lg  Other _______         don’t 
know/refused 
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APPENDIX 4. SAS CODES FOR MANUSCRIPT 3 
 
 
The following SAS codes were used by the authors to estimate the propensity scores 
using logistic regression and to model caffeine exposure on SAB with propensity scores 
using unconstrained continuation odds ratio model. Steps that were used to estimate 
propensity scores and quintile assignments were adapted from paper by D’Agostino.17 
 
 
Sample data 
ID x z1 z2 z3 y
303 214.9 1 0 1 0
1122 98.2 1 1 0 0
1210 1540.3 0 1 1 0
3486 785.4 0 1 1 1
7832 0 1 1 0 0
10268 468.9 1 0 0 1
 
 
 
Step 1: Estimating propensity scores using a saturated logistic regression model 
 
proc logistic data=final descending;  
model y= x z1 z2 z3….zn; 
output out=pscoffpreg p=predict; 
run;  
 
x= main exposure  
y= outcome 
z1 …zn = confounders  
 
 
Step 2: Creating quintiles based on the estimated propensity scores  
 
 proc rank groups=5 data=pscoffpreg out=quintile; 
  ranks rnks; 
 var predict; 
 data qtile; set quintile; quintile=rnks + 1; 
 run; 
 proc freq data=quintile; tables rnks; run; 
 proc freq data=qtile; tables quintile; run; 
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Step 3: Fitting the SAB model  
 
proc logistic data=final descending; 
class quintile/param=ref; 
model abort = ind5 ind6 ind7 ind8 ind9 ind10 ind11 ind12 ind13 ind14 
 ind15 ind16 ind17 ind18 ind19 ind20 quintile x z1 z2 z3; 
contrast 'OR for x in any given quintile' x 1/estimate=exp; 
title 'propensity scores for exposure on SAB'; run; 
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